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ABSTRACT
The synapse is the primary locus of cell-cell communication in the
nervous system. The elaboration of a functional synapse requires both a
specialized structure and an efficient communication system. For my
thesis work, I studied proteins implicated in each of these functions:
the structural molecules dystroglycan and dystrophin, and the signaling
elements Insulin Receptor Substrate p58/53 and insulin receptor.
The a/ dystroglycan complex, believed to be the heart of cell-
matrix adhesion in muscle and other tissues, provides a link between
dystrophin, a cytoskeletal protein at the base of the muscle cell'
Dystrophin Associated Protein Complex, and the extracellular matrix. In
addition, dystrophin is found at central synapses, tightly associated
with the postsynaptic density. The absence of dystrophin and the
secondary loss of its associated proteins causes the genetic disease
Duchenne Muscular Dystrophy. DMD affects both muscle and brain, causing
a severe muscular dystrophy and lower IQs than control groups.
In the first portion of my thesis work, I sought to determine the
role of dystroglycan, dystrophin I s peripheral partner, at central
synapses. I probed Northern blots of brain regions to delineate the
distribution of brain dystroglycan mR and to uncover any 
dystroglycan-related transcripts in brain. Then, using subcellular brain
fractions, and cultured hippocamal neurons, I determined that whereas
dystroglycan is associated with central synapses, dystroglycan is
not. This discovery is surprising, and differs from the finding that
dystrophin and a- and dystroglycan colocalize at the presynaptic
memrane of retinal photoreceptors.
In the course of the above mentioned work, using the anti-
dystroglycan antiseru Ab98, I discovered a pair of proteins that were
tightly associated with the postsynaptic density. These polypeptides of
58 kDa and 53 kDa (pS8/53) were highly enriched in postsynaptic density
(PSD) fractions from rat cerebral cortex, hippocampus, and cerebellum.
In pursuit of a potential synapse-specific dystroglycan relative, I
purified p58 and p53 by a combination of hydrophobic interaction
chromatography and two-dimensional gel electrophoresis. Mass
spectroscopy and peptide microsequencing revealed that pS8/S3 is
identical to the insulin receptor tyrosine kinase substrate pS8/S3
(IRSpS3). Whereas IRSpS8/53 has no significant homology to ~-
dystroglycan other than the one span of peptides that confers its
antibody cross-reactivity, its localization to the PSD newly implicates
insulin signaling at synapses.
Analysis of IRSpS8/S3 mass profiles, peptides, and mR indicated
that IRSpS8 and IRSp53 are the product of the same coding sequence.
Immunolocalization showed that IRSpS8/S3 is expressed in the synapse-
rich molecular layer of the cerebellum. Immunostaining of cultured
hippocampal neurons showed that both IRSpS8/S3 and insulin receptor are
highly concentrated at synapses. Like IRSpS8/S3, insulin receptors are a
component of the PSD fraction. Together, these data suggest that the
synapse is a specialized site for insulin signaling in the brain.
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CHAPTER I
DYSTROGLYCAN'S NONTRADITIONAL ASSOCIATIONS IN THE BRAIN
Introduction
Muscle and brain are two of the may tissues that contain the
protein dystroglycan. In muscle, the a/~-dystroglycan complex works in
at least two capacities. Along the muscle memrane, dystroglycan is 
component of the dystrophin associated protein complex (DAPC). Within
the sarcolema, ~-dystroglycan associates with dystrophin, a
cytoskeletal protein that is aberrant in some forms of muscular
dystrophy. The absence of dystrophin and the associated DAPC causes the
muscle pathology, and perhaps the CNS abnormalities, characteristic of
many muscular dystrophies. Dystroglycan is also a component of a
modified DAPC that is specifically expressed at the neuromuscular
junction (NM). Whereas a-dystroglycan interacts with the extracellular
matrix protein lamnin all along the surface of the muscle cell, it
exhibits a particularly high binding affinity for agrin, a matrix
molecule secreted by motor neurons exclusively at the site of the NM.
At both synaptic and nonsynaptic sites, dystroglycan links
elements of the muscle cytoskeleton to components of the extracellular
matrix. It is believed that dystroglycan participates in the maintenance
of healthy muscle cells and has a role in norml brain development and
function. The exact actions of dystroglycan in muscle continue to be
elusive, and dystroglycan I s role in the brain appears to be even more
complex. The investigation of dystroglycan I s role in the brain, and
specifically at synapses, is therefore compelling. In this portion of my
thesis work, I learned that what is true for dystroglycan in muscle is
not necessarily true for dystroglycan in the brain. In brain, dystrophin
is not ubiquitously associated with ~-dystroglycan, and a- and ~-
dystroglycan are not invariably co-distributed. My findings indicate
that the rules governing dystroglycan in muscle do not appear to be in
effect in some brain regions, and forecast an unconventional role for
dystroglycan at central synapses.
Background
Dystroglycan was first identified as a muscle protein that
associates with dystrophin. Soon after, dystroglycan emerged as a 
protein with high binding affinity for laminin and agrin. Today, these
associations are well established, but the ways in which dystroglycan
contributes to the pathophysiology of muscular dystrophy, or to the
, .
development and maintenance of the NM, remain largely unknown.
Exression of dystroglycan is not limited to muscle: many tissues
contain this protein, including brain. Below is a sumry of what is
known about dystroglycan in muscle, in some non-muscle tissues, and in
the CNS.
2. 1 Dystroglycan in the Periphery
Dystroglycan is encoded by one gene, which is located on mouse
chromosome 9 and human chromosome 3. The coding sequence includes two
exons, 285 bp and 2400 bp, separated by a large intron. The 5. 8 kb
dystroglycan transcript encodes a 97 kDa precursor protein that is
cleaved to produce a- and ~-dystroglycan (Ibraghimov et al. , 1992;
Ibraghimov-Beskrovnaya et al., 1993; Gorecki et al., 1994).
Dystroglycan is a peripheral memrane protein that associates
with the extracellular matrix. The primary sequence of a-dystroglycan
predicts a 72 kDa protein, but tissue-specific post-translational
carbohydrate additions give a-dystroglycan an apparent molecular weight
that ranges from 120 kDa in brain to 156 kDa in muscle and to 190 kDa in
Torpedo electric organ (Ibraghimov et al., 1992; Bowe et al.
, 1994). a-
dystroglycan is tethered to the memrane by its noncovalent association
with ~- dystroglycan. dystroglycan is a 43 kDa transmemrane protein
that acquires carbohydrate additions on its extracellular portion as
well. Additionally, an intrachain disulfide bond forms within the
extracellular domain of ~-dystroglycan, between Cys669 and Cys713 (Deyst
et al., 1995) (Figure 1).
1 Dvstrocrlvcan is a DvstroDhin Associated Protein.
Dystroglycan is a prominent memer of the dystrophin associated
protein complex (DAPC), a group of proteins that remain tightly
associated with dystrophin in muscle extracts purified on wheat germ
agglutinin colums (Ervasti et al., 1990). To date, the DAPC includes
laminin, a/~-dystroglycan, the sarcoglycan complex, the syntrophins, and
the dystrobrevins (Figure 2) 
Inside the muscle cell, the N-terminus of dystrophin associates
with the actin cytoskeleton. The C-terminal tail of dystrophin contains
a cysteine-rich region that binds to ~-dystroglycan I s proline-rich C-
terminus (Jung et al., 1995). Outside the cell, a-dystroglycan binds
the extracellular matrix molecule laminin-2. In this capacity, the a/~-
dystroglycan unit links extracellular matrix to the cytoskeleton. This
connection is thought to stabilize the myomemrane during the stress of
muscle fiber contraction (Petrof, 1998).
In 1986, Dr. Lou Kunkel and colleagues discovered that defects in
the gene for the 427 kDa protein dystrophin are responsible for the most
well-studied of the muscular dystrophies, Duchenne and Becker (Monaco et
al., 1986) (Table 1). Duchenne Muscular Dystrophy (DMD) is a severe X-
linked genetic disorder that affects 1 in 3, 500 boys. The disease is
characterized by a progressive muscle degeneration that causes an
affected boy to lose the ability to walk, potentially lose lung and
cardiac function, and suffer an early death (Worton
, 1995). In skeletal
muscle from DMD patients, dystrophin is absent and levels of DAPC
proteins are significantly decreased (Ohlendieck anq Cambell, 1991). It
is hypothesized that when some or all of the DAPC is missing, the
myomemrane is more likely to tear and be damaged, but the exact
pathophysiology of muscular dystrophy remins unknown.
Following the identification of the dystrophin gene as the primary
defect in DMD, all memers of the DAPC came under consideration as
candidate genes for muscular dystrophies. It is now clear that genes
encoding at least five of the DAPC proteins are responsible for muscular
dystrophies. A defect in alpha, beta, gama, or delta sarcoglycan can
cause types of Limb Girdle Muscular Dystrophy (Table 1). The function of
the sarcoglycan complex in muscle remains unknown, however. Laminin-2 is
a heterotrimer that is composed of one alpha-2 chain, which can bind a-
dys troglycan as well as a beta-1 and gam-1 chain. Laminin-2 is highly
expressed in striated mus le and peripheral nerve and is also found in
the brain. Laminins participate in cell adhesion and migration, as well
as in axon guidance and neurite outgrowth. Defects in the alpha-2 chain
of laminin-2 are responsible for a type of muscular dystrophy as well
(Bonneman et al., 1996). Although exression of dystroglycan and the
other components of the DAPC is reduced in most of the muscular
dystrophies, no further DAPC components have been implicated in muscular
dystrophies to date. Indeed, no disease has been linked to defects in
the dystroglycan gene. Notably, "knocking out" the dystroglycan gene in
mice is emryonically lethal (Williamson et al., 1997).
2 Dvstrocrlvcan is associated with the Neuromuscular Junction.
Dystroglycan is also associated with a complex of proteins at the
NM (Figure 2). This peripheral point of cell-cell contact encompasses a
motor neuron terminal, which secretes the neurotransmitter
acetylcholine, and at the apposing muscle cell memrane, a specialized
postsynaptic apparatus. This specialization develops as components of
the synaptic machinery, including acetylcholine receptors (AChRs),
cluster together under the nerve terminal. At this exceptional site the
concentration of AChRs in particular swells to several thousand times
that along the cell' s non-synaptic memrane. At the NM, ~-dystroglycan
binds utrophin, an autosomally-encoded relative of dystrophin
(Camanelli et al., 1994). Exression of beta- syntrophin and the form
of dystrobrevin that contains a phosphotyrosine tail (dystrobrevin+PYCT)
is restricted to the NM (Balasubramanian et al., 1998). Further, a-
dystroglycan abandons its association with laminin-2, and is instead the
maj or agrin binding protein (Bowe et al., 1994).
Agrin is secreted into the extracellular matrix by peripheral
motor neurons. As the neuron approaches its target muscle, agrin works
to shape and maintain the NM. First, agrin induces the clustering of
AChRs and other molecules that contribute to the postsynaptic
specialization (Bowe and Fallon, 1995). Whereas agrin has high affinity
for dystroglycan, agrin specifically activates MuSK, a 
scle ecific
tyrosine kinase (Glass et al., 1996). Agrin and MuSK are both essential
in NM synaptogenesis: mice with homozygous mutations in either agrin or
MuSK die at birth. There is poor postsynaptic differentiation in muscle
from these animals, with few to no AChR clusters at the NM. Since the
communication system between nerve and muscle fails to develop, these
mice canot take their first breath (DeChiara et al., 1996; Gautam et
al., 1996).
The steps that follow the agrin-MuSK interaction and lead to the
special molecular organization of the NM are slowly being dissected.
The activation of MuSK by agrin initiates multiple signaling pathways.
The retrograde signal that instructs the incoming neuron to terminate
its progression and form a presynaptic terminal depends on agrin.
Similarly, the preferential transcription of AChR mRAs by the muscle
cell' s sub-synaptic nuclei requires agrin and MuSK. This pathway
requires the binding of ARIA, a neuregulin released by the nerve
terminal, to its receptor tyrosine kinase erbB, which is clustered at
the postsynaptic apparatus (Wells and Fallon, 1996). As mentioned, agrin
also induces the clustering of postsynaptic components, including AChRs
and some memers of the DAPC. This phenomenon requires rapsyn, an AChR-
associated protein. Since a-dystroglycan does not directly transduct
the agrin signal that initiates this clustering of the postsynaptic
apparatus, the function of a-dystroglycan at the NM remains undefined
(Wells and Fallon, 1996).
There is some evidence that portends a role for ~-dystroglycan in
such signaling pathways, however. The juxtamemrane region of 
dystroglycan binds rapsyn, the 43 kDa cytosolic protein that is required
for agrin-induced AChR clustering (Cartaud et al., 1998). In addition,
the proline-rich C-terminus of dystroglycan interacts with the SH3
domain of Grb2, a small adapter protein that links receptor tyrosine
kinases to small GTP binding proteins (Yang et al., 1995). Although the
details of the complex mechanisms that coordinate the development and
maintenance of the NM remain unknown, a- and ~-dystroglycan undoubtedly
participate.
3 Dvstrocrlvcan in non-muscle tissues
Dystroglycan exression is also high . in non-muscle tissues,
including heart, brain, placenta, lung, liver, and pancreas. A prominent
role for dystroglycan in emryonic development as well as during tissue
epithelium morphogenesis is emerging. When the dystroglycan null mouse
was created, it was abruptly evident that the dystroglycan gene product
has important functions in development. Dystroglycan is required for the
elaboration of Reichart' s extra-emryonic basement memrane. Disruption
of this structure causes gross abnormalities in the affected emryo
development that are incompatible with life (Williamson et 
al., 1997).
Dystroglycan also has a major role in the maternal mouse uterus
during the peri implantation stage of pregnancy. The amount of
dystroglycan mR in the decidual layer of the uterus 8. 5 days after
conception is 100 times higher than in a non pregnant uterus or in a
mature placenta 12. 5 days after conception. This dystroglycan expression
is specifically localized to the decuidual cells that surround the
implantation site. It is thought that dystroglycan mediates adhesion
between decidual cells or between maternal decidual and placental
trophoblast cells at this early stage in pregnancy (Yotsumoto et al.,
1996). The associations that dystroglycan forms during the development
of the emryo I s Reichart I s memrane and temorally in maternal decidual
cells remin to be elucidated.
In several non-muscle tissues, dystroglycan is exressed on the
basal side of epithelial cells and may help to affix these cells to
basement memranes. In the kidney for examle, dystroglycan is
implicated in the morphogenesis of renal epithelium (Durbeej et al.,
1995). Although epithelial cells express no dystrophin, the short
dystrophin isoform DP71 (Figure 3) is exressed by all studied emryonic
epithelial cells (Cullen et al., 1998; Stevenson et al., 1998).
Interestingly, another short dystrophin isoform, DP140, is transiently
expressed in a subset of kidney epithelial cells (Durbeej et al.
, 1997).
It appears that dystroglycan acts as to link one of these short form of
dystrophin to the extracellular matrix. The extracellular matrix protein
that binds dystroglycan may be a non-muscle type of laminin: the E3
fragment of lamnin-1 has been found to be involved in epithelial
morphogenesis (Durbeej et al., 1998). Another extracellular matrix
molecule that is expressed in kidney is 
agrin. In fact, a-dystroglycan
from kidney binds agrin with a higher affinity than laminin-1, and agrin
can coimunoprecipitate a- and dystroglycan (Gesem et al., 1998).
Indeed, in epithelia of various cell types, dystroglycan appears
to provides a link between the cytoskeleton and the extracellular
matrix. This may be dystroglycan I s role early in development, in
Reichart' s memrane, and in the maternal uterus as well. The specificity
of dystroglycan I s cytoskeletal and extracellular matrix associations in
these developmentally regulated contexts requires more thorough
investigation.
2 Dystroglycan in the CNS
Dystrophin, dystroglycan and other selected DAPC memers are
expressed in the CNS. Interestingly, a substantial fraction of the
muscular dystrophy phenotypes manifest a CNS component. This suggests a
role for dystroglycan and other DAPC memers in brain. Agrin is also
expressed throughout the brain, although its role there is as yet
unknown. It is therefore instructive to review what is known about
dystroglycan in the CNS in the context of disease 
maifestations and
dystroglycan s binding partners.
1 The CNS co onent of stro ino athies
Duchenne Muscular Dystrophy, Classical Congenital Muscular
Dystrophy, Walker-Warberg syndrome, and Fukuyar Congenital Muscular
Dystrophy are muscular dystrophies with CNS involvement (Table 1). In
addition , two animal mutants that have been used extensively as models
of DMD exhibit CNS involvement. DMD patients, and to a lesser extent BMD
patients, suffer a mild, non progressive mental retardation (Emery,
1993). In general, the verbal IQ of a DMD patient is more affected than
his performance or full scale IQ (Bushby 
et al., 1995). It is well
established that the mental retardation is a primry deficit, and is not
secondary to the child' s musculoskeletal deficit. In addition, abnorml
electroretinograms (ERGs), which indicate defective synaptic
transmission in the retina outer plexiform layer (OPL) , are seen in
patients with DMD (Cibis et al., 1993; Pillers et al., 1995). The
pathophysiology that leads to these CNS abnormalities in DMD is 
unknown.
Two animal mutants are available for studying the effects of these
disease genotypes in the CNS. One, the mdx mouse , has a defect in the
dystrophin gene. These mice exress a dystrophin protein that is
defective in its N-terminus. Correspondingly, the expression of DAPC
proteins in muscle of mdx mice is diminished (Ohlendieck and Campbell,
1991). These mice suffer only a mild muscular dystrophy, however. During
the first month of life, they experience muscle degeneration and extreme
weakness, but after this critical period they no longer exhibit
significant muscle impairment (Muntoni et al. , 1993). A few behavioral
studies reveal that mdx mice exhibit impaired passive avoidance
learning, and are deficient in the consolidation processes required for
long term memory in behavioral tasks (Muntoni et al., 1991; Vaillend et
al., 1995). Unlike in DMD, ERGs from mdx mice reveal no abnormalities
(Cibis et al., 1993). This raises the possibility that retinal function
as measured by ERG does not require a functional dystrophin N-terminus
or a complexed DAPC. The integrity of the dystrophin C-terminus in 
mice may allow for retention of much of dystrophin
' s function, however.
The most common mutations in the dystrophin gene (65% in DMD and
85% in BMD) involve the N-termnus and rod domains of dystrophin (Figure
3). In general, mutations in which the reading frame is disrupted cause
DMD, whereas mutations in which the reading frame is maintained cause
the less severe BMD. Thus, most of the DMD mutations create premature
stop codons, which presumably result in the expression of trucated
proteins that lack the dystrophin C-terminus (Monaco et al.
, 1988).
The giant dystrophin gene has at least seven different promoters
(Figure 3). Products of the dystrophin gene include tissue specific
full-length dystrophins as well as trucated dystrophin isoforms. There
are at least three promoters producing full- length dystrophin proteins:
Muscle, rain, and rkinje. These three promoters each encode a
different first exon which is spliced in frame with the common
dystrophin second exon. The "Brain" promoter lies 5' to the muscle first
exon, and expresses dystrophin in the cerebral cortex, the cerebellar
Purkinje cell-specific dystrophin promoter s fir t exon is downstream of
the first muscle exon. The overall product of these promoters is
virtually identical, since the divergent first exons add only 3-
unique amino acids (Gorecki et al., 1992). DP240 is a retina-specific
transcript that uses a promoter located midway along the dystrophin gene
(D' Souza et al., 1995). DP140 is a brain and kidney specific isoform
with a start methionine in exon 51 (Lidov et al., 1995). A major brain
product of the dystrophin gene is the shortest isoform, DP71. This
transcript encodes seven new amino acids plus the very last 609 amino
acids of dystrophin (Blake et al., 1992; Lederfein et al., 1993).
Since the genetic defect in 
mdx is a point mutation in exon 23 of
the dystrophin gene, only the expression of full- length dystrophins is
disrupted and short dystrophin isoforms are expressed normally. In 
mdx
muscle, exogenous DP71 can reconstitute the missing DAPC (Cox et al.,
1994; Greenberg et al., 1994). It is likely therefore that in brains of
mdx mice, many of dystrophin ' s C-terminal associations can be achieved
by unaffected endogenous short dystrophin isofor.. The genetic defect
in the mdx 3CV mouse is different from that found in the classical 
mdx.
In 3CV, a mutation in intron 64 causes aberrant splicing and the gene
products are terminated early, presumably lacking the dystrophin C-
terminus. In 3CV no forms of dystrophin are expected to be expressed.
This mutant is somewhat leaky" however, and minor amounts of dystrophin
are expressed. Although no neuropathology is detectable on histologic
sections of 3CV brain and spinal cord (Cox et al., 1993), ERGs performed
on 3CV mice reveal abnormalities simlar to those observed in DMD
patients (Pillers et al., 1995). In 3CV, it is expected that all
'''- ,
dystrophin C-terminal associations are disrupted. Since the g neti
defect in 3CV is similar to those found in DMD, one anticipates that 3CV
mice will display a CNS phenotype more similar to that seen in DMD
patients than hat reported in mdx mice. The 3CV mouse is therefore a
valuable tool in furthering the understanding the role of dystrophins in
the CNS.
2 . 2 . 2 The CNS comDonent of other muscular dvstroDhies
Fukuyar-type Congenital Muscular Dystrophy is one of Japan s most
common autosomal recessive genetic disorders, affecting 1 per 10, 000
births. The FCM phenotype comprises a muscular dystrophy, mental
retardation, and brain malformation due to a defect in neuronal
migration that causes disruption of the orderly six layer neuronal
lamination of the cortex. The disease gene for FCM has recently been
identified. In 87% of individuals with FCM, the 3 ' UTR of a gene within
chromosomal region 9q31 is disrupted by a 3 kb retrotransposal insertion
of tandemly repeated sequences. This insertion is likely to cause a
decrease in the mRA I S transcription or stability and thereby produce a
loss of function phenotype. Two distinct point mutations in this gene
can also cause FCM (Kobayashi et al., 1998).
The predicted product of the FCM disease gene is fukutin, a 461
amino acid secreted protein, with one site for N-linked glycosylation.
Normally, fukutin mR is expressed predominantly in striated muscle,
brain, and pancreas (Kobayashi et al., 1998). The role of fukutin in
muscle and brain remains unknown. In FCM muscle, whereas dystrop in is
expressed at a normal level, the exression of laminin alpha-2 chain and
memers of the DAPC, especially ~-dystroglycan, are greatly reduced
(Hayashi et al., 1993; Matsumura et al., 1993). Electron microscopy of
FCM tissue reveals abnormlities in the basal lamina of muscle and
brain (Ishii et al., 1997).
There are at least two other muscular dystrophies that commonly
involve the CNS. Many patients with one form of congenital muscular
dystrophy exhibit abnormalities of white matter
, a slowing of motor
nerve conduction velocities, and delayed somatosensory evoked
,. 
vp,
potentials. The genetic mutation that causes this type of muscular
dystrophy occurs in the alpha-2 chain of laminin-2. As mentioned,
laminin-2 is a dystrophin associated protein due to the binding of the
alpha-2 chain to a-dystroglycan. Individuals with Walker-Warberg
syndrome may display severe CNS abrrations such as a cobblestone-
appearing cortex and cerebellar hypoplasia, and eye abnormalities
including retinal dysplasia (Bonnem et al., 1996). Muscle biopsies
from two Walker-Warberg patients exibit decreased imunostaining for
laminin alpha-2 chain and ~-dystroglycan (Kanoff et al., 1998). The
genetic basis of Walker-Warberg syndrome has not been identified.
Since its level of expression is affected in the above mentioned
disorders, dystroglycan is imlicated in the CNS abnormalities
associated with these disease. To determine the role of dystroglycan and
its associated proteins the CNS however
, the distribution of these
proteins in the brain must first be detailed.
2 . 2 . 3 EXDress ion of dvs trocr l vcan and associated Droteins in the retina
The retina provides a useful window through which to begin an
examination of dystroglycan in the CNS. Dystroglycan rn is expressed
by photoreceptors and retinal ganglion cells. a- and ~-dystroglycan are
found in the outer plexiform layer (OPL) of the retina, along with short
dystrophin isoforms (DP240, DP140 and DP71) (Ueda et al., 1998). In
irnunostained mdx retina, the expression of a- and ~-dystroglycan and a
dystrophin isofor. in the photoreceptor synaptic memrane (OPL) is
unaffected. Additionally, 
mdx ERGs are normal (Montanaro et al., 1995).
In bovine retina, these proteins localize to the intracavital processes
of the photoreceptor that form the lateral boundary of the synaptic
cavity, distal from the synaptic vesicles but adjacent to the dendritic
ending of the bipolar cell, indicating a presynaptic localization. In
contrast, no irnunostaining for ~-dystroglycan or dystrophin is observed
at the postsynaptic triad (Figure 4). Agrin, which has been detected in
the chicken retina OPL (Kroger et al., 1996), may participate in a
dystroglycan-associated complex as well. It is likely that dystroglycan
and its traditionally associated proteins are involved in healthy
synaptic transmission between photoreceptor cells and bipolar cells in
the retina. (Schmitz and Drenckhah, 1997; Ueda et al., 1998).
Disruption of this complex may cause the ERG abnormalities seen in
DMD patients. A C-terminal missense mutation in the dystrophin gene
(cysteine 3340) has been identified in a DMD patient who exibits mental
retardation and abnorml ERG. This mutation, which is in the region of
dystrophin that binds ~-dystroglycan, causes decreased levels of
dystrophin in all tissues, and a concomitant decrease in the level of ~-
dystroglycan staining in muscle. The phenotype of this patient suggests
that a dystroglycan-dystrophin association is required for dystrophin to
function properly in muscle, retina, and brain (Lenk et al., 1996). A
causative role for this association could be shown by careful comparison
of the behavioral and biochemical characteristics of a mice genetically
engineered to express dystrophin defective only in its ~-dystroglycan
binding domain. An understanding of the exact role of the dystrophin and
dystroglycan association in mental retardation and abnormal retinal
function will require a deeper understanding of this relationship in the
heal thy CNS.
4 E ression of stro can and associated roteins in the brain
There is a significant level of dystrophin expression in the
healthy brain. In the hippocampus, pyramidal cells express dystrophin
whereas granule cells of the dentate gys do not. Throughout the
cerebral and cerebellar cortex, dystrophin imunoreactivity is localized
almost exclusively in neurons (Lidov, 1996). Surprisingly, dystroglycan
expression in brain does not match the pattern of dystrophin expression.
In situ hybridization studies show that dystroglycan mR does
colocalize with dystrophin rn in hippocampus, dentate gys, olfactory
bulb and cerebellar Purkinje neurons, but no dystroglycan message is
detectable in the cerebral cortex, a region in which significant amounts
of dystrophin rn and protein are observed. In contrast, significant
dystroglycan rn appears in neurons in the lateral septal nucleus of
the thalamus, where no dystrophin mR is observed (Gorecki et al.,
1994) .
Based on what is known about dystroglycan at the NM, one would
expect dystroglycan to link agrin to utrophin or PYCT+dystrobrevin at
the central synapse. While neurons do express utrophin, glial cultures
express significantly more (Khurana et al., 1992), and utrophin is
absent from central synapses. It appears that utrophin and dystroglycan
interact not at synapses but at the blood-brain interface. Utrophin, ~-
dystroglycan, and laminin imunoreactivities are found along brain-
penetrating blood vessels and the pial surface (Lidov, 1996). In
particular, both ~-dystroglycan and utrophin localize to the
perivascular endfeet of glial cells, and a-dystroglycan associates with
the basement memrane of brain blood vessels (Khurana et al., 1992; Tian
et al., 1996). Agrin is found associated with brain microvasculature as
well. In the cerebellum at least, dystroglycan appears to link laminin-
and utrophin, forming a complex that participates in the normal
maintenance of the blood-brain barrier (Figure 5) (Tian et al., 1996).
The cell-cell contact of the central synapse incorporates
dystrophin and not utrophin. Dystrophin immunostaining appears in a
punctate pattern around the cell bodies and along the dendrites of
cerebral cortical cells and cerebellar Purkinje cells (Lidov, 1996).
Unlike in the photoreceptors of the OPL, dystrophin is associated with
the postsynaptic specializations of cortical neurons (Lidov et al.,
1993) and is concentrated in mouse and human brain postsynaptic density
fractions (Kim et al., 1992). a-dystroglycan immunoreactivity appears
in a similar pattern on the surface of Purkinje cell bodies, dendrites,
and dendritic spines (Smalheiser and Kim, 1995; Tian et al., 1996).
Surprisingly, ~-dystroglycan immunoreactivity is not detected in these
localizations (Lidov, 1996). In no other region is a-dystroglycan
without p-dystroglycan (Figure 6).
In the periphery, agrin is made by both muscle cells and motor
neurons. Neurons produce the agrin (4
, 8), agrin (4, 11), and agrin (4 , 19 )
splice forms, which are secreted into the extracellular matrix at the
NM. In cultured chick my tubs , neuronal agrin possess much more
clustering AChR activity than muscle-produced agrin(o, O) and binds a-
dystroglycan with higher affinity (O' Toole et al., 1996). In the brain,
large amounts of agrin are made by neurons and glia and are secreted
into extracellular matrix. Neuronal-type agrin appears to bind to
cultured hippocampal neurons at synaptic sites. In contrast, other agrin
isoform do not demonstrate synapse-specific binding sites (David Wells,
Brown University). Unfortunately, the identity of these binding sites
has not yet been determined.
Thus, in some areas, brain dystroglycan continues to be involved
in linking the extracellular matrix to the cytoskeleton. At the blood-
brain barrier for example, a- and ~-dystroglycan .colocalize with
utrophin and laminin. In contrast, there appear to be brain regions in
which dystroglycan does not colocalize with its usual partners. The
presence of dystrophin and a-dystroglycan, and the absence of
detectable dystroglycan, in synapse-rich regions is quite remarkable,
and difficult to accept. Intrigued, I undertook a deeper examination of
dystroglycan s brain distribution, hoping to reconcile dystroglycan '
nontraditional arrangement at central synapses.
Methods
Northern blot hybridization
The 32P- labeled dystroglycan oligonucleotide probes (probe1 and
probe3) were synthesized by PCR using the dystroglycan clone DNI22
(provided by Yiu-mo Chan, Kunel Lab) as template and the following
primer pairs.
probel : Fl=GACTGCGACTCCAAGCCCCC R1=GGCTGTAGGGGGCATI
probe3 : F3 =AGCCCCCACCGCCCTTACAGTA R3=GGCATAGGAGGAGGTGACCG
The human Multiple Tissue Northern Blots (MTj CIon tech; Palo
Alto, CA) were prehybridized in ExressHyb for 30 minutes at 68 C. The
probe (probe1 or probe3) was denatured at 9S C, diluted in ExressHyb,
and incubated with the blot for 1. 5 hours at 68 C. After hybridization,
the blot was washed extensively; the most stringent wash performed was
lX SSC, 0. 1% SDS, at SSoC for 40 minutes. Probe hybridization was
analyzed by autoradiography.
Brain cDNA Library Screen and DNA sequencing
A random primed, rat hippocamus cDNA library constructed in the
vector Agt11 (Clontech) was plated and screened as per manufacturer
protocol. Screening by hybridization was performed first for probe1.
Positively hybridizing phage were plaque purified, and rescreened by
hybridization with probe3. PCR with Agtl1 primers was then used to
determine the insert length of phage that hybridized positively with
probe3. Each of the unique phage inserts was then sequenced at the
Children s Hospital/HHI sequencing facility (Boston, MA). Sequences
were analyzed using the software Sequencher.
Brain Subcellular Fractions
Postsynaptic density (PSD) fractions were prepared using a
modification of the procedures of Carlin and Dosereci (Carlin et al.,
1980; Dosereci and Reese, 1993). Frozen rodent brains were obtained as
follows: mdx mice and agel sex matched controls were obtained from the
Jackson Laboratory, frozen 3CV mice brain and muscle tissue was a
generous gift from Jeff Chamerlain, University of Michigan (Cox et al.
1993), and frozen adult rat brains were obtained from Pel-Freeze. Brain
tissue was homogenized with a motor operated, tight-fitting, Teflon-
glass homogenizer in homogenization solution (0. 32M sucrose, 1 mM MgC12,
1 mg/ml leupeptin). The homogenized tissue was centrifuged 1400 x for
10 minutes. The supernatant (Sl) was saved and the pellet was
resuspended, rehomogenized, centrifuged at 710 x for 10 minutes, and
the supernatant (S2) was collected and pooled with above (Sl). This
pooled material was spun 710 x for 10 minutes and this supernatant is
referred to as the "homogenate fraction
" (H). The homogenate was
centrifuged 13800 x for 10 minutes, and the resulting pellet was
resuspended in O. 32M sucrose, and layered onto a discontinuous sucrose
gradient (1. 2/1. 0/0. 85 M sucrose). Following centrifugation at 82, 500 x
for 2 hours, the synaptosome-containing fraction was collected from
the 1. 2/1. 0 M sucrose interface. This material was resuspended in 1 mM
HEPES, pH 7. 4, and is referred to as the " synaptosomal fraction
" (SX).
This was diluted with 1 volume of 1% Triton-X 100, 0. 32 M sucrose and
stirred on ice for 15 minutes. This solution was centrifuged 36,
000 x 
for 30 minutes. The Triton-insoluble pellet was resuspended in 0. 32M
sucrose with a Dounce homogenizer. This sample was layered onto a
discontinuous sucrose gradient (2. 1/1. 5/1. 0M). The gradients were
centrifuged at 200, 000 x for 30 minutes. The fraction enriched with
postsynaptic densities was collected from the 2. 1/1. 5M interface and
diluted with 1 mM HEPES, pH 7. 4. This fraction was then diluted with one
volume of 1% Tri ton-X 100, 150 mM KCI, and layered onto a 2. 1 M sucrose
cushion and spun 200, 000 x for 30 minutes. The material at the
interface was collected, resuspended in 20 mM HEPES, pH 7.
4, and furtherpurified on a final 2. 1M sucrose cushion. The resulting " PSD fraction
(PSDs) was resuspended in 20% glycerol and stored at -80
C. The absence
of presynaptic contaminants and presence of PSD proteins in the PSD
fraction was confirmed by western blotting with antibodies to 
NMAR1,
aCaMII, and synaptophysin (Wu et al., 1998).
;Ii
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Antibodies and Western Blotting
Ab98 antiseru was raised by immunizing a rabbit with the peptide
KAPLPPPEYPSQ (a sequence in the cytosolic domain of dystroglycan that
was used for the production of antibody PA3a (Yoshida et al., 1993) and
affinity purified (Quality Controlled Biochemicals, Hopkinton, MA). The
anti-peptide antiseru 12031C to ~-dystroglycan was a generous gift of
L. Kunkel. The anti-~-dystroglycan and anti-dystrophin monoclonal
antibodies NCL-43DAG and DYS2, respectively, were obtained from
Novocastra. DYS2 recognizes full-length dystrophin, as well as short
forms of dystrophin. The anti-aCaMII (#6G9) and anti-synaptophysin
monoclonal antibodies were obtained from Boehringer Maneim, the anti-
NMAR1 monoclonal antibody was obtained from Pharmingen, and the
polyclonal anti-mouse CPEB antibody was obtained from Joel Richter,
University of Massachusetts, Worcester (Wu et al., 1998).
Protein concentrations were determined with the BCA protein assay
(Pierce , Rockford, IL), using bovine seru albumin (BSA) as a standard.
Equal quantities of muscle lysate (provided by Helene Sadoulet-Puccio,
Kunkel Lab), homogenate, synaptosomal, and PSD proteins were separated
by SDS-PAGE, and transferred onto nitrocellulose. The primry antibodies
used are described above. Species specific alkaline phosphatase-
conjugated goat anti-rabbit or anti-mouse IgG (Boehringer Maneim) was
used as the secondary antibody, and the bound antibody was visualized
using the BCIP/NBT substrate system (Promega, Madison, WI). For Western
blotting with DYS2 , horseradish peroxidase-conjugated anti-mouse IgG was
used as the secondary and the immunoreacti vi ty was visualized by ECL
chemiluminescence with equivalent exosures (Amersham).
Ligand Overlay Assay
Nitrocellulose blots of homogenate, synaptosome, and PSD proteins
were blocked for 4 hours at 4 C in Hanks Buffered Saline Solution, 5%
nonfat dr milk, 1% bovine seru albumin, 10% horse seru, pH 7. 4. Blots
were incubated overnight at 4 C in the presence of 1 ro EGTA or 1 ro
++ and heparin (1 mg/ml) or antibody IIH6 (1:5
, gift from Kevin
Campbell (Ervasti and Campbell, 1991)) where indicated. Recombinant rat
"' 
agrin was collected from the conditioned medium from COS cells
transfected with cDNA clones encoding rat agrin(4, 8) or agrin(o, 0).
Blots were washed and incubated with a second layer containing 1 g/ml
iodinated (1251) (IODOEN, Pierce) anti-agrin monoclonal antibody 131
(Arersham) (12SI-MA-131) for 30 minutes. Blots were then washed and
dried, and agrin binding polypeptides were visualized by
autoradiography.
Hippocampal neuron cultures and immunohistochemistry
Low density cultures were created as previously described (Goslin
and Banker, 1991). Briefly, the hippocampus was removed from E18 rat
emryos, trysinized (0. 25%), dissociated by trituration, and plated
onto poly- lysine (1 mg/ml) coated glass coverslips in modified Eagle I s
medium (ME, Gibco) with 10% horse seru for 4 hours. The coverslips
were then transferred to dishes containing a monolayer of glial cells in
growth medium consisting of ME, ovalbumin (100 g/ml) pyrvate (1.
g/ml), glucose (0. 6%) and N2 supplement. The culture medium was changed
weekly. After 19-21 days, the cells were fixed with 4% paraformaldehyde
at 37 C for 20 minutes, covered with saponin (0. 05%) for 5 minutes and
then incubated in blocking solution (ME, 10% horse seru, 1% goat
seru, 1% BSA). The primary antibodies, mouse anti-synaptophysin
(Boehringer), NCL-43DAG (Novocastra), were applied overnight at 4 C and
species specific secondary antibodies, directly conjugated to either
FITC (Caltag) or Cy3 (Jackson Laboratory), were applied for 1 hour at
room temperature. The covers lips were mounted onto glass slides with
Citifluor (Ted Pella).
Neuron and glia cell lysates
Neuron and glia cultures were plated at high density (300, 000
cells/10 cm culture dish), and grown as described above. After 1 week in
culture, cells from 3-4 dishes were rinsed in 16 ro HEPES, pH 7. 4, lysed
for 20 minutes at 4 C in 20 ro HEPES, pH 7. 4, 1% Triton X-100, 150 ro
NaCi, 0. g/ml leupeptin, 1 ro PMSF, and collected by scraping.
Collected material was homogenized (10 strokes) in a small Dounce
homogenizer. Cell homogenate was spun at 36, 000 x for 45 minutes and
supernatant (trichloroacetic acid precipitate) and pellet were analyzed
by western blotting.
Results
In muscle, dystroglycan is both a memer of the DAPC and a 
protein with high affinity for agrin and laminin. At the presynaptic
memrane of photoreceptors in retina, dystroglycan and dystrophin
colocalize. Since dystrophin is also found concentrated at central
synapses, I hypothesized that brain dystroglycan or a dystroglycan- like
protein colocalizes with dystrophin at these synapses. I therefore
initiated a careful examination of dystroglycan ' s expression in the
brain and at synapses. I first assayed the exression of the
dystroglycan transcript (s) in various brain regions and pursued a
potential dystroglycan splice variant. Next, I established the
distribution of a- and dystroglycan in norml brain biochemical
fractions enriched for synaptic proteins, and assessed the effects of
dystrophic genotypes on dystroglycan ' s synaptic fractionation profile.
Lastly, I determined the pattern of dystroglycan expression in cultured
glial and hippocampal neuronal cells.
1 Distribution of dystroglycan mRNAs in regions of brain
I began my investigation of brain dystroglycan by determining the
distribution of dystroglycan transcripts among various regions of the
brain. I screened a human brain region Northern blot with two DNA
fragments, probe 1 and probe3, that corresponded to the proximal and
distal C-terminal regions of dystroglycan, respectively (Figure 7). Both
probes hybridized to an approximtely 6 kb rn that was highly
exressed in all brain regions. Hybridization with probe1, but not with
probe3, revealed other transcripts. A larger transcript (over 10 kb),
which was expressed in cerebral cortex as well as occipital and frontal
lobe, represented a potential splice variant of dystroglycan that lacked
the sequence encoding the dystroglycan C-terminus.
This observation suggested that in brain there is at least one
transcript in addition to dystr?glycan that contains sequence similar or
. .
identical to probe1 but not probe3. To pursue such brain-specific,
potentially dystroglycan-related transcripts, I used both probes to
screen a rat brain (hippocampal) library. By pursuing only plaques that
were positive for probe1 and negative for probe3, I avoided many
standard dystroglycan cDNAs that were positive for both dystroglycan
probes.
The proximal probel hybridized to approximtely SO plaques. I
plaque purified these, and found that the distal probe3 did not
hybridize to approximately 20 of the 49 probe1-positive phage. I
determined that 15 of these phage contained uniquely-sized cDNA inserts
and each was sequenced. I compared all of the cDNA insert sequences to
the published mouse dystroglycan cDNA (DAG1). With the exception of one
exceptionally large insert (4. 5 kb), which contained genomic sequence in
addition to dystroglycan coding sequence, there was complete sequence
identity to the published dystroglycan cDNA. Since many of the sequences
ended abruptly just upstream of the region corresponding to the distal
probe3, it appeared that in the course of the library s construction
this region of the dystroglycan cDNAs was disproportionately targeted
for cleavage. None of the cDNA fragments that I isolated contained
sequence that diverged from the dystroglycan sequence (Figure 8).
-- \
Y The 
Northern analysis verified the extensive dystroglycan
expression in all regions of hum brain. The extensive library screen
however furnished no evidence of alternative splicing in dystroglycan
' s
C-terminal region.
Distribution of dystroglycan and an inuunologically
related protein
Since dystroglycan ' s associations in muscle and retina suggested
that brain dystroglycan is present at central synapses
, I then focused
my investigation on the potential synaptic distribution of brain
dystroglycan.
1 SvnaDtic Subcellular Fractions
Like the NM, central synapses have elaborate postsynaptic
apparatuses. At central synapses, just below the postsynaptic memrane,
is a dense parcel of proteins, the postsynaptic density (PSD). The
position and make-up of this neuronal specialization suggests that it is
important in the development, function, and plasticity of the synapse
(see Chapter II) .
Biochemical preparations that are enriched for this synaptic
machinery have proven valuable for investigating the synaptic structure.
Many molecules that have a role in synaptic function are concentrated in
preparations that successively enrich for synaptic memranes
(synaptosomes) and postsynaptic densities (PSDs) (Figure 9). To
determine if brain dystroglycan associates with synaptic components, I
biochemically prepared brain homogenate, synaptosome, and PSD-enriched
fractions and probed western blots of these subcellular fraction
proteins for a- and ~-dystroglycan.
2 Dvstrocrlvcan in SvnaDtic Subcellular Fractions
To first follow the subcellular fractionation profile of a-
dystroglycan I employed a well-described method for a-dystroglycan
detection, the ligand blot overlay (Deyst et al., 1995). I incubated a
blot of subcellular fraction proteins with in vitro produced rat agrin,
and then detected the agrin, specifically bound to a-dystroglycan, with
a radiolabeled anti-agrin monoclonal antibody.
I found that a-dystroglycan was present in brain homogenate and
was concentrated in the synaptosome fraction. In addition, a small
population of a-dystroglycan was detectable in the PSD fraction. The
agrin-binding properties of rat brain a-dystroglycan appeared to mirror
those of Tor.edo electric organ a-dystroglycan (Bowe et al., 1994;
Toole et al., 1996): the binding of the isoform agrin ( 0 , 0) exceeded
the binding of agrin(4, 8) (Figure IDA). a-dystroglycan s agrin-binding
capacity required the presence of Ca
, was increased in the presence of
heparin, and was inhibited by the anti-a-dystroglycan antibody IIH6
(not shown).
Then, using standard western blotting techniques, I probed similar
blots of subcellular fractions with antibodies to 
~-dystroglycan. Like
its associate a-dystroglycan, ~-dystroglycan was present in brain
homogenate and was concentrated in the synaptosomal fraction. This
pattern was observed in subcellular fractions isolated from rat cortex,
hippocampus, and cerebellum. In contrast, ~-dystroglycan was not
detected in the PSD fraction (Figure 10B, C).
One ~-dystroglycan antiseru, Ab98, recognized not only ~-
dys troglycan but also a pair of polypeptides of 58 kDa and 53 kDa that
were selectively enriched in PSD fractions from all brain regions. These
PSD-enriched polypeptides were designated pS8/S3. Antibodies NCL-43DAG
and 12031C revealed a similar distribution of ~-dystroglycan in these
fractions, but these reagents bound neither pS8 nor p53 (not shown). The
presence of dystrophin and a-dystroglycan in the PSD fraction, and the
absence of detectable ~-dystroglycan in the PSD fraction, made these ~-
dystroglycan- like proteins intriguing.
stro can in s tic subcellular fractions from brains of mdx
and 3CV mutant mice
Whereas full-length dystrophin is concentrated in the PSD
fraction, I found that ~-dystroglycan was concentrated in the
synaptosome fraction. Interestingly, I determined that the brain-
specific short dystrophin isoform DP71 fractionated in a pattern like
that of ~-dystroglycan (Figure 11). In DMD mdx, and 3CV affected
muscle, the exression of the DAPC is diminished, presumly in response
to the absence of dystrophin. To assess the response of brain
dystroglycan to the absence of full-length dystrophin and to the absence
of all short dystrophin isoforms, I performed the exeriments described
above using subcellular fractions prepared from 
mdx and 3CV mice.
It has been shown that levels of ~-dystroglycan are unaffected in
mdx brain (Ibraghimov et al., 1992). To confirm this, I demonstrated
that levels of a- and ~-dystroglycan were normal in synaptosomes
prepared from mdx mice. Others have shown this as well (Greenberg et
al., 1996). Before examining the effect of the 
3CV genotype on the
expression of brain dystroglycan, I established that the synaptic
markers aCaMII and NMAR1 were unaffected in 3CV fractions, and
verified that DP71 was absent from 3CV mice subellular fractions (not
shown) .
Then, using ligand overlay exeriments, I found that the level of
dystroglycan was slightly lower in 3CV brain as compared to mdx 
unaffected mice. By probing western blots with
antibody NCL-43DAG, I determined that levels of
the ~-dystroglycan
~-dystroglycan in the
(Figure 12). Greenbergbrains of 3CV mice were substantially decreased
et al. have obtained similar results (Greenberg et al., 1996). In
contrast, levels of pS8/53 were unaffected in 
mdx or 3CV mice,
suggesting that pS8/S3 does not interact with any form of dystrophin
(not shown).
The results from the mdx subcellular fraction studies suggest that
no population of a- or p-dystroglycan functionally interacts with full
length dystrophin in mouse brain. In contrast, the parallel distribution
and decrease of DP71 and a/~- dystroglycan in the fractions from 3CV
mouse brain suggests that, unlike in muscle, a population of a-
dystroglycan and a majority of ~-dystroglycan are associated with DP71
and/ or other short forms of dystrophin.
Dystroglycan in cultured neurons and glia
The concentration of the a- and ~-dystroglycan in the synaptosomal
fraction suggests that they cofractionate with synaptic memranes and
may be associated with synapses in vivo. Indeed, immunofluorescent
staining of cultured hippocamal neurons with an antibody directed
against brain a-dystroglycan (cranin) revealed a striking pattern of
staining that colocalizes with synapses (not shown; David Wells, Brown
University) .
The distribution of ~-dystroglycan did not parallel that of a-
dys troglycan however. Immunofluorescent staining with a b-dystroglycan-
specific monoclonal antibody revealed ~-dystroglycan imunoreactivity
throughout glia and hippocampal neurons in a pattern that was not
synapse-specific (Figure 13A). To corroborate this finding, I used
Western blotting to demonstrate large quantities of ~-dystroglycan in
cell lysates from cultured glia (not shown) and hippocamal neurons
(Figure 13B).
4 p58/53 is not a ~-dystroglycan-related protein
In contrast to ~-dystroglycan, pS8/S3 was not detected in glial or
hippocampal neuron lysates. However, pS8/S3 was found associated with
the neuronal detergent insoluble pellet (Figure 13C), while ~-
dystroglycanwas not (riot shown). Interestingly, pS8/S3 was found
specifically concentrated at synapses in the hippocampal neuron
cul tures .
amoun t
Resolved to determine if pS8/53 was a ~-dystroglycan relative, I
the identity of this polypeptide pair. I purified a sufficient
of p58/53 for MADI-TOF analysis and peptide microsequencing.
sought
Database searches with these data revealed that pS8/S3 is a known
protein, Insulin Receptor Tyosine Kinase Substrate pS8/S3, and its cDNA
has been cloned (IRSpS3) (see Chapter II). Sequence analysis exposed a
region of similarly between IRSpS8/53 and ~-dystroglycan that accounts
for their immunologic relatedness. In addition, both proteins possess
proline-rich regions that probably represent WW binding domains. This is
the extent of the similarity between IRSpS8/S3 and ~ dystroglycan,
however.
Discussion
The dystroglycan transcript, which is exressed throughout the
brain, encodes a single propeptide from which both a- and ~-dystroglycan
derive. Although a- and ~-dystroglycan are linked at the level of
translation, it appears that once cleaved into distinct proteins, their
association is customary but not compulsory. As a unit, a/~-dystroglycan
link matrix molecules to dystrophin-like cytoskeletal proteins. As a
complex or individually, the dystroglycans may have additional
associations .
The function of dystroglycan in muscle has been inferred by both
its protein-protein associations , and the cellular consequences of its
decreased expression in disease environments. For the most part,
dystroglycan I s protein associations are similar in brain and in muscle:
dystroglycan binds utrophin, dystrophin, and short dystrophin
isoforms, while its associate, a-dystroglycan, binds types of laminin
or agrin. Thus, one of dystroglycan ' s main biologic functions in muscle
and in some areas of the brain is to anchor cells to the basement
membrane. In many muscular dystrophies, the secondary loss of
dystroglycan contributes to the breakdown of the muscle cell. Thus,
dystroglycan is believed to participate in maintaining the integrity of
the muscle cell memrane. The CNS consequence of these disease states is
more complex, however. To understand the role of dystroglycan in
diseased brains, the associations and function of dystroglycan in the
healthy brain must first be understood.
At some brain sites, including the blood-brain barrier,
dystroglycan maintains typical associations and performs its usual
function, linking the cellular cytoskeleton to the extracellular matrix.
In retina, at the photoreceptor s presynaptic memrane, a/ dystroglycan
and a form of dystrophin colocalize, and appear to form a complex. At
central synapses however, traditional dystroglycan associations may be
abandoned. Here, dystrophin is concentrated at the postsynaptic
apparatus, and a-dystroglycan colocalizes to synapses as well
, in the
absence of detectable ~-dystroglycan. These results indicate that at
brain synapses, neither a-dystroglycan nor full- length dystrophin is
associated with ~-dystroglycan. This atypical situation suggests that a-
and ~-dystroglycan may have functions distinct from their traditional
cell-matrix union work and that there may be dystroglycan associations
that have yet to be uncovered.
A variety of experimental strategies can be used to obtain further
information about dystroglycan ' s role in the brain. To directly assay
the physiologic role of dystroglycan in brain, the new technology of
tissue specific knockout animals is obviously attractive. Using the Cre
recombinase loxP system, with tissue specific, inducible promoters,
transgenic mice can be created that overexpress or underexpress a chosen
gene in a selected tissue during a given time. Careful examination of
the cells, tissue, and behavior of an animal whose brain lacks
dystroglycan is the most direct way to assess the effects of
dystroglycan on CNS development as well as during adulthood. Though this
method is enticing, it is not yet well tested, is labor-intensive, and
may yield nonviable pups or animals without an identifiable mutant
phenotype. Alternatively or additionally, more traditional biochemical,
immunochemical, and molecular methods can be used to establish further
insight into the role of dystroglycan in the brain.
1 A dystroglycan-utrophin complex at the blood-brain
barrier
At the blood-brain barrier, a- and ~-dystroglycan appear to
function in cell-matrix adhesion, linking glial utrophin to larinin in
the epithelial extracellular matrix. It appears that a "utrophin
associated protein complex
" helps to enforce the blood-brain barrier.
One would thus predict a leaky blood-brain boundary in individuals with
the congenital muscular dystrophy caused by mutations in the gene for
the alpha-2 chain of laminin. This hypothesis could be directly tested
by analyzing the integrity of the blood-brain interface in the dy mouse,
which carries a mutation in the gene for the alpha-2 chain of laminin.
since there are many types of laminin, it is likely that other laminins
can partially compensate for the loss of the alpha-2 chain. Thus, in
individuals or mice that lack alpha-2 laminin, the matrix defects may be
subtle. The phenotype exhibited by patients with abnormal expression of
alpha-2 chain indicates that the role of this larinin in brain is
complex.
2 Dystroglycan and DP71: A brain "DAPC"?
The above-mentioned results from experiments using tissue from mdx
and 3CV mice indicate that a population of a- and dystroglycan are
associated with one or more of the short form of dystrophin. Mice
lacking full- length dystrophin (mdx) exhibit normal levels of brain
dystroglycan, whereas mice with diminished expression of all forms of
dystrophin (3CV exhibit a decreased expression of dystroglycan. The
retention of dystroglycan in mdx mice may be partially explained by a
compensation for full- length dystrophin by short dystrophin isoforms.
Alternatively, it may be that dystroglycan does not associate with any
of the full-length dystrophin in brain, and the major dystroglycan-
associated cytoskeletal components are utrophin and short dystrophins
such as DP71.
Indeed, new results indicate that the 3CV mouse is a more
appropriate model than classical mdx for studying the CNS effects of
DMD. This is not surprising in light of the observation that, unlike DMD
patients and 3CV mice, mdx mice have normal ERGs. New data shows that
microsomes isolated from DMD affected brains exhibit greatly reduced
levels of ~-dystroglycan (Finn et al., 1998). This result parallels the
finding that 3CV synaptosomes have decreased levels of ~-dystroglycan
and a-dystroglycan. These results implicate dystroglycan I s relationship
with short dystrophins in the cognitive impairment seen in DMD. One
would thus expect 3CV mice to suffer from mild " cognitive" deficits.
However, no cerebral abnormalities have been identified to date.
In order to pursue the existence of this putative dystroglycan-
DP71 complex in brain, the brain regions and cell types in which the
presumed dystroglycan-DP71 complex exists must be established. In situ
hybridization studies show that DP71 mR is specifically expressed in
the granule cells of the dentate gys in the hippocampus, as well as in
olfactory bulb, cerebral cortex, and the CA-3 region of the hippocampus
(Gorecki and Barnard, 1995). Thus, DP71 and dystroglycan transcripts are
found together in at least the dentate gys and olfactory bulb. Do the
patterns of protein expression overlap as well? Although standard
immunofluorescence studies would be well suited to this task,
distinguishing amongst the dystrophin isoforms is, at present,
difficult. One way to simplify this investigation would be to utilize
tissue from mdx mice. Dystroglycan levels are unaffected in these
mutants and, since full-length dystrophin is not expressed, antibodies
directed against the C-terminus of dystrophin will identify only short
forms. SDS-PAGE can be used to subsequently determine the relative
isoform exression in the region or cell types studied.
Another piece of evidence supporting the existence of a
dystroglycan-DP71 complex exists. When solubilized brain samples are run
on sucrose gradients, the majority of the DP71 and ~-dystroglycan
cofractionate, whereas in liver samples
, only a fraction of the DP71
co fractionates with p-dystroglycan (Greenberg et al., 1996). Despite the
likelihood of a physical interaction between p-dystroglycan and DP71,
coimmunoprecipitation attempts have failed (Greenberg et al. , 1996).
Upon identification of cell types that express both dystroglycan and
DP71, that cultures of these or similar cells can be examined.
Successful coimmunoprecipitation might be accomplished from sources
enriched for these two molecules, such as synaptosomes or an appropriate
cell lysate. It is possible that ~-dystroglycan associates with other
short forms of dystrophin such as DP140, instead of or in addition to
DP71. As mentioned, the antibodies that recognize the C-terminus of
dystrophin canot distinguish amongst the short isoforms. Thus,
isolation of a native dystroglycan-dystrophin isoform complex would
verify which of the isoforms interacts with dystroglycan, since the
molecular weight of the dystrophin form can be determined by SDS-PAGE.
Methods for the isolation of such a complex are discussed below.
What is the role of a dystroglycan-DP71 complex in the brain?
Although the absence of short dystrophins in causes abnorml retinal
findings, in 3CV no additional CNS dysfunctions have been identified.
When this brain complex is disrupted in 3CV, what is the consequence?
These mice must be carefully examined and compared to 
mdx and norml
mice in behavioral and learning paradigms. In addition, the subcellular
expression of dystroglycan and DP71 (DP140) in norml and affected cells
must be examined. Primary neuronal and glial cultures from dystrophin
mutant mice (mdx and 3CV or from their heterozygous litter mates (which
express both dystrophin positive and negative cells) can be generated.
Using this system, the glial as well as synaptic and nonsynaptic
expression of a- and dystroglycan, full-length dystrophin, and short
dystrophin isoforms can be compared in normal and affected cells.
Does this putative dystroglycan-DP71 complex represent the core of
a brain DAPC? Although one expects the DAPC to be recapitulated
centrally, such a complex has not yet been isolated from brain.
Standardly, the DAPC is isolated from muscle extracts using affinity
chromatography (WGA) methods. Presumably, these techniques can be
optimized to isolate dystroglycan-DP71 complexes from brain fractions
such as synaptosomes, or from cell cultures of neurons or glial cells.
Similarly, immunoaffinity chromatography might yield a non denatured
dystroglycan-dystrophin isoform complex. Successful biochemical
isolation of a dystroglycan-DP71 complex from brain would indicate
whether or not a brain DAPC that resemles the muscle DAPC exists.
Indeed, the identification of any brain proteins that associate with
dystroglycan and DP71 would shed light on this current question.
It may be that the complex formed by dystroglycan-DP71 and
associated proteins canot withstand biochemical isolation. If this is
the case, then associated proteins must be identified individually.
Overlay methods are commonly used to successfully identify binding
proteins for a protein of interest. It is often difficult to uncover
interacting brain proteins because of the complexity of this protein
source. On a standard protein blot of brain homogenate, many bands will
appear to bind a protein such as dystrophin. To successfully identify
brain proteins that specifically interact with dystroglycans or
dystrophins, the complexity of the protein source must be lessened. One
way to achieve this end employs standard biochemcal techniques.
Synaptosomes represent a brain protein source that is likely to be
concentrated for proteins which interact with synaptic dystrophin forms.
The powerful separation technique of two dimensional (2D) gel
electrophoresis can then be used to increase the electrophoretic
resolution of the synaptosome fraction (see chapter II). One might
successfully identify brain DAPC memers by probing a blot of
synaptosomes, separated by 2D gel electrophoresis, for protein spots
which bind dystroglycan and/or form of dystrophin. since 2D separated
proteins have a characteristic shape and isoelectric mobility, binding
proteins exposed in this way would be readily identified.
Alternatively, valuable information about dystroglycan ' s protein-
protein interactions might be obtained through the use of molecular
methods. The yeast two hybrid assay has been used extensively by many
labs to screen muscle cDNA libraries for interactions among DAPC
proteins. In this case, one would screen a brain cDNA library for
protein fragments that interact with regions of dystroglycan and/or
DP71. A cDNA that interacts with one of these "baits " may represent a
novel protein, or may encode a brain protein that had not yet been
appreciated as a dystroglycan or DP71 binding partner. Identification of
dystrophin-DP71 associated proteins would provide valuable information
about the nature of this alliance.
Dystroglycan at central synapses
It is increasingly evident that in many regions of the CNS, a/~-
dystroglycan interacts with short forms of dystrophin, including DP240,
DP140, and DP71. In retina, this complex has been implicated in healthy
retinal synaptic transmission. In brain homogenate and synaptosomes,
there are substantial amounts of both dystroglycan and DP71, and a
similar complex is now thought to exist in vivo in some regions of the
brain. In the DMD and 3CV (but not mdx) genotypes, the level of brain
dystroglycan expression is affected, indicating that dystroglycan and
forms of dystrophin are likely to interact. Additionally, the CNS
component of many muscular dystrophies suggests a role for dystroglycan
in cognition. Dystroglycan appears to have many roles in the CNS. Of
these however, its role in neurons is the most mysterious.
Large amounts of ~-dystroglycan are produced by rat hippocampal
neurons in culture. Does neuronal dystroglycan have a role at synapses?
Indeed, dystroglycan appears to be engaged in atypical associations at
central synapses. Here, the localization, makeup, and perhaps function
of dystroglycan and its associated proteins is altered. The results
presented above show that at synapses, ~-dystroglycan is not detected,
while a-dystroglycan and full-length dystrophin are colocalized. One
surprising conclusion may be that synaptic a-dystroglycan does not
associate with ~-dystroglycan, and ~-dystroglycan does not associate
with full-length dystrophin. This would suggest that, individually, a-
and ~-dystroglycan may find alternate associations and have distinct
functions. The observation that a- and ~-dystroglycan do not coexist at
synapses must be validated with further investigation, since this is the
first instance in which a- and ~-dystroglycan are not found together. Is
the synapse site extraordinary, or are there other sites in which a-
and p-dystroglycan do not coexist? Often, evidence for the presence of
one dystroglycan species has been considered sufficient proof that the
other is present as well. Now, at all sites, both a- and ~-dystroglycan
must be accounted for before it is concluded that the two coexist.
What is the role of DAPs at synapses? In the healthy brain,
dystrophin is localized to the postsynaptic apparatus, and a-
dystroglycan colocalizes with dystrophin at synapses in vivo. First, the
role of dystrophin at synapses can be examined. In 
mdx mice, disruption
of full- length dystrophin expression may affect memory. At 
mdx synapses,
is dystrophin replaced by an alternate such as DP71 or utrophin? What
are the physical or functional consequences from the absence of
dystrophin s N-terminus in mdx? If compensation does occur, mice that
express no dystrophins (3CV) or neither dystrophin nor utrophin
(mdx/utrophin null) must be examined for functional synapses. To achieve
this, neurons from mutant mice can be grown in culture, and the
development of spines and the function of the synapses can be assayed.
Both a- and ~-dystroglycan are associated with the synaptosomal
subcellular fraction. At least two explanations for this finding must be
considered. High levels of ~-dystroglycan have been demonstrated in the
pia mater layer of the brain (see above). If memranous pial material
co-fractionates with synaptic memranes in the synaptosomal fraction
this subset of brain a-dystroglycan may be that associated with pial ~-
dystroglycan. This question could be answered by comparing the standard
synaptosome preparation to one that includes a simple filtering step to
trap the pial material.
Alternatively, ~-dystroglycan may be associate with a subset of a-
dystroglycan at a synaptic location. Interestingly, only a-dystroglycan
is concentrated at synapses in culture. This synaptic population of a-
dystroglycan may correspond to the small subpopulation of a-
dystroglycan that associates with the PSD fraction. What is the role of
the synaptic a-dystroglycan? There is not yet enough data to form a
convincing conclusion. Currently there is no evidence for an agrin
activated, brain specific kinase analogous to MuSK. However, blot
immobilized brain a-dystroglycan has the capacity to bind in vitro
expressed agrin(o, O) and agrin(4, 8). Interestingly, the pattern of a-
dystroglycan immunostaining on cultured hippocampal neurons overlaps the
pattern of agrin(4 8) binding sites, but not that of agrin(o, O) binding
sites. Demonstration of a physical or functional association between
neuronal agrin and a-dystroglycan has yet to be firmly established,
however.
In some way, a-dystroglycan is associated with the synaptic
memrane. Whether this association is pre- or postsynaptic could be
resolved with immuno-electron microscopy, as it was for dystrophin. More
importantly perhaps, is the question of whether or not synaptic a-
dystroglycan and dystrophin are functionally linked. Although there is
no apparent change in the level of a-dystroglycan expression in brains
from mice that lack dystrophin (mdx) , it may be that only a very small
population of a-dystroglycan associates with dystrophin. Thus, synapses
from these mutants must be assayed for the presence of a-dystroglycan.
If a-dystroglycan remains associated with the synapse in the
absence of dystrophin, there is little reason to suspect that the two
are physically linked. Otherwise, a fascinating question arises: what
links a-dystroglycan and dystrophin if not dystroglycan? The
successful isolation of a synaptic dystrophin complex or the
identification of new a-dystroglycan or dystrophin interacting proteins
might resolve this question. The C-terminus of dystrophin contains a WW
domain, a protein-protein interaction module. This region is distinct
from dystrophin ' s dystroglycan binding site. Dystrophin has a site
available for interaction with the proline-rich (WW binding) region of a
potential binding protein. To date, no proteins have been identified
that interact with dystrophin ' s WW domain. This region of dystrophin
therefore represents a potentially fruitful bait for the yeast two
hybrid assay.
Although a-dystroglycan and dystrophin are each associated with
synapses, a relationship between the two has not been established. If
there is a physical association, the mechanism by which this occurs
remains unknown; the traditional physical link, dystroglycan, is
missing at synapses. Could there be a ~-dystroglycan-like protein at
synapses? Seemingly not. The Northern analysis and a cDNA library screen
presented above provided no evidence for brain-specific splice forms of
dystroglycan. Two proteins that are immunologically related to ~-
dystroglycan have been identified in the PSD fraction. Mumery et al.
describe a 164 kDa protein in PSD fractions that is recognized by a ~-
dystroglycan antibody (Mumery et al., 1996). No further similarities
between the 164 kDa PSD polypeptide and dystroglycan have been shown
since, however. I have identified the PSD polypeptide pair, pS8/S3, that
is bound by our ~-dystroglycan antiseru and determned that it is
decidedly not a dystroglycan-like protein.
Novel dystroglycan associations
There may be dystroglycan binding partners that have yet to be
realized at synapses, as well as at nonsynaptic sites. One potential
dystroglycan associated protein may be fukutin, the product of the FCM
disease gene. In muscle, a functional association between dystroglycan
and fukutin is probable. Muscle levels of ~-dystroglycan and laminin
alpha-2 chain are reduced when fukutin is absent, and the basal lamina
surrounding the muscle is abnorml. Fukutin is expressed in brain too,
where the basal lamina of FCM brain is similarly disrupted (Hayashi et
al., 1993; Matsumura et al.
, 1993).
If indeed an association between dystroglycan and this novel
protein is established in vitro and in vivo, a new role for dystroglycan
in muscle and brain may emerge. Antibodies specific for fukutin have not
yet been successfully generated. Once this tool is available, the
pattern of overlap between fukutin and dystroglycan expression can be
determined and perhaps a fukutin protein complex can be isolated. Then,
an examination of the effect of fukutin deficiency on dystroglycan
expression in brain may indicate a relationship between dystroglycan and
fukutin. The identification of any fukutin-associated proteins will
further our knowledge about how fukutin deficiency causes the CNS
abnormalities seen in FCM. The potential association between fukutin
and dystroglycan is intriguing. If dystroglycan-fukutin associations are
detected, the understanding of one of dystroglycan
' s roles in the brain
will advance significantly.
Conclusion
The functions of dystroglycan in the brain and at synapses remain
largely undiscovered. It seem likely that in the brain, alternative
associations occur among proteins known to interact with dystroglycan.
As information regarding the cellular and subcellular brain expression
profiles of proteins such as DAPC memers and agrin are obtained, the
functions of these proteins in the brain can be considered. Further
studies of disease phenotypes such as FCM should provide insights
concerning the function of affected gene products and their partners.
Brain specific dystroglycan knockouts are likely to provide functional
information as well. The presence of CNS pathologies in a variety of
muscular dystrophies, and the potential nontraditional associations of
dystroglycan in the brain and at synapses, suggest that an understanding
of dystroglycan ' s role in the brain will provide deep insights into
brain development and function.
Tables and Figures
1 Figure Legends
Figure 1. Dystroglycan
The dystroglycan coding sequence includes two exons separated by one
large intron. The dystroglycan mR is 5. 8 kb. The regions of the
transcript that correspond to the two DNA probes (probe1 and probe3)
used for the Northern blotting and cDNA library screen (discussed in
Results) are indicated. The dystroglycan transcript encodes a 97 kDa
precursor protein that undergoes posttranslational modifications
including cleavage and carbohydrate additions. a-dystroglycan contains
a short signal peptide and a mucin-like region in its midsection. Other
sites of potential glycosylation and glycosarinoglycan (GAG) additions
are indicated. dystroglycan ' s transmemrane region is noted. Within
its intracellular C-terminus are binding sites for rapsyn and
dystrophin. regions. The C-terminal regions that correspond to the
peptides against which the polyclonal antiseru Ab98 and the monoclonal
antibody NCL-43DAG are directed are indicated.
Figure 2. The Dystrophin Associated Protein Complex (DAPC)
The details of the DAPC, as well as the differences between the
extrajunctional (A) and the NM (B) complex, continue to be elucidated.
The following represents the current understanding of these complexes.
Along the muscle memrane, dystrophin, an actin binding cytoskeletal
molecule, associates with the DAPC memers, while at the neuromuscular
junction, a similar complex associates with the dystrophin related
protein utrophin. a-dystroglycan (also known as the 156 kDa Dystrophin
Associated Glycoprotein, lS6DAG) and ~-dystroglycan (43DAG) are
expressed in many tissues and form the dystroglycan complex (DG). The
memers of the sarcoglycan complex (SG) are expressed in skeletal and
cardiac muscle and include alpha SG (also known as adhalin and SODAG),
beta SG (A3b, 43DAG, the only SG expressed in brain), gam SG (35DAG),
and delta SG. Recently, the cardiac-specific epsilon SG was identified.
There are at least three 59 kDa syntrophins, with different patterns of
expression. Alpha syntrophin is expressed only in muscle, beta1
syntrophin is ubiquitously expressed, and beta2 syntrophin is restricted
to the NM. Two major dystrobrevins (also known as AD or tOrPedo 87
kDa), alpha and beta, head a family of dystrobrevin isoforms with
varying tissue expressions. Dystrobrevin containing a phosphotyrosine
tail (PYCT) is specifically localized to the NM. Neuronal nitric oxide
synthase (nNOS) is a DAPC memer as well. In fast twitch myofibers, a1
and/or b1 syntrophin bind nNOS. Slow twitch myofibers lack nNOS. Other
dystrophin associated molecules include caveolin and the transmemrane
sarcospan.
Figure 3. Dystrophin and Isoforms
The dystrophin gene (white rectangle) comprises 2. 4 million bases of the
chromosome and has 79 exons (note that there are three different
promoter-specific first exons, B1 , M1, and PI, each encoding a full-
length dystrophin). A total of seven promoters (arrows) have been
identified. Thus, the dystrophin gene encodes dystrophins of 427 kDa,
260 kDa, 140 kDa, 116 kDa, and 71 kDa. Protein domains include the N-
terminal actin binding domain, present only in full-length forms and the
rod domain, present in all but DP71.
Figure 4. Dystroglycan in Retina: Outer Plexiform Layer
dystroglycan interacts with one of the short dystrophin isoform in
the presynaptic memrane of photoreceptor cells. a- and ~-dystroglycan
and a short dystrophin are found along the intracavital processes of the
photoreceptor that form the lateral boundary of the synaptic cavity but
not at the postsynaptic triad.
Figure 5. Dystroglycan at the Blood-Brain Barrier
This schemtic depicts likely dystroglycan associations at the blood
brain barrier. A dystroglycan complex is found at brain-penetrating
blood vessels and the pial surface. p-dystroglycan and utrophin localize
to the perivascular endfeet of glial cells, and a-dystroglycan
associates with the basement memrane of brain blood vessels.
Figure 6. Dystroglycan at Central Synapses
Unlike at the photoreceptor OPL, dystrophin is associated with the
postsynaptic (and not presynaptic) specializations of cortical neurons
and is concentrated in mouse and human brain postsynaptic density
fractions. a-dystroglycan immunoreactivity appears on the surface of
Purkinje cell bodies, dendrites, and dendritic spines. ~-dystroglycan
immunoreactivity is not detected in these localizations, however.
Figure 7. Northern Blot analysis of dystroglycan rnAs
Northern blots of human tissues and brain regions were probed with
probe1 and probe3, which correspond to the proximal and distal C-
terminal regions of dystroglycan, respectively (see Figure 1). Both
probes hybridized to an approximately 6 kb mR that was highly
expressed in all tissues and brain regions. Hybridization with probe 1 ,
but not with probe3, reveals a larger transcript (over 10 kb), in
cerebral cortex as well as occipital and frontal lobe.
Figure 8. Rat brain cDNA library screen " contig
From a rat brain cDNA library, 15 phage that contained uniquely-sized
cDNA inserts to which probe1 but not probe3 hybridized were isolated and
sequenced. Using the Sequencher software, each of the phage insert
sequences was compared to the mouse dystroglycan cDNA (DAG1). Each
sequence obtained was found to be identical to a region of the DAG1
cDNA. The location of each of insert-DAG1 homologies is depicted
graphically in this " contig. II Epitope1 = probe1, epitope3 = probe3.
Figure 9. Brain subcellular fraction proteins
A. Subcellular fractions (H, homogenate; SX, synaptosomes; PSD
postsynaptic densities) were separated by SDS-PAGE and protein stained
(CB) , revealing enrichment for many proteins in the PSD fraction.
B. Western blots (WE) of subcellular fractions were probed with
antibodies against presynaptic components (synaptophysin) and components
of the postsynaptic density, including the NMAR1 subunit, the mR
3 ' UTR binding protein CPEB , and aCaMII.
Figure 10. a/~-dystroglycan distribution in subcellular fractions
A. Ligand overlay with agrin isoforms on blots of subcellular fractions
reveals that a-dystroglycan is present in brain homogenate (H),
concentrated in the synaptosome fraction (S), and is detectable in the
PSD fraction (PSD). The binding of the agrin (0, 0) isoforr exceeds the
binding of agrin (4, 8) .
B. Western blots of subcellular fractions were probed with ~-
dystroglycan antibody Ab98. ~-dystroglycan is present in brain
homogenate and is concentrated in the synaptosomal fraction in
subcellular fractions isolated from rat cortex (as well as from brain
ster, cerebellum, and hippocampus, not shown). Ab98 also recognizes a
pair of polypeptides that are selectively enriched in the PSD fraction,
p58/53.
C. Western blots of synaptosomal fractions prepared from brain stem
(BS), cerebellum (CB), and hippocampus (HP) were probed with NCL-43DAG.
Different amounts of ~-dystroglycan are detected in each of the regional
synaptosomal fractions examined (equal protein loading) 
Figure 11. Comparison of dystrophin, DP71, and ~-dystroglycan
distribution in subcellular fractions. Equivalent western blots probed
with DYS2 (A) or NCL-43DAG (B). Whereas full- length dystrophin is
concentrated in the PSD fraction, ~-dystroglycan and DP71 are
concentrated in the synaptosome fraction. (M, muscle extract)
Figure 12. a- and p- dystroglycan expression in. mdx, 3CV and control
mice brain fractions.
Ligand overlay with agrin(o, O) shows that the level of a-dystroglycan
(aD) in 3CV synaptosomes is similar to control. Western blot with the
antibody NCL- 43DAG shows diminished dystroglycan DG) expression in
fractions isolated from 3CV mouse brain.
Figure 13. dystroglycan in glia and hippocampal neurons and lysates
A. Inverse images of immunofluorescent staining with anti ~-
dystroglycan antibody NCL-43DAG reveals ~-dystroglycan immunoreactivity
throughout glia and hippocampal neurons. This pattern is not synapse-
specific.
B. Western analysis of cell lysates from cultured hippocampal neurons
shows large quantities of soluble ~-dystroglycan.
C. Western analysis with Ab98 comparing the p58/53 in the detergent-
insoluble pellet from hippocampal neuronal cell lysate to PSDs.
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CHAPTER I I
INSULIN RECEPTOR TYROSINE KINASE SUBSTRATE p58/53 AND
INSULIN RECEPTOR ARE COMPONENTS OF THE SYNAPSE
Introduct ion
I have characterized the protein IRSpS8/S3, a known substrate of
the insulin receptor tyrosine kinase, and determined that it is
selectively concentrated in the rat brain postsynaptic density (PSD)
fraction, is localized to the synapse-rich layers of the cerebellum, and
is concentrated at synapses in cultured hippocampal neurons. The insulin
receptor is also concentrated at synapses in cultured hippocampal
neurons. In addition, I have found that a population of brain insulin
receptors is localized to the postsynaptic density fraction. I expect
that other components of a synaptic insulin receptor pathway will be
found at the postsynaptic apparatus in vivo, and a regulatory role for
insulin signaling at the central synapses will emerge.
Background
The importance of peripheral insulin as a regulator of the body
energy balance is undisputed. More contested however, is the consequence
of insulin in the brain. Whereas the signaling pathways that execute the
biological effects of insulin in the periphery are quickly being
dissected, the mere presence of insulin signaling systems in the brain
has not been appreciated until recently. A brief overview follows of
insulin-dependent signaling pathways and their biologic consequences in
peripheral tissues, the current understanding of these systems in the
brain, as well as a review of the central synaptic signaling apparatus
that lies below the postsynaptic memrane of glutamatergic synapses, the
postsynaptic density (PSD).
1 Insulin Signaling Peripheral Tissues
Insulin plays an essential role in the regulation of the body
glucose metabolism. An increase in the level of circulating glucose
causes pancreatic beta cells to release the anabolic hormone insulin
into the bloodstream. Insulin stimulates the uptake of glucose into
muscle, liver, and adipose cells, and the synthesis of protein,
glycogen, and triglycerides in these cells. At these target cells,
insulin initiates a series of signaling events that result in multiple
biologic outcomes. In target cells that express the GLUT4 glucose
transporter, insulin dependent signaling processes lead to a
translocation of GLUT4 from intracellular sites to the plasma memrane,
enabling the cell to rapidly import circulating glucose. Insulin can
have other types of cellular effects as well, such as affecting gene
transcription. For example, chronically low insulin states, such as in
insulin dependent diabetes or during sustained fasting, lead to a
reduced expression of the gene that encodes GLUT4.
1 Insulin and Diabetes
Close to 5% of the United States ' population suffer from diabetes.
This chronic disease is characterized by hyperglycemia (high levels of
circulating glucose), a condition that can adversely affect virtually
every organ in the body. At the cellular level, diabetes is caused by
target cells ' insufficient response to insulin. Despite high levels of
circulating glucose, the absence of effective insulin causes glucose
uptake by target cells to dwindle. This shifts the body into a catabolic
state wherein protein, glycogen, and fat are broken down. Chronic
hyperglycemia and inappropriate catalysis have harmful effects on the
body. Complications of diabetes can include nephropathy which can lead
to kidney failure, retinopathy which can lead to blindness, neuropathy
and extensive vascular disease which can lead to limb amputation.
Diabetes is caused by either an absolute deficiency of insulin
secretion (type I or insulin-dependent diabetes mellitus (IDDM)) or
resistance of peripheral target tissues to insulin (type II, or non-
insulin-dependent diabetes mellitus (NIDDM)). IDDM develops following
the destruction of the insulin-producing beta cells by auto-antibodies.
The cause of the beta cell autoimmunity is unknown. Once more than 90%
of an individual' s beta cells have been destroyed, diabetes becomes
clinically apparent. Patients with IDDM require exogenously supplied
insulin to maintain their body I s homeostasis.
It is NIDDM that accounts for -90% of the diabetes cases in the
United States. In these patients, despite sufficient insulin secretion,
the effects of insulin on target tissues are blunted. Often, even
elevated levels of insulin are unable to maintain the body s normal
glucose levels, and a state of relative insulin deficiency results.
Unlike IDDM patients, NIDDM patients do not depend on exogenous insulin.
For many type II diabtics, their condition can be greatly or even
completely overcome by weight loss and diet control. Some patients
however canot control their diabetes in this way, and they require
treatment with oral hypoglycemic agents or even insulin injections
(Lieberman, 1996). The cause of type II diabetes is not yet well
understood and is likely to involve many levels of insulin s signaling
pathways.
2 The Insulin Rece tor is a Rece tor osine Kinase
For insulin to achieve its biological effects, it must bind to a
functional insulin receptor on the surface of the target cell. The human
insulin receptor (IR), cloned in 1985 (Ullrich et al., 1985), is one of
a large family of growth factor receptors. Generally speaking, these
receptors are group I memrane proteins. They span the cell memrane
once, the N-terminal protein domain is on the extracellular side of the
memrane, and the C-terminus is on the cytoplasmic side of the memrane.
Some growth factor receptors are single polypeptides, like the epidermal
growth factor (EGF) receptor. Others, including the insulin receptor,
are disulfide bonded dimers (Figure 1). Some of these receptors have
phosphatase activity, and all of them possess protein kinase activity.
Protein kinases transfer phosphate groups onto their target
proteins. They exist either within the memrane, as receptor protein
kinases, or within the cytoplasm as cytosolic protein kinases. There are
two major types of kinases, categorized by the amino acids on which they
phosphorylate their target proteins. The majority of the receptor
kinases, including EGF and insulin receptors, phosphorylate substrates
tyrosines. More than 50 receptor tyrosine kinases (RTKs) are known.
Al though there are many cytosolic tyrosine kinases, and some dual
specificity cytosolic kinases, serine/threonine kinases are the most
common type of cytosolic kinases, and are responsible for the maj ori ty
of cellular phosphorylation events. In addition, tyrosine and
serine/threonine phosphatases are available to reverse the
phosphorylation events procured by RTKs.
Enzymatic activity can activate two types of signaling pathways.
For one, small second messengers can be activated by phospholipases,
which cleave lipids from larger substrates, or kinases, which
phosphorylate lipids. phosphatidyl inositol 3' kinase (PI3-K) works by
phosphorylating the lipid inositol. Alternatively, enzymatic activation
can initiate a cascade of interacting proteins. Usually, these proteins
are kinases, each activating the next by phosphorylating it. The
ultimate kinase in the relay typically acts on proteins that elicit
global changes in the cell, such as transcription factors. These
signaling pathways amplify the initial stimulus as it passes from one
component to the next. If a component of the pathway has multiple
downstream targets, the signal may branch into multiple pathways. In
this way, an initial stimulus can elicit diverse biologic responses
(Lewin, 1997).
The insulin receptor is very similar in size and structure to the
insulin-like growth factor-I receptor (IGF-I) and the insulin-receptor
related receptor. These receptors have some affinity for each other
ligands, but the insulin receptor exhibits a pharmacological preference
for insulin. The insulin receptor is a dimer of units each composed of
an a and a ~ subunit linked together by disulfide bonds. The
extracellular a subunit contains the ligand binding domain and the ~
subunit, a group I memrane protein, comprises a short extracellular
domain and the cytoplasmic tyrosine kinase activity (Fujita-Yamaguchi,
1984) (Figure 1).
When insulin binds to the extracellular domain of its receptor, it
induces a conformational change that affects the overall organization of
the receptor, which activates the kinase activity of the cytoplasmic
domains. The receptor then autophosphorylates; the kinase activity of
one subunit phosphorylates the other, and vice versa.
Autophosphorylation has at least two consequences. For one,
phosphorylation within the receptor s kinase region can increase its
catalytic activity. Alternatively, receptor phosphorylation at other
cytoplasmic tyrosine residues leads to transfer of the signal to
downstream components as target proteins associate with these
phosphorylated tyrosines of the receptor s cytoplasmic domains. The
quintessent function of RTKs is tyrosine phosphorylation; a receptor
with a mutated kinase domain is biologically inactive, despite its
preserved ability to bind ligand (Lewin, 1997).
Activated receptors may interact with several types of signaling
proteins. In one type of association, a target protein is activated by
binding the intracellular domain of the receptor, but is not
phosphorylated. This tethered target protein then activates an enzyme,
which amplifies and continues the pathway. Second, proteins that are
substrates of the receptor s kinase activity can bind to and become
phosphorylated by the receptor. If the substrate itself is a kinase,
this phosphorylation event may activate it, and in turn the pathway will
proceed by activating successive kinases. Finally, some receptor
substrates, such as a cytoskeletal proteins, are end targets of the
pathway. Phosphorylation of such proteins alters their physical state
and leads to assemly of a new structure.
3 Insulin s actions are mediated dockincr Droteins
In many cases, the primary interaction between signaling proteins
and an activated receptor kinase is mediated by SH2 domains. Either the
autophosphorylated tyrosines bind grc homology 2 (SH2) domains of
signaling proteins, or the increased activity of the kinase mediates
tyrosine phosphorylation of cytosolic substrates known as "docking
proteins " that recruit SH2 proteins. The signaling pathway is continued
through other protein-protein or protein-lipid interaction domains
including 2hosphotYosine inding (PTB) and 2leckstrin homology (PH),
grc homology 3 (SH3) , PDZ, and WW domains (see below). The first
identified memer of this famly of proteins, which link RTKs to
downstream signaling molecules, is the insulin receptor substrate, IRS-
(White and Yenush, 1998) (Figure 2).
These functionally-related docking proteins, IRS-I, IRS-2, and
IRS-3, and Gab-1 and p62dok, share several protein motifs. At the N-
terminus is a PH and/or PTB domain; at their C-terminus are proline-rich
regions which mediate binding of SH3 or WW domains, multiple tyrosine-
containing sequences which can bind SH2 domains, and serine/threonine-
rich regions which may regulate function as well. Shc is a memer of
another group of docking proteins. It has an N- terminal PTB domain, a
C-terminal SH2 domain, a proline-rich region, and a few phosphotyrosine
sites through which it binds the SH2 domain of Grb2. SH2 domains mediate
high affinity interactions, close to three orders of magnitude tighter
than the usual kinase substrate interaction. Tyically, the site that
binds an SH2 domain contains only a phosphotyrosine and a few amino
acids C-terminal to it. Whereas Shc interacts with the insulin receptor
by its PTB domain, its SH2 domain allows Shc to interact with another
RTK, the activated EGF receptor.
Docking proteins are useful for coordinating flexible and diverse
signaling systems. Receptors that specifically interact with IRS
proteins can achieve an amplified signal: since the docking interaction
is transient, many IRS proteins can be phosphorylated by one receptor.
In addition, they escape the fate of internalization that is likely to
await ligand-bound receptors, and can carry the signal to downstream
signaling components. Lastly, many receptors have the specificities to
engage different IRS proteins. By engaging multiple pathways, one
receptor can initiate diverse signals. Similarly, different RTKs share
specifici ties for the same IRS proteins. This allows for the integration
of multiple signals (White and Yenush, 1998).
The biologic effect of insulin and insulin receptor substrates is
dependent on a specific insulin receptor motif. A decade ago, the
importance of the juxtamemrane NPXY motif of the insulin receptor was
revealed: mutations here reduce the tyrosine phosphorylation of IRS-
while diminishing insulin I s biologic effects. It is now understood that
the tyrosine phosphorylated NPXY motif can bind PTB domains. In fact,
many IRS proteins achieve specific and transient docking through their
PTB domain. This domain binds weakly but specifically to the
phosphorylated NPXY motifs of the insulin receptor, the IGF-1 receptor,
and the IL-4 receptor. The interaction of several residues N-terrinal to
the NPXY motif adds specificity to individual PTB:NPXY associations.
In addition to the PTB domain, this family of docking proteins
utilizes another protein motif in its interactions with RTKs. The PH
domain of IRS-1 is important for its interaction with the insulin
receptor. The PH motif is similar to the PTB domain, yet its specific
three dimensional structure cannot be predicted based by primary amino
acid sequence alone. PH domains bind a diverse set of ligands, yet this
motif does not bind the insulin receptor directly, suggesting that other
docking protein domains participate in this interaction. The presence of
IRS- 1' s PH domain and not its PTB domain is sufficient for its
activation by the activated insulin receptor. However, IRS- 1 lacking its
PH domain undergoes little tyrosine phosphorylation following insulin
s timula tion.
Activated IRS proteins generate downstream signals by engaging SH2
domains of other signaling proteins. IRS-1 interacts with PI3-K, as well
as with others including Grb2, SHP2, Fy, and a numer of proteins that
do not contain SH2 domains, including 14- 3. IRS-1 and PI3-K are
implicated in many biologic effects including insulin-stimulated
translocation of GLUT4 and subsequent glucose transport (Figure 3). The
heterodimer PI3-K: is composed of an 85 kDa regulatory subunit and a 110
kDa catalytic subunit. The p85 subunit contains an SH2 domain that binds
phosphotyrosine residues of IRS-1. This interaction causes activation of
the associated catalytic subunit' s kinase activity and phosphorylation
the 3 I position on inositol molecules. since IRS-1 and IRS-2 contain
about nine phosphotyrosine motifs with which to bind SH2 domains, and
PI3-K activation is maximal when both of the p85 SH2 domains are bound,
these IRS proteins are ideal for signal transmission via PI3-K.
IRS-1 also interacts with the phosphotyrosine phosphatase SHP2,
which contains two SH2 domains. During insulin stimulation, SHP2 binds
IRS-1 as well as the insulin receptor itself. It is likely that SHP2
regulates insulin signaling. SHP2 may diminish the insulin signal by
reversing the tyrosine phosphorylation of IRS-I. SHP2 may be important
for some downstream insulin signaling events: when Shpt' s phosphatase
activity is inactivated, insulin stimulated MAP Kinase and c- fos
transcription is disrupted (White and Yenush, 1998).
Insulin stimulation is linked to intranuclear events by Grb2, a
small, SH2 containing adapter molecule. Tyosine phosphorylated docking
proteins IRS-lor Shc bind Grb2. Once associated, the Shc/Grb2 complex
recruits SOS, a Ras guanylnucleotide exchange factor, to the memrane
through one of Grb2' s two SH3 domains. SOS can then interact with Ras, a
small GTP-binding protein which is confined to the memrane, causing 
to exchange its GDP for GTP and regain its activated state. Activated
Ras can then react with its target molecule. The signaling component
that follows Ras in this signaling pathway is the cytosolic
serine/threonine kinase Raf. It is known that ras and Raf interact at
the memrane, but the events that cause the activation of Raf are
unknown. Raf directly phosphorylates two serine residues on ME, a dual
specificity cytosolic kinase. The activation of ME represents a point
where pathways can converge. ME Kinase, which is activated by G
proteins, can activate ME as well. Activation of MAP Kinase, a
serine/threonine kinase with several targets, requires both tyrosine and
threonine phosphorylation by MEK. From this step on, the cascade
continues along various branches through serine threonine
phosphorylation events. Ultimately, this pathway of kinases activate or
inactivate nuclear transcription factors which can modulate
transcription events.
It is clear that subcellular localization plays an important role
in executing signaling pathways. Components require close proximity for
interaction. IRS- (pp60), like IRS-1 and IRS-2, has a PH and a PTB
domain and phosphotyrosine motifs that interact with the SH2 domains of
PI3-kinase and Grb2, yet IRS-3 is much smaller than its relatives and
has regions of sequence dissimilar from IRS-1/2. Interestingly, IRS-
exhibits a different subcellular distribution than IRS-1/2. In rat
adipocytes, IRS-1/2 are primarily associated with the low density
microsome and cytosol fractions, yet IRS-3 remains associated with the
plasma memrane fraction (Anai et al., 1998).
It is clear that insulin accomplishes its many biologic effects by
employing an array of substrates, diverse in their domain structure,
binding specificities, and their cellular and subcellular localizations,
to initiate a variety of complex signaling pathways.
2 . 1. 4 IRS and Dia etes
The relationship between insulin signaling components and NIDDM is
not well understood. Persons who express one of the known IRS-
polymorphisms are twice as likely to develop type II diabetes as control
individuals (Laakso et al., 1994), yet in mice, the absence of IRS-
does not lead to type II diabetes. Mice lacking IRS-1 are only mildly
insulin resistant, since insulin secretion increases to compensate for
the resistance (Araki et al., 1994; Taremoto et al., 1994). The
functional relationship between the insulin receptor and its substrate
IRS-1 may have a role in type II diabetes however.
Mice that are double heterozygous for null alleles in both the
insulin receptor and IRS-1 genes are, at birth, slightly more insulin
resistant that mice heterozygous for either the enzyme or substrate
alone. During their first 4-6 months however, about half of these mice
develop type II diabetes (Bruing et al., 1997). This is one piece of
evidence for the importance of the enzyme-substrate relationship between
the insulin receptor and insulin receptor substrates in glucose
metabolism.
IRS- 1 and IRS-2 are highly homologous, yet have different
interactions with activated insulin receptors and distinct tyrosine
phosphorylation motifs in their C-termini (Miele et al., 1999). These
findings portend unique signaling patterns for these insulin receptor
substrates. Indeed, recent work has shown that disrUption of IRS-
causes diabetes in mice. These mice suffer progressive deterioration of
glucose homeostasis and, at 10-16 weeks of age, develop severe NIDDM due
to end-tissue insulin resistance and beta cell failure (Withers et al.,
1998) .
Mutations in insulin signaling at more than one level may
contribute to the development of diabetes in some individuals. Despite
much research, the genes responsible for the majority of NIDDM cases
have not yet been identified (Kah, 1998).
Insulin Signaling in the Brain
The presence of insulin in the CNS was first recognized two
decades ago by immunohistochemical staining of the brain with anti-
insulin antibodies (Havrankova et al., 1978). Later studies documented
the expression of insulin in neurons (Darn et al., 1981). The relevance
of insulin signaling in the brain suffered years of controversy however,
primarily because the origin of this brain insulin was disputed.
Substantial evidence now exists for the transport of peripheral insulin
across the blood-brain barrier by GLUT1 and GLUT3 (Frank et al., 1986;
Duffy and Pardridge, 1987; Pardridge et al., 1990) as well as for the
local production of insulin in neurons (Clarke et al., 1986; Young,
1986; Wozniak et al., 1993). Today, the distributions of components of
the insulin signaling pathways are being characterized, and the effects
of insulin on the brain and on neuronal cells in culture are being
dissected. The consequence of insulin in the brain has yet to be
elucidated, however.
2 . 2 . 1 The Insulin Rece tor in Brain
The presence of insulin receptors in the CNS is now well
documented (Havrankova et al., 1978; Wozniak et al., 1993; Kenner et
al., 1995; Smit et al., 1998). Immunocytochemistry, binding studies, and
other experiments indicate that insulin receptors are dispersed
throughout the brain. The highest densities of insulin receptor are in
the olfactory bulb, cerebral cortex, hypothalamus, and hippocampus. In
situ hybridization studies show insulin receptor mR distributed in
various parts of the olfactory bulb, cerebral cortex, cerebellum,
hypothalamus, and brain stem (Wozniak et al., 1993).
Two types of insulin receptors are found in brain. Studies in
primary cell culture indicate the glial insulin receptor, like the
insulin receptor in peripheral tissues, has a higher apparent molecular
weight than the neuronal insulin receptor. Denaturing gel
electrophoresis demonstrates that the apparent molecular weight of the
neuronal insulin receptor about 5-10 kDa lower than those of their
peripheral counterparts: 115 kDa for the a subunit and 85 kDa for the 
subunit. This distinct feature of brain insulin receptors is conserved
in mamals, birds, reptiles, and amphibians (Wozniak et al., 1993;
Kenner et al., 1995).
Peripherally, two forms of the insulin receptor have been
identified. These are generated by alternative splicing of exon 11,
which differ by a 12 amino acid insert at the C-terrinus of the a
subunit. This does not reflect the difference between peripheral and
neural insulin receptors, however. Careful sequence analysis of the
entire coding region of brain insulin pro-receptor cDNA has shown that
neural and peripheral insulin receptors have identical primry
structures, and has ruled out the possibility of alternative splicing as
the origin of the lower apparent molecular weight of brain insulin
receptors (Kenner et al., 1995)
Biochemical studies support the conclusion that the brain insulin
receptor differences are due to distinct carbohydrate additions. The a
subunit of the insulin receptor contains multiple N-linked glycosylation
sites, and the ~ subunit contains a numr of these sites as well.
\1-ereas endoglycosidase H (cleavage of N- linked manose) and
endoglycosidase F (cleavage of N- linked manose and complex
carbohydrates) treatments affected both brain and peripheral insulin
receptor a subunits equally, treatment of insulin receptors with
neuraminidase, an enzyme that cleaves N-linked terminal sialic acid
residues, had no effect on the molecular weight of brain insulin
receptor a subunit but it reduced the molecular weight of the
peripheral insulin receptor a subunit by approximately 10 kDa
(Hendricks et al., 1984; McElduff et al., 1988; Wozniak et al., 1993).
Despite the structural difference between the glial and neuronal
insulin receptor, the insulin binding characteristics and the ligand
induced autophosphorylation of these receptors are the same. However,
the insulin-induced cell biological response achieved by these cells is
not the same (Wozniak et al., 1993). For examle, chronic insulin
exposure causes expression of the glial insulin receptor to be down-
regulated, an effect not observed in neuronal cells (Clarke et al.,
1984). In glial cells, insulin binding to its receptor stimulates
glucose uptake, a biologic consequence that does not occur in neurons
(Wozniak et al., 1993). Insulin has different effects on neurons. For
example, insulin stimulates the uptake of serotonin, while it inhibits
the uptake of norepinephrine. Although neurons exress both insulin
receptor and IGF-I receptor, this effect is not achieved with IGF-I
treatment. Similarly, immunodepletion of neuronal IGF-I receptors has no
effect on insulin-stimulated insulin receptor kinase activity (Boyd et
al., 1985). These results indicate that the neuronal effects of insulin
are specifically mediated by the insulin receptor.
2 The Insulin Rece tor Si alin Pathw in Brain
Since both insulin and insulin receptor are present in brain, and
insulin binding appears to exact biological responses in neurons and
glia, one expects to locate downstream elements of the insulin-signaling
pathway to be present in the brain as well.
In situ hybridization reveals that the patterns of insulin
receptor mR and IRS-1 mR are similar in both distribution and
relative intensity. In most regions, hybridization is observed primarily
in neuronal cell body layers. In olfactory bulb and hippocampus, IRS-
and insulin receptor mR are also concentrated in synaptic layers
(Baskin et al., 1994) suggesting that there may be a role for insulin
signaling processes at synapses.
Significant amounts of IRS- 1 and insulin receptor proteins are
expressed in brain as well. Immunocytochemical studies ascertained that
a large numer of neurons in the adult CNS express IRS-1, insulin
receptor and/ or IGF- I receptor, and PI3 - kinase. No staining for IRS-1 is
detected in glial cells. Although IRS-1 and insulin receptor staining
patterns tend to overlap, in a few areas of the brain the expression
patterns of IRS-1 and PI3-K do not parallel the insulin receptor and/or
IGF-I receptor expression patterns. In general, IRS-1 and insulin
receptor imunoreactivity is restricted to cell bodies, although in
certain regions including the cerebellar cortex, staining is appreciated
in the initial portions of proximal dendrites (Baskin et al., 1994;
Folli et al., 1994).
Although IRS-1 and the insulin receptor have been localized to
neurons, it appears unlikely that IRS-1 acts discriminately in the brain
as a substrate in the insulin signaling pathway. In cultured cerebral
cortical neurons, IRS-1 and its close relative IRS-2 participate in the
neurotrophin signaling pathway. In these cultures, IRS-1/2 are tyrosine
phosphorylated, and associated with PI3-kinase, in response to brain-
derived neurotrophic factor (BDNF) treatment. This response is mediated
by the BDNF /NT3 receptor tyrosine kinase TrkB. There is no direct
interaction between TrkB and PI3-kinase in response to BDNF treatment,
so the binding of BDNF to TrkB induces the activation of PI3-kinase in
an IRS-1/2 dependent maer (Yamada et al., 1997).
2 . 3 Insulin Sicralina at SvnaDses
Although the expression of insulin signaling proteins, including
insulin receptor, IGF-I receptor, IRS-1/2, and PI3-kinase, is primarily
concentrated at cell bodies, new experiments suggest a role for insulin
at synapses.
Synaptosomal preparations, rich in sealed synaptic terminals,
contain -200 pg of insulin per mg of protein, a four- fold enrichment
from whole brain extracts (Wei et al., 1990). The depolarization of
synaptosomes (elicited by raising the extracellular K+ concentration
from 5 ro KCl to 60 ro KC1) induces a four-fold greater release of
insulin than the amount of basal insulin release, measured by
radioimmunoassay. Removing Ca++ from the medium, or blocking voltage-
dependent Ca++ entry with elevated Mg++ or Co++ concentrations, inhibits
this release. Synaptosomes can also be depolarized by the activation of
neuronal voltage-gated Na+ chanels by the drug veratridine. This
treatment induces an even greater increase in insulin release, eight-
fold greater than basal levels. Tetrodotoxin treatment, which blocks Na
chanels, inhibits this effect. It is well-established that depolarizing
synaptosomes with high K+ levels or with veratridine leads to increased
intrasynaptosomal Ca++ levels and neurotransmitter release. Thus,
elevated intra-synaptosomal Ca++ levels induce insulin release as well
(Wei et al., 1990). A similar result occurs following the depolarization
of cultured neuronal cells, but not of astrocyte or glial cells (Clarke
et al., 1986). These authors propose that the brain is "capable of
restricting and controlling the availability of insulin in a maner
consistent with that of neurotransmitters and modulators (Wei et al.,
1990) .
Theories about the biologic response to insulin at synapses
converge on learning and memory. A recent Science note (Wickelgren,
1998) proposes a link between insulin and memory, citing several new
publications. Rats that receive brain injections of streptozotocin, a
drug that damages the insulin receptor, exhibit an impaired ability to
rememer the compartment in which they had received a shock (Hoyer,
1997). Further, a study in human subjects finds that insulin mediates
improvements in verbal memory in both early stage Alzheimer 
I s disease
patients and controls (Craft et al., 1996). Exeriments in neuronal cell
cultures show that insulin inhibits the hyperphosphorylation of tau, a
process that has been linked to the formation of neurofibrillary
tangles, a hallmark of Alzheimer I s disease (Hong and Lee, 1997).
Linking insulin s action to learning and memory is intriguing, yet
direct evidence for this is scant. It must be first demonstrated that
insulin receptor signaling elements are localized to synapses, and
subsequently, that such signaling pathways play role in the mechanisms
of synaptic plasticity. One compelling piece of evidence for a direct
insulin effect at synapses establishes that insulin induces a rapid
recrui tment of functional type A GABA receptors, the principal
neurotransmitter at inhibitory synapses, from intracellular to
postsynaptic and dendritic memranes. Inhibition of protein tyrosine
kinases by the drg genistein blocked this translocation, suggesting
that an activated insulin receptor is required to execute insulin '
effect. This translocation of GABAA receptors is observed in HE cells,
hippocampal neurons in culture, and neurons in hippocampal slices (Wan
etal., 1997).
The postsynaptic Density
It is becoming clear that, at excitatory synapses in particular,
an elaborate signaling machine rests just below the postsynaptic
memrane, in the form of the postsynaptic density. It is reasonable to
propose that, if insulin has a role at excitatory synapses, then the
downstream effectors of the insulin signal are likely to be tethered at
the PSD, positioned to transform the presynaptic insulin signal into a
pas tsynaptic, biologic consequence.
1 Hi and descri tion
The postsynaptic density, or PSD as it has since become known, was
remarked upon in the 1950' s by an electron microscopist, Sanford Palay.
He stained CNS synapses with osmium tetra ide and described what he saw,
a prominent thickening on the cytoplasmic side of the postsynaptic
memrane of synapses, as a ' postsynaptic density. ' Microscopists
observed that these PSDs varied in thickness, and a classification
system developed wherein PSDs were subdivided morphologically, the
thicker being classed as ' asymetric, I or type I, and the thin, sparse
PSD as I symetric, ' or type II. This morphologic classification was
later paired with the observation that the thicker, type I PSDs were at
excitatory, or glutamatergic synapses, whereas the thinner, type II PSDs
were correlated with inhibitory, or GABAergic, synapses (Kennedy, 1993).
In the 1970 ' s, cell biologists advanced biochemical methods for
the subcellular fractionation of brain tissue into fractions enriched
for structures morphologically similar to type II PSDs. From brain
homogenate, Philip Siekevitz ' group purified synaptosomes (synaptic
memranes), treated these with 0. 5% Triton X-100, and purified this
extract by further centrifugation. This PSD-enriched fraction, when
separated by SDS-PAGE, appears to contain about 15 major and 10 minor
protein bands. Carl Cotm used a similar technique, but extracted with
3% N-lauroyl sarcosinate, a harsher detergent. SDS-PAGE of this PSD
fraction revealed about 10 maj or bands (Cotman et al., 1974) (Cotman et
al., 1974 (Kennedy, 1993)).
The PSDs isolated with our procedure are apparently
derived from the asymetric type of synapse (type I). They
are generally similar in size to the PSDs from cortical
asymetric synapses, and no structures in these fractions
resemle the thin sparse PSDs often present at symetric
(type II) synapses. On this basis, the purified PSDs most
likely arise predominantly from excitatory axodendritic
synapses. Thus our PD fraction represents the distinctive
organelle of this specific synaptic type in isolation
(Cotman et al., 1974).
These techniques are the basis of today ' s protocols for the
preparation of PSD fractions. Often, aD. 5% Triton extraction is
referred to as yielding a PSDI fraction, this followed by a second 0.
Triton extraction as PSDII, or followed by a 3% N-
lauroyl sarcosinate
extraction as PSDIII, or ' core PSD' (Kennedy, 1997). Today,
biochemically purified PSD fractions are generally believed to be
enriched for the dense thickenings of proteins that lie apposed to
excitatory, glutaratergic, active zones.
During the early days of PSD investigation, there were two major
impediments to working with the PSD fraction. First, the PSD was
regarded by some as a morphological entity that was not physiologically
significant. Moreover, the PSD structure was technically challenging,
disruptable only by treatment with SDS, a harsh detergent. Nonetheless,
tubulin, actin, and fodrin (brain spectrin), as well as calmodulin were
identified as PSD components. In the 1980'
s the ' major PSD protein ' was
identified as a subunit of the brain calcium/calmodulin dependent
protein kinase (aCaMII). This discovery ushered in growing support for
the hypothesis that the PSD organizes signaling molecules.
Though some PSD characterization proceeded, it was not until the
first half of the 1990' s, when the techniques of peptide microsequencing
were widely available, that biochemsts were able to begin to 
identify
individual components of the PSD. In many cases, the fraction was
separated by SDS-PAGE, individual protein bands were excised and
trytically digested, and the peptide sequence obtained was used to
identify or clone the abundant protein.
During this time, the first novel PSD protein was identified and
cloned: PSD-95 (Cho et al., 1992; Kistner et al., 1993). The lack of
known interactions for this protein spurred the utilization of a newly
emerging technique for discovering protein-
protei interactions, the
yeast two hybrid assay. In 1995, using this technique, investigators
selected regions of PSD-95 to use as ' bait' and uncovered an interaction
between one portion of PSD-95 and the C-terminal tail of the 2B subunit
of the NMA receptor (Kim et al., 1995; Kornau et al., 1995). Meanwhile,
a biochemical approach had led to the discovery that a protein that had
previously had been observed to be phosphorylated by kinase activity
inherent to the PSD, the concavalin-A binding PSD protein gp180, was the
2B subunit of the NMA receptor (Gurd, 1985).
Evidence of interactions between neurotransmitter receptors,
kinases, and novel proteins at the PSD greatly advanced the appreciation
of the PSD as a functional unit, as well as significantly modified the
way in which researchers approached dissecting the components of the
PSD. Today, due to the continued successes of the yeast two-hybrid
technique, molecular biologists regularly fish the PSD and uncover new
protein-protein interactions that occur within this clearly significant
density of proteins.
2 The excitatorY DostsvnaDtic aDDaratus
Ion channels and a cohort of receptors dive through the
postsynaptic memrane and are anchored to the PSD. Glutamate binds to
and activates several types of receptors on the postsynaptic memrane of
excitatory synapses. NMA and AMA receptors are ligand gated ion
chanels that transduce ligand binding into cation influx. Metabotropic
glutamate receptors are G-protein coupled seven transmemrane receptors
that mediate the slower action of glutamate by intracellular second
messengers. Communication depends on these receptors being concentrated
at the postsynaptic apparatus where they can respond to presynaptically
released glutamate. Glutamte receptors maintain a specific topological
relationship there: AMA receptors are central, facing the presynaptic
zone, and metabotropic receptors lie at the edges. The mechanisms that
lead to their specific clustering are beginning to be understood (Sheng,
1997; Ziff, 1997).
One of the proteins that clusters glutamate receptors and connects
them to cytoplasmic proteins is the above mentioned 95 kDa protein
isolated from PSD fractions, PSD95 (Ziff, 1997). PSD9S is the prototype
for a family of memrane ssociated gyanylate kinase (MAGUK) proteins 
These proteins contain at the N-terminus, three PDZ domains, an SH3
domain and a guanylate kinase domain at the C-terrinus. The cloning of
PSD95 revealed the existence of the PDZ domain, named after the three
proteins in which it was first identified, ESD9S, giscs large (dig), and
zona occulens (ZO-l). PSD95 contains three PDZ domains that specifically
bind to peptide sequences at the C-terrinus of interacting proteins. The
PDZ domain creates a hydrophobic pocket in which rests the C-terminal
motif T/SXV-COOH. A diverse set of proteins bears this peptide motif at
their C-terminus, including Fas.
The first 2 PDZ domains of PSD9S interact with the C-terrinus of
the NMA receptor subunit NR, as well as with the Shaker K+ chanel.
MAGUK proteins also can link receptors to cell adhesion molecules that
are concentrated at synapses. The third PDZ domain of PSD95 binds
neuroligan, a cell surface protein (Ziff, 1997). PDZ domains have also
been shown to bind intracellular proteins. PSD95 and chapsyn110/PSD93
interact with neuronal nitric oxide synthase (nNOS) through a PDZ-PDZ
interaction. As mentioned in Chapter I, nNOS can similarly interact with
a PDZ domain in syntrophin.
Following the identification of the PSD fraction protein PSD95,
two other synapse-associated glutamate receptor interacting proteins
were identified. The AMPA receptor subunits GluR2 and GluR3 bind the
synaptic glutamate eceptor interacting urotein (GRIP) and bMPA inding
urotein (ABP). This theme continues for the metabotropic glutamate
receptor. Homer, which contains a single PDZ-like domain, binds mGluR1a
and mGluRS. The level of Homer expression is dramatically upregulated by
synaptic activity. It appears likely that these types of proteins couple
receptors to downstream signaling pathways (Sheng, 1997).
PSD9S and chapsyn110 not only bind, but also cluster NMAR
receptors and Shaker chanels. It is now known that MAGUK proteins can
multimerize through disulfide bridges between pairs of cysteines located
at the N-terrnus (Hsueh et al., 1997). It is likely that PSD9S and
other MAGUKs use this mechanism to cluster their target proteins.
Although GRIP and ABP represent a different class of PDZ proteins (they
lack the SH3 and GK domains of MAGUK proteins) it is likely that they
multimerize as do MAGUKs (Ziff, 1997). The existence of separate
proteins for the postsynaptic clustering of glutamate receptor types may
allow for their differential distribution within the postsynaptic
apparatus.
The GK domain enables MAGUK proteins to serve as intermediaries
between chanels and Guanylate Kinase domain Associated Proteins
(GKAPs). While the GK domain exibits high homology to guanylate
kinases, and can bind GMP, it has no catalytic activity. The GK domain
binds the PSD fraction associated protein GKA, three other SAPAPs (SAP-
associated proteins) and two DAP (hDLG and PSD9Sassociated protein)
proteins. To date, no interactions have been found for MAGU proteins
SH3 domain.
3 A DostsvnaDtic sicrnalina aDDaratus
The excitatory synapse rapidly obtains and transmits information.
As scientists map the interconnections among postsynaptic proteins, it
is becoming clear that the PSD is a relay station on this information
highway that encompasses the synapse I s elaborate signaling machine.
CaMII, the major PSD protein, has been shown to be involved in
synaptic plasticity, namely in LTP. Numerous regulatory molecules reside
in the PSD, including calmodulin. Calmodulin binds to CaMII until the
kinase becomes autophosphorylated. CaMII then trans locates to the PSD
and is poised to serine/threonine phosphorylate glutamate receptors.
Al though there is as yet no known functional role for the serine
threonine phosphorylation of NMA receptors by CaMII, tyrosine
phosphorylation of NMA receptor has been shown to regulate ion channel
function under certain conditions (Kennedy, 1997).
Other enzymes, including the non receptor tyrosine kinase Fy, and
the neurotrophin RTK TrkB, are found in PSD preparations. TrkB has been
shown to binds its ligand BDNF at PSDs (Wu et al., 1996). The substrates
of this RTK at the postsynaptic apparatus are not yet known. NMA
receptor subunits NRA/B have been shown to bind SH2 domains in a
tyrosine phosphorylation dependent maner, but the identity of such SH2
domain containing proteins are not known.
Several cytosolic serine/threonine kinases are tethered near to or
within the PSD by adapter proteins. Tye II PKA is anchored at the PSD
by b kinase gnchoring roteins AK79 and AK1S0. AKP79 also anchors
PKC, a cytoplasmic serine/threonine kinase found at the PSD (Ziff,
1997). Other types of signaling elements are found in PSD fractions,
including rotein hosphatase 1 (PP1) and G proteins. The Ras-GTPase
activating protein Syn-GAP is a component PSD fractions. Sy-GAP binds
to ras-GTP and decreases the signal by turning on ras
' GTPase activity.
PSD fractions also contain the downstream signaling component ERK2-type
MAP Kinase and its substrates.
These signaling pathways are likely anchored by the cytoskeletal
elements of the PSD. Actin and a-actinin-2 are abundant in PSD
fractions, and fodrin (non-erythroid brain spectrin) is a major
calmodulin binding protein in PSD preparations. Other less abundant
cytoskeletal components that are found in the PSD fraction include
dystrophin, amyloid precursor protein- like protein-1, and a-adducin. a-
actinin-2 binds to the cytoplasmic tails of NR1 and NRB through its
central rod domain. This interaction is antagonized by Ca
++ 
/calrodulin
binding to NR1. Ca++ fluxes through the NMAR may activate calmodulin
and release the receptor from the cytoskeleton. The reduction in NMAR
channel currents that result from Ca
++ 
/calmodulin binding to the NR1 C-
term may occur due the channel dissociating from the cytoskeleton. In
sum, a variety of discrete signaling pathways are woven into the PSD,
placed to elicit the coordinated functions required at the synapse.
4 SvnaDse re lation
While the cytoplasm of most cells is filled with signaling
pathways that coordinate and intersect to allow for diverse coordinated
functions, it appears that these tools are specifically enriched
locally, for short term plasticity, and are locally modified, for the
construction of long term changes. How can the crucial structure of the
postsynaptic apparatus change to reflect its active environment?
The latest hypothesis focuses on local mR regulation and
translation. This type of self-contained mechanism would be necessary if
all of the synapse s signaling machinery was locally arranged. Perhaps
at the postsynaptic signaling apparatus, the signal that originates in
the synaptic cleft and migrates to the postsynaptic memrane, weaves
about the PSD and induces, in conjunction with the PSD protein CPEB
(cytoplasmic polyadenylation element binding protein), synthesis of new
synaptic components. This inducible, local, new synthesis, allows for
maintenance or modulation of the synaptic structure. Indeed, the
polyadenylation of CaMII mR is regulated in a CPEB dependent maner,
and activity can induce CaMII synthesis at the synaptic apparatus (Wu
et al., 1998). Other PSD protein mRs also possess these 3' UTR CPEB
binding consensus sequences, and thus may have the potential for local
translation. Whether or not these mRs are locally translated remains
to be tested.
The PSD, a small subcellular structure, is dense with the tools
that cells use to elicit change and the potential to modify and modulate
the strength of an individual synapse. As PSD proteins continue to be
identified, the diverse signaling pathways that the postsynaptic
signaling apparatus comprises can be carefully reconstructed, aiding our
understanding of how mechanisms at this small structure lead to such
complex biologic outcomes as learning and memory.
The Postsynaptic Density and Insulin Signaling
Indeed, it appears that insulin and its signaling pathways are at
excitatory synapses. The experimental data that I proffer in this
chapter implicate the insulin receptor and the insulin receptor
substrate IRSp58/S3 in insulin dependent signaling mechanisms at the
synapse.
Methods
Brain Subcellular Fractions
Brain homogenate, synaptosome, and postsynaptic density (PSD)
fractions were prepared as described in Chapter I, Section 3 (Methods).
Frozen porcine brain tissue was provided by Susan Lacy (Children
Hospital, Boston, MA).
Antibodies
Ab98 antisera was raised by imunizing a rabbit with the peptide
KALPPPEYPSQ (a sequence in the cytosolic domain of ~-dystroglycan that
was used for the production of antibody PA3a (Yoshida et al., 1993) and
affinity purified (Quality Controlled Biochemicals, Hopkinton, MA). The
anti-IRSpS8/S3 polyclonal antibody was raised by injecting a rabbit with
the MAP-conjugated peptide DKDDLAPPPDYGT (Research Genetics, Inc.,
Huntsville, AL) and was affinity purified. Irnunoabsorption experiments
were performed by mixing the primary antibody with its corresponding
peptide for 2 hours to overnight at 4 C then western blotting or
immunostaining as described below. H720, an anti-IRSp53 monoclonal
antibody, was generously provided by Dr. Roth and is described elsewhere
(Yeh et al., 1996).
The anti-dystrophin monoclonal antibody DYS2 was obtained from
Novocastra, the anti-aCaMII (#6G9) and anti-synaptophysin monoclonal
antibodies were obtained from Boehringer Maneim, the anti-NMAR1
monoclonal antibody was obtained from Pharmingen, and the polyclonal
anti-mouse CPEB antibody was obtained from Joel Richter, University of
Massachusetts, Worcester (Wu et al., 1998). Insulin Receptor subunit
polyclonal (C-19) antibody was obtained from Santa Cruz Antibodies. Fas
Ligand monoclonal (33) antibody was obtained from Transduction
oratories. Insulin Receptor ~ subunit polyclonal antibody (#C-19) was
obtained from Santa Cruz Biotechnology, Inc. An anti -peptide antiseru
to ~-dystroglycan (12031C) was a generous gift of Lou Kunkel (HHI,
Children s Hospital, Boston, MA). Monoclonal anti-~-dystroglycan
antibody NCL-43DAG was obtained from Novocastra.
Western Blotting
Protein concentrations were determined with the BCA protein assay
(Pierce, Rockford, IL), using bovine seru albumin (BSA) as a standard.
Equal quantities of homogenate, synaptosomal, and PSD proteins were
separated on a 10% or a 5-15% gradient gel by SDS-PAGE, transferred onto
nitrocellulose memranes, and incubated with primary antibodies followed
by alkaline phosphatase-conjugated goat anti-rabbit or anti-mouse IgG
(Boehringer Maneim). Bound antibody was visualized using the BCIP/NBT
substrate system (promega, Madison, WI). In some experiments, lysates of
CHO. T cells, which overexpress insulin receptors (generous provided by
M. Czech, Univ. of Mass Medical Center), were also analyzed. For Western
blotting with DYS2, horseradish peroxidase-conjugated anti-mouse IgG was
used as the second layer, and bound antibodies were visualized by ECL
chemiluminescence (Arersham).
2D gel electrophoresis
Isoelectric focusing (IEF) was performed essentially as instructed
by the manufacturer (Pharmacia Biotech). Briefly, IEF strips (Immobiline
Dry Strips, pH 3-10L, 11 cm) were rehydrated for 6 hours to overnight at
room temperature in 2D sample/rehydration buffer (8M urea, 2% CHAPS, 2%
IPG buffer 3-10L (Pharmacia), 0. 3% DT). Strips were stored at -
after rehydration , Samples were diluted or resuspended to 100 l 2D
sample buffer. The soluble fraction was loaded at the anodic end of the
IEF strip (pH 3-10 linear gradient, Pharmacia). IEF was performed at
C on a Multiphor II apparatus (Pharmacia) for 1 hour at 300V, 15
hours at 1400V. Following IEF, the strips were equilibrated at room
temperature for 10 minutes in 20 mg DT per ml equilibration buffer (50
ro Tris-HC1, pH 6. 8, 8M urea, 35% glycerol, 0. 3% SDS) , followed by 10
minutes in 25 mg iodoacetamide per ml equilibration buffer. Strips were
then placed horizontally (cathode to anode, left to right) on aD. 5 mm
thick 10% SDS-polyacrylamide gel and anchored with a stacking solution
(0. 5% agarose, 125 ro Tris, pH 6. 8, 1% SDS). Sample or protein standard
was loaded into one lane on the gel and was separated by SDS-PAGE only.
The samples were electrophoresed in the second (SDS-PAGE) dimension and
gels were either silver stained (Morrissey, 1981), stained with
commassie blue, or transferred to nitrocellulose (10 volts, 16 hours)
for western blotting.
Hydrophobic Interaction Chromatography
For hydrophobic interaction chromatography (HIC) , PSDs were
solubilized overnight at 4 C in 8M urea, 1M NaCl, 5 ro dithiothreotol
(DT), SO ro sodium phosphate buffer, pH 7. 5. The soluble fraction was
then made 4M in urea and incubated with HIC matrix (high performance
phenyl sepharose, Pharmacia Biotech) for 3 hours at 4 C. The HIC matrix
was then washed, pre-eluted in the same buffer with 0. 8M NaCl, and
eluted with the same buffer in a. 1M NaCI. Apomyoglobin (Sigma Chemicals,
St. Louis, MO) was added to the eluate as a carrier protein, and the
solubilized proteins were subsequently precipitated with trichloroacetic
acid.
MALDI-TOF Mass Spectrometry and peptide s equenc ing
HIC eluates separated by 2D electrophoresis were visualized by
cornassie stain and the bands corresponding to pS8 and pS3 were excised
from the gel. The polypeptides were recovered from the gel and subj ected
to trysin digestion. Peptide masses were determined by Matrix Assisted
Laser Desorption Ionization Time-of-flight Mass Spectrometry (MADI-TOF
MS). MS-Fit search software was then used to compare the pS8 and pS3
mass profiles to known proteins. Trytic fragments from pS8 and pS3 were
separated by HPLC and peptide sequence was obtained from 3 fragments of
pS8 (J. Leszyk, Worcester Foundation Protein Sequencing Facility,
Worcester, MA).
In vitro phosphorylation of PSD fraction proteins
The method used is a modification of a procedure described
elsewhere (Dosemeci et al., 1994). PSDs were pretreated on ice for 3
hours with occasional mixing in 20 ro HEPES, pH 7. 4, 100 ro DT. PSDs
were diluted to a final concentration of 0. 4 mg protein/ml in
phosphorylation solution (5 ro MgC12, 50 g/ml leupeptin, 20 ro DT, 
ro HEPES, pH 7. 4, 1 ro CaC12, 1 ro orthovanadate, +/- 100 ATP)) , and
incubated at 37 C for 5 minutes. The reaction was quenched by the
addition of SDS sample buffer.
Northern blot hybridization
The 32p labeled IRSp58/S3 oligonucleotide probe was synthesized by
PCR using the IRSpS3 cloned DNA (provided by Roth, described in (Yeh et
al., 1996)) as temlate and the primer pair:
F1:
R1:
AAGAGCGTGACCCCGAAGAACAGC
AACCAGCCCCGCATT .
The rat Multiple Tissue Northern Blot (MT; Clontech, Palo Alto, CA) was
prehybridized in ExressHyb for 1 hour at 55 C. The IRSp58/S3 probe was
denatured, diluted in ExressHyb, and incubated with the blot overnight
at 55 C. After hybridization, the blot was washed extensively; the most
stringent wash performed was O. lX SSC, 0. 1% SDS, at 65 C for 40 minutes.
The 32p labeled human ~actin cDNA control probe was generated
using random hexamer labeling (Gibco). The blot was prehybridized in
ExressHyb for 1 hour at 68 C. Hybridization with the actin cDNA probe
was performed overnight at 68 C. The blot was then washed extensively;
the most stringent wash performed was O. 5X SSC, 0. 1% SDS at 60 C for 60
minu tes .
RNA isolation and RT-PCR
RNA was isolated from 20 mg of rat cerebral cortex by the RNeasy
mini kit (Qiagen). cDNA was synthesized by reverse transcription of 30
g of the RNA, using either oligo- (dT) or random primers and reverse
transcriptase (Gibco). Conditions for reverse transcription were 40 X 
minutes at 94 C, 1. 2 minutes at 37 C, 4. 3 minutes at 60 C). The product
of this reaction was used as the template for PCR. The PCR conditions
were 3 minutes at 94 C, 40X (30 sec. at 94 C, 1 minute at S5 C; 4
minutes at 68 C) , 8 minutes at 68 C. The sequences of the primers used
are as follows:
(UTR/C):
(MIDF):
C (F1):
D (R1):
(MIDR):
F (ENR):
5' GTGTAGCCGGACCCAGGACCAT 3 
5' CGAGGGCGGAGGAGGTITGC 
5' AAGAGCGTGCCCCGAAGAACAGC 
5' AACCAGCCCCGCATT 3'
5' ACGGCACACTGTAGGTCTCTGC 3 I .
5' TCTAGTCAGGGCTCAATC 3'
Tissue sections and immunohistochemistry
Brains were dissected out of adult female rats, and immersed in
freezing isopentane, mounted in OCT emedding medium and equilibrated to
C. 8 frozen sections were cut, air-dried onto glass slides, fixed
in MeOH at - 2 DoC for 10 minutes, and rehydrated in PBST (PBS , O. 1 
Triton-X 100). The sections were blocked for one hour at room
temperature with PBST, 1% BSA, 10% horse seru, 1% goat seru. The
primary antibodies, anti-IRSp58/53 (1 ug/ml +/- peptide (1 mg/ml)),
rabbi t anti -synapsin- I (1: 3000, pietro DeCamilli, HHI (Malgaroli et
al., 1989)), or control rabbit IgG (Sigma, 1 ug/ml) were diluted in
blocking solution and were applied overnight at 4 C. The slides were
washed at room temperature for 2 hours in PBST with stirring and one
wash solution change. Cy3-conjugated goat anti-rabbit IgG (1:500-1:4000,
Jackson ImmunoResearch) or FITC-conjugated goat anti-mouse IgG, rat
absorbed (1:100, Vector Laboratories, Burlingame, CA) was applied for 3
hours at room temperature. The sections were washed as above, dehydrated
in - C MeOH for 10 minutes , allowed to air dr, and mounted in
Citifluor (Ted Pella Inc., Redding, CA). Immunostaining was visualized
by indirect fluorescence using a Nikon E800 fluorescent microscope.
Images were recorded with a Photometrics CCD camera using IP Lab systems
software.
Hippocampal neuron cultures and immunohistochemistry
Low density cultures were maintained primarily by David Wells, a
postdoctoral fellow in the lab (Wu et al., 1998)), as described in
(Goslin and Banker, 1991). Briefly, the hippocampus was removed from E18
rat emryos, trysinized (0. 25%), dissociated by trituration, and plated
onto poly- Iysine (1 mg/ml) coated glass coverslips in modified Eagle
medium (ME, Gibco) with 10% horse seru for 4 hours. The coverslips
were then transferred to dishes containing a monolayer of glial cells in
growth medium consisting of ME, ovalbumin (100 g/ml) pYrvate (1.
g /ml) , glucose (0. 6%) and N2 supplement. The culture medium was changed
weekly. After 19-21 days, the cells were fixed with 4% paraformaldehyde
at 37 C for 20 minutes, covered with saponin (0. 05%) for 5 minutes and
then incubated in blocking solution (ME, 10% horse seru, 1% goat
seru, 1% BSA). The primary antibodies, mouse anti- synaptophysin
(Boehringer, diluted 1: 20), mouse anti- insulin receptor ~ subunit (Santa
Cruz, diluted 1:100), and rabbit anti-IRSp58/53 (diluted 1:5) were
applied overnight at 4 C and the second layer antibodies, directly
conjugated to either FITC (Caltag) or Cy3 (Jackson ImmunoResearch), were
applied for 1 hour at room temperature. The coverslips were mounted onto
glass slides with Citifluor (Ted Pella) .
In vitro transcription/translation and immunoprecipitation
IRSp53 was subcloned from the Bluescript vector into the Bam1
site of the expression vector pMGT. The clones C2797 and DP71 (in pMGT,
provided by L. Kunkel CAlm and Kunkel, 1995; Chan and Kunkel, 1997)),
encode a dystrophin fragment from bp 2797 to the C-terminal end, and the
small dystrophin isoform that is highly expressed in brain,
respectively. The clone aO is in the expression vector pMGT and
encodes a dystroglycan fragment from bp 345 to 653. These plasmids were
used for in vitro transcription/translation (TN Quick Coupled In Vitro
Transcription and Translation System, Promega) using 35S-methionine. In
vi tro expressed proteins were diluted in TEST (10 ro Tris pH 7. 8, 150 ro
NaCI, 0. 1% Tween-20) and incubated with each other on ice for 1 hour.
The mixtures were then incubated with the immunoprecipitating monoclonal
antibody (DYS2 or H720) for one hour. The samle-antibody mixture was
then incubated with Protein G-sepharose (Sigma Chemicals) for 1 hour.
The beads were washed with TBST and then incubated in protein sample
buffer at 100 C for 10 minutes. The supernatants were analyzed by SDS-
PAGE and autoradiography.
Biotinylation and solubilization of PSDs
Purified PSDs (2 mg) were resuspended in 1 ml 50 ro HC03, pH 8.
Following the addition of 74 ul biotin (1 mg/ml), PSD proteins were
incubated for 30 minutes at room temperature and then solubilized as
described in (Blackstone et al., 1992). Briefly, PSDs were reisolated by
centrifugation, and resuspended in 10 ro Tris, pH 7. 4. 1/10 volume of
10% DOC, 500 ro Tris pH 9. 0 was added to the PSD and the mixture was
incubated at 37 C for 30 minutes with occasionalvortexing. 1/10 volume
of 1% Triton X-100, 50 ro Tris pH 9. 0 was added, and the PSD solution
was dialyzed overnight against 50 ro Tris pH 7. 4, 0. 1% Triton-X100. The
following day, the PSD solution was centrifuged at lOOK x 
for 30
minutes This supernatant was used for imrunoprecipitations and for
incuba tion wi th GST- tagged proteins.
GST-tagged IRSp53
PCR mutagenesis was used to introduce EcoR1 sites that flanked the
coding region of IRSp58/53 using the primers:
F= 5' CGGAATTTCGCTCTCACGCTCGGAG 
R= 5' GGAA'ICATCTGCAC'I 3'
The PCR product was gel-purified (Qiagen), and linearized pGEX- 1AT
(Pharmacia), was ligated with or without the insert (T4 ligase). BL21
(and DH10B cells for plasmid maintenance) were electroporated with the
ligation products and screened for inserts. I isolated DNA isolated from
several colonies, and performed PCR with a IRSp58/S3 specific primer
pair to determine the presence or absence of the IRSpS8/S3 insert. The
restriction enzymes Sph1 and Bam1 were then used to determine the
orientation of the insert. Identification of a clone with a correctly
oriented IRSp58/53 insert was verified by sequencing the plasmid from
each end of the ligation. Sequencing primers were:
F= 5' GGCTGAAGCCACG'I'I 3'
R= 5' CCGGAGC'ICA'I'ITCAGAGG 3' .
Fusion Proteins
BL21 cells were grown overnight in Luria broth with 1 g/ml
ampicillin (LBA). The overnight cultures were diluted 1: 10 in fresh LBA
and grown until the absorbance at OD600 = 0. 8. Protein exression was
induced by adding IPTG to the cultures to a final concentration of 1 ro.
Induced cultures were incubated with agitation at 2S C for 3 hours. The
cells were pelleted and resuspended in 1/100th culture volume with SO ro
Tris, 150 ro NaCl. Triton X-100 was added to the resuspended cells to a
final concentration of 1% and DT was added to 1 ro. The cell suspension
was sonicated for 3 x 10 seconds and the sonicate was centrifuged for 5
minutes at 14, 000 rpm. The supernatant was collected and placed on ice.
The pellet was resuspended as above and sonicated 2 x 10 seconds. The
sonicate was centrifuged for 5 minutes at 14, 000 rpm and the supernatant
was pooled with above. The pooled supernatants were spun and the
supernatant was incubated for 1. 5 hours at 4 C with glutathione-
sepharose beads that had been rinsed with 20 volumes of PBS. The beads
were washed with 50 ro Tris, 150 ro NaCI, 1% Triton X-100 and packed for
elution. Glutathione elution buffer (10 ro reduced glutathione, 50 ro
Tris-HC1, pH 8. 0) (1 ml) was added, the beads were incubated for 10
minutes at room temperature, the eluate was collected, and elution was
repeated. Eluate fraction were pooled and dialyzed overnight at 4
against 50 ro Tris pH 7. 5, 0. 1% Triton X-100. Following dialysis, salt
was added to a final concentration of 150 ro NaCl. The purified GST
protein solutions were then tumled with an equal volume of solubilized,
biotinylated PSDs or synaptosomes for 4 hours at 4 C. This mixture was
then incubated with fresh, rinsed glutathione-sepharose beads for 1.
hour incubation at 4 C, and subsequently washed thoroughly. GST-sample
complexes were released from the glutathione sepharose by boiling the
pellet for 10 minutes in sample buffer. Eluates were analyzed by western
blot, and biotinylated PSD proteins were identified by incubating the
blot in ABC reagent and visualizing the reaction with the BCIP/NBT
system (Vector).
35S labeled in vitro expressed IRSp58/53 blot overlay
The subcellular fractions were separated by SDS-PAGE and blotted
to nitrocellulose. The blot was immediately rinsed in wash buffer (Hanks
Buffered Saline Solution (HESS), 0. 1% BSA, pH 7. 4) for 30 minutes with
multiple wash changes. The blot was blocked for 3 hours at 4 (HESS, 1%
BSA, 1 ro DT, 5 ro HEPES, pH 7. 4). 35S-labeled proteins (IRSp58/53,
aD) were made as described above. The radiolabeled proteins were
diluted in block and incubated with the blot overnight at 4 C. The blots
were washed for 1 hour with multiple changes of wash buffer, dried, and
exposed to film for 6 hours to overnight.
Results
The postsynaptic density is a structure that appears to be the
morphological consequence of a complex scaffold of signaling molecules
that rests just below the postsynaptic memrane of central synapses. I
have identified a protein that is selectively enriched in the PSD
fraction as the insulin receptor substrate IRSpS8/53. The protein
IRSp58/53 was recently identified in a non neuronal cell line and found
to be an insulin receptor substrate (Danielsen and Roth, 1996; Yeh et
al., 1996; Yeh et al., 1998). I have determined that the IRSpS8/53 
is most highly expressed in brain, and that alternative splicing of the
transcript does not appear to account for IRSp58/53' s appearance as 
doublet following electrophoresis, nor do traditional post-translational
modifications. Additionally, I have shown that IRSp58/53 is concentrated
at synaptic sites: in cerebellar tissue and in cultured hippocampal
neurons. I have found that the ~ subunit of the insulin receptor,
IRSp58/53' s functional partner, is a component of the PSD fraction as
well. I have uncovered no interaction between IRSp58/53 and the
potential binding partners dystrophin or FasL in vitro. I have
identified a potential binding partner for IRSpS8/53, PSD255. The
resul ts that I present here provide evidence for a synaptic insulin
receptor signaling pathway.
1 polypeptides pS8 and pS3 are enriched in the postsynaptic
density fraction
While surveying adult rat brain homogenate, synaptosome, and PSD
fractions to determine the relative enrichment of 
dystroglycan in
subcellular fractions (see Chapter I), I discovered that one antiseru,
Ab98, cross-reacted with a pair of polypeptides of 58 kDa and 53 
kDa,
termed p58 and p53, that were highly concentrated in the PSD fraction
(Figure 4). p58 and p53 were highly enriched in the PSD fraction,
these polypeptides were not detected in blots of homogenate and
since
synaptosomes that contained the same amount of total protein 
(Figure
4A). p58 and pS3 were enriched in PSD fractions isolated from rat
cerebral cortex, cerebellum, and hippocampus (Figure 
4B). In contrast,
dystroglycan (migrating at 43 kDa) was present in brain homogenate and
was modestly enriched in synaptosomes, but was not detected in the PSD
fraction from cerebral cortex (Figure 4A) or other brain regions 
(not
shown, see Chapter I).
Like other components of the PSD fraction, p58 and p53 were
virtually insoluble in all non-ionic detergents tested. In addition,
these polypeptides were not extracted in 3% N- lauroyl sarcosinate (not
shown). Such solubility properties indicate tight association with the
core ' PSD (Kennedy, 1993). Relatively few proteins have been found
specifically enriched in the postsynaptic density fraction. This feature
of p58/53 suggested that it was a synapse specific protein. Since the
identification of the components of the synapse is essential to
understanding its structure and function, I was resolute to determine
whether p58 and p53 were relatives of ~-dystroglycan, proteins not yet
localized to the PSD fraction, or novel proteins. Since p58 and p53 were
observed as immunologically related to ~-dystroglycan, I first pursued
the identification of these polypeptides in that context. Although I
found no evidence of alternative splice form of 
dystroglycan in brain
(see Chapter I), I concluded that, in order to positively discount the
possibility that p58 and p53 were related to dystroglycan, and to make a
conclusive identification, I must obtain peptide microsequence from
these polypeptides.
purification of p58 and p53
Protein staining of SDS-PAGE separated PSD fraction proteins
demonstrated that, within the molecular weight range of 50-
60 kDa, pS8
and p53 were interdigitated among at least three major PSD proteins
(Figure 4C). When I carefully extracted the p58 and p53 bands from blots
of PSD fractions and obtained MADI-TOF masses, it was clear that within
the bands there was overwhelming contamination from at least one of
these major PSD proteins, tubulin. To achieve an improved gel separation
of pS8 and p53 from the 50-60 kDa major PSD proteins, and to further
investigate their biochemical properties, I separated the PSD sample
proteins by charge and by size using two-dimensional gel
electrophoresis. This method yielded substantial improvement in the
isolation of p58 and p53: unlike the maj ori ty of the PSD proteins, this
doublet migrated to a basic isoelectric point (pI -9), free from the
bulk of PSD proteins (Figure 5A). The pS8 and p53 bands each migrated as
a series of closely spaced spots of differing isoelectric points,
suggesting that these polypeptides may be post-translationally modified
(see below) .
Next, I established conditions for the solubilization of pS8 and
p53 in the absence of detergents. Many chromatographic methods did not
contribute to the purification of p58 and pS3. Affinity chromatography
with the antibody Ab98 was far too inefficient to attain significant
quantities of p58 and p53; anion and cation exchange chromatography, and
fast performance liquid chromatography (FPLC) provided no separation of
p58 and p53 from other components of the fraction. In contrast,
hydrophobic interaction chromatography (HIC) provided an excellent
separation of p58 and p53 from the majority of other PSD components. HIC
yielded a protein fraction that was highly enriched in pS8 and p53.
Comparison of silver stained gels of HIC starting material (total PSD
fraction proteins) and HIC eluate, both separated by 2D gel
electrophoresis, demonstrated that the hydrophobic subpopulation of PSD
proteins, including p58 and p53, is a small component of the total PSD
fraction (Figure SB). Ultimately, to obtain a quantity of p58 and p53
sufficient for peptide microsequencing, I exploited a purification
scheme which combined subcellular fractionation, HIC, and 2D gel
electrophoresis.
Mass Spectrometry Analysis and Peptide Microsequencing of
p58 and p53
To identify p58 and p53, I used MADI-TOF mass spectrometry to
analyze trytic digests of the purified polypeptides. Comparison of the
profile of masses obtained from both p58 and p53 to computer-generated
mass profiles of protein sequences in the NCBI database showed that p58
and p53 from rat were highly homologous to hamster Insulin Receptor
TYosine Kinase Substrate p53 (IRSp58/S3, Figure 6). This pair of
polypeptides had been isolated from CHO cells by Yeh et al., and the
cDNA encoding IRSp53 was cloned (Yeh et al., 1996). The precise
relationship between IRSp58 and IRSp53 was not established in that
study, but it seems likely that they are encoded by the same sequence
(see below) .
Sixty-five percent of both the p58 masses (15/23) and the p53
masses (13/20) matched the trytic digest masses computed from the
deduced IRSp53 amino acid sequence (Table 1). There were eight p58
masses that did not correspond to an IRSp53 mass, but six of these
masses were shared by p53. Two p58 masses and one p53 mass were unique.
Only slight differences were observed when the HPLC chromatograms of the
p58 and p53 trytic digests were compared (not shown). Together, these
data indicate that the primary structures of p58 and pS3 are very
s imi lar .
To verify the identification of p58 and p53 as IRSpS3, I obtained
amino acid sequence from three of the p58 trytic fragments. Of the 33
amino acids obtained, all perfectly matched the published sequence of
the IRSpS3 cDNA (Table 1, Figure 6). I further confirmed the
identification of pS8 and p53 as IRSp53 by western analysis of PSD
fractions with monoclonal antibody H720 (not shown). Hereafter, p58 and
p53 will be referred to as IRSp58/53.
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4 Relationship of IRSp58 and IRSp53
In the course of my biochemical studies of IRSp58/S3, I have
consistently encountered a -5 kDa difference in the molecular weights of
IRSp58 and IRSpS3. However, neither mass spectrometry nor HPLC analysis
indicated differences in the primary structures of these polypeptides.
One modification that could potentially account for this difference is
phosphorylati . Indeed, in vitro phosphorylati of PSD proteins caused
an upward shift in the electrophoretic mobility of both IRSp58 and
IRSp53, suggesting that they are substrates of a kinase(s) in the PSD
fraction. However, this shift did not account for the 5 kDa difference
(Figure 7A). Similarly, enzymatic deglycosylatio
did not yield any
consolidation of the doublet (not shown). Thus, I found no evidence that
these posttranslational modifications cause the 5 kDa apparent molecular
weight difference between IRSp58 and 
IRSp53.
To further investigate the relationship between IRSp58 and 
IRSp53,
I analyzed their expression in brain tissue from 
rat, mouse, and porcine
PSD fractions. Western analysis revealed that in the rat and mouse PSD
fractions, the IRSp58/53 pair was indistinguishable 
(not shown) 
However, in the porcine PSD fraction the IRSp58 species was prominent,
and the IRSp53 species was barely detectable 
(Figure 7B). This
observation raises the possibility that IRSp53 is a proteolytic cleavage
product of IRSp58. However, it should be noted that the relative levels
of IRSp58 and IRSp53 remains stable when PSD fractions are stored for
prolonged periods at - C or incubated overnight at room 
temerature
(not shown).
5 Distribution of IRSp58/53 mRNA
Hoping to learn more about the molecular relationship between
IRSp58 and IRSp53, I investigated the possibility that IRSp58/53
represent alternative splice forms. To examine the distribution and
configuration of the IRSp58/53 transcript, I probed rat tissue Northern
I'i "I. 
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blots with a radiolabeled oligonucleotide probe that corresponded to the
putative SH3 domain (see below) of the IRSp53 clone (Yeh et al., 1998).
This probe hybridized predominantly to transcripts of two sizes, 2. 4 and
5 kb (Figure 8). The mR tissue exression pattern revealed in this
experiment is more extensive than the tissue exression of the IRSpS8/53
protein. Yeh et al. showed that IRSpS8/53 exression is significant 
brain, and is undetectable in spleen, muscle or liver (Yeh et al.,
1996). Brain contained the highest level of IRSpS8/53 mR, with the 3.
kb transcript predominating. Varying amounts of the two transcripts were
observed in other tissues. Notably, neither transcript was detected in
skeletal muscle. Thus, there appear to be at least two IRSp58/53 mRs,
and the highest hybridization is to the 3. 5 kb IRSp53 transcript, which
is most prevalent in brain.
6 Organization of IRSp58/53 rnRNA
Considering the possibility that the two transcripts observed in
the Northern blots might correspond to alternatively spliced mRs, I
then searched the EST database using the BLAST algorithm (Altshcul,
1990) for sequences that might represent IRSp53 homologues. I identified
a large set of IRSp53-homologous ESTs that spaned the entire open
reading frame of IRSp53 (not shown). However, this analysis revealed no
divergences from the reported IRSp53 cDNA sequence, and thus provided no
evidence for the existence of alternatively spliced transcripts.
To determine whether the size difference between the 3. 5 kb and
the 2. 4 kb mRs was due to variation in their coding sequence, I
performed RT-PCR. I isolated RN from rat cortex and used random primers
to reverse transcribe the RNA. I then used an array of primers that
spaned the IRSp53 coding region for PCR analysis. Each of the generated
RT-PCR products corresponded in size to a product obtained using IRSp53
cDNA as template: no major additional products were detected (Figure 9) 
Together, these RT-PCR products covered the entire coding region of
IRSp53. Thus, in rat brain I found no evidence of alternative splicing
within the coding region of IRSpS3 mRA, suggesting that both IRSp58 and
IRSpS3 are products of a highly similar or identical rn.
Localization of IRSp58/53 to synapses
The enrichment of IRSp58/53 (pS8 and p53) in the synaptic
subcellular fractions suggested that IRSp58/53 is a component of the
synapse. Since the antisera Ab98 cross-reacts with dystroglycan, and
the IRSp58/53 monoclonal antibody H720 was unsuitable for
immunohistochemistry, I raised and affinity purified a specific anti-
IRSp58/53 antiseru. Importantly, this antiseru did not recognize ~-
dystroglycan. The specificity of this reagent for IRSp58/53 was verified
by western blotting and immunoabsorPtion (Figure 10).
To determine it IRSp58/53 has a synaptic distribution in intact
brain, I performed immunohistochemistry on frozen sections (Figure 11A).
In the cerebellum, a zone of granule cells lies next to a band of
Purkinje cells, whose synapse-laden dendrites lie in the adjacent
molecular layer. Staining with this anti-IRSp58/53 antibody demonstrated
that IRSp58/53 immunoreactivity is prominent in the synapse-rich
molecular layer as well as in the granule cell layer of this tissue. The
specificity of the IRSp58/53 antibody staining was demonstrated by
peptide immunoabsorPtion. This pattern of staining suggested that
IRSp58/53 may be expressed selectively at synaptic sites.
Therefore, to assess the distribution of IRSpS8/53 in further
detail, I exploited a system in which individual synapses can be
resolved. Primary hippocampal neurons in low density cultures have well-
differentiated axons and dendrites, and numerous functional synapses.
These synapses can be reliably visualized using antibodies to synaptic
vesicle proteins such as synaptophysin. Double labeling with anti-
synaptophysin and anti-IRSpS8/53 antibodies showed that IRSp58/53
immunoreactivity was localized at the majority of synapses on these
cells (Figure lIB). Together, the findings from my biochemical and
immunohistochemical studies indicate that IRSpS8/S3 is a component of
central synapses. I exect that this finding will verified by future
imuno-electron microscopy studies.
IRSp58/53 binding partners
IRSpS8/53 contains several potential protein-protein binding
domains: an src homology 3 (SH3 ) domain, as well as an SH3 binding and a
WW-binding domain (Figure 6) (Yeh et al., 1998). . In light of IRSp58/S3 '
potential for protein-protein interactions, I searched for binding
partners for IRSp58/53. I both used a candidate partner approach and
pursued novel protein binding interactions.
1 Fas Licrand Associated Factor 3 is a human homolocre of IRSD53
A BLAST search with the IRSpS3 cDNA reveals a NCBI database entry
that is 95% identical to the N-terminal 320 amino acids (60%) of
IRSp58/53 (Hachiya et al., 1997). The entry s annotation states that
this cDNA, Fas Ligand Associated Factor 3 (FLA3) , encodes a large
portion of a human homologue to IRSp53. The FLA3 cDNA was obtained
using the intracellular tail of Fas Ligand (FasL) as bait in a yeast two
hybrid screen of a human placental cDNA library. FasL, a 37 kDa type II
transmemrane protein, is known to wield the " death domain " which
initiates Fas-mediated apoptosis. Whereas the extracellular portion of
FasL and its role in apoptosis are well studied, little is known about
the endodomain of this molecule.
To determine if FasL has a distribution that coincides with that
of IRSpS8/53, I probed western blots of brain subcellular fractions with
an antibody directed against FasL. Following reducing gel
electrophoresis of subcellular fractions proteins, FasL is observed in
predominantly in brain homogenate and synaptosome fractions (Figure
12A). The immunogen against which this FasL antibody was made is the
extracellular, C-terminal portion of FasL. This portion of FasL is often
cleaved however, producing a soluble factor and presumly leaving
behind a transmemrane " root. " One explanation for the absence of FasL
in the PSD fraction is that the portion of FasL reported to interact
with IRSpS3, the intracellular " root" does in fact fractionate with the
PSD, while the epitope containing extracellular portion is cleaved. The
intracellular fragment is thus rendered virtually invisible, since
antibodies directed against the less studied intracellular portion of
FasL are currently unavailable. Such antibodies would be valuable for
pursuing this potential interaction between FasL and IRSp58/S3.
2 Dvstrophin: a PSD Drotein with an available WW domain
The cytoskeletal PSD protein dystrophin (see Chapter I) is
localized to the PSD and contains a WW domain (Bark and Sudol, 1994).
The WW or WWP domain, identified in 1994, is a protein-protein
interaction module which likely functions is a way analogous yet
distinct from SH3 domains. This module contains approximately 40 amino
acids and contains two highly conserved trytophans and an invariant
proline (Rotin, 1998). I hypothesized that at synapses, IRSp58/53 might
interact with this protein-protein interaction domain within
dystrophin s C-terminus. I attempted to co- immunoprecipitate in vitro
expressed dystrophin fragments that contained the WW binding domain with
vitro expressed IRSp58/53. I observed no interaction between these
proteins, however (Figure 12B).
3 A search for novel IRS 53 rotein- rotein interactions
I continued to pursue IRSpS8/53 interacting proteins by screening
the conglomerate PSD fraction for binding proteins. First, to
investigate the possibility that IRSpS8/S3 are tightly associated with
other proteins in the PSD fraction, I immunoprecipitated IRSp58/53 under
non-denaturing conditions from a preparation of biotin- labeled,
solubilized PSD proteins. However, no PSD proteins co- immunoprecipitated
with native IRSp58/53 (Figure 12C).
I next screened the PSD fraction for components that possessed
affinity for IRSp58/53. I generated a glutathione s-transferase-tagged
IRSp58/53 (GSTp53) and co-incubated GSTp53 with a preparation of biotin-
labeled, solubilized PSD proteins. The GSTp53 precipitated a numer of
biotinylated PSD proteins, while few PSD proteins bound to the GST
control (Figure 13, left). To enhance this finding, I used an
alternative approach and performed a blot overlay experiment. I probed a
blot of subcellular fraction proteins with 3SS- thionine labeled in
vitro expressed IRSp58/53. Again, IRSp58/53 appeared to bind a numer of
PSD proteins (Figure 13, right). To verify the specificity of these
interactions, I also performed the overlay with an in vitro expressed
fragment of a-dystroglycan, another synaptic protein. Each method
revealed multiple binding proteins. However, by coordinating these two
methods and directly comparing the results, I found one PSD- fraction
protein, PSD22S, that was identified by both fusion protein affinity and
blot overlay. Thus, PSD225 is significantly more likely to be a true
binding partner for IRSp58/53 than the many proteins identified using
one of the two binding assays. If the interaction shown in this pair of
experiments is shown to withstand increasingly stringent conditions,
then this binding interaction should be pursued. Further studies will
then be required to determine if PSD225 is a true IRSp58/53 binding
partner in vivo.
Localization of the insulin receptor to synapses
Although a binding partner for IRSp58/53 has not yet been
substantiated, a functional partnership has been established. IRSp58/53
has been shown to be an insulin receptor substrate in cultured
fibroblasts. Further, IRSp58/53 isolated from brain can be tyrosine
phosphorylated in vitro by insulin receptor (Yeh et al., 1996). Insulin
receptor is known to be expressed in brain, and other components of
insulin signaling pathways have been localized to brain regions as well
(see above). I thus sought evidence for the presence of the insulin
receptor at postsynaptic apparatus in vivo. Indeed, staining specific
for the subunit of the insulin receptor is concentrated at synapses in
cultured hippocampal neurons (Figure 14A; David Wells, Brown
University). This evidence is in agreement with recent findings of Beju
and Schechter. Using irnuno-gold electron microscopy, they demonstrate
insulin and insulin receptor within the axon and dendrites of
hippocampal neurons in brains of rats 10 days old. They have localized
insulin ultrastructurally to presynaptic regions, and the insulin
receptor to presynaptic and postsynaptic memranes (Beju and Schechter,
1998) .
10 The Insulin Receptor is a component of the PSD fraction
After determining that a population of inulin receptor is
concentrated at synapses in culture, I was interested in whether the
insulin receptor is associated with the pre- or postsynaptic
specialization. I probed western blots of brain subcellular fractions
with an antibody to the ~ subunit of the insulin receptor. The insulin
receptor was detected in homogenate, and was enriched in both
synaptosome and PSD fractions (Figure 14B). Thus, both the ~ subunit of
the insulin receptor tyrosine kinase and its substrate IRSp58/53 are
components of the PSD fraction. Indeed, using EM, Beju and Schechter
have localized insulin ultrastructurally to the PSD structure itself (D.
Beju, personal communication). Taken together with other data showing a
functional relationship of the insulin receptor and IRSpS8/S3, this co-
localization suggests that these molecules are part of an insulin-
dependent signaling pathway at the postsynaptic apparatus.
The co-fractionation of the insulin receptor and its tyrosine
kinase substrate IRSp58/S3 strongly suggests that their established
functional relationship is maintained within the synaptic signaling
structure of the PSD.
Discussion
In this portion of my thesis work, I show that a substrate of the
insulin receptor, and insulin receptors themselves, are localized at CNS
synapses and are components of the postsyn pti density. Insulin is
likely to have diverse roles in the CNS, including but not restricted to
the regulation of glucose metabolism. Interestingly, there is a growing
body of evidence that implicates insulin signaling in processes other
than homeostasis (reviewed in (Wickelgren, 1998)). The multivariate
downstream effects of insulin signaling may be coordinated through
spatially regulated expression of the insulin receptor tyrosine kinase
substrate molecules. signaling via a synapse-specific substrate,
IRSp58/53, may define a subset of the insulin signaling pathway.
1 IRSp58/53 and Insulin Receptor are localized to 
synapses
I began my investigation of synaptic insulin signaling proteins at
the level of the PSD, an electron-dense conglomeration of proteins that
lies just below the postsynaptic memrane of central synapses. I have
characterized and purified a pair of proteins of unknown 
identity, p58
and p53, that is selectively concentrated in the biochemical fraction
enriched for PSDs. Using MADI-TOF mass spectrometry, peptide
sequencing, two-dimensional electrophoresis, and western blotting,
' I
have identified these PSD proteins as the Insulin Receptor Substrate
p58/53 (IRSp58/53). A small numer of p58 and p53 peptide masses
obtained by MADI-TOF analysis do not match computed IRSp53 masses
(Table 1). This presumly reflects species-dependent divergences
(hamter versus rat) or posttranslational modifications. Notably, IRSp53
has sites for N-linked glycosylation, two potential tyrosine
phosphorylati sites, and 25 potential serine/threonine phosphorylati
si tes.
I have shown that another key insulin signaling protein, th
insulin receptor, is also a component of the PSD fraction. Generally,
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transmemrane proteins such as the insulin receptor do not remain
associated with the Triton X-100 insoluble PSD. There are significant
exceptions however, and the most well-studied of these is the NMA
receptor. Specific subunits of the NMA receptor are thought to be
tethered to the PSD through an interaction between the NMAR C-terrinus
and the second PDZ domain within PSD-95 (Kornau et al., 1995j Kim et
al., 1996). The receptor tyrosine kinase TrkB has also been localized to
the PSD fraction (Wu et al., 1996).
Although the PSD fraction is a powerful tool for identifying
molecules that are specifically localized to the synaptic apparatus,
this biochemical preparation can not precisely reflect the constitution
of the synapse in vivo. Thus, with the help of David Wells (Brown
University) " I demonstrated the presence of insulin signaling
components at intact CNS synapses in culture. IRSp58/53 is expressed in
the synapse-rich layers of the cerebellum, and both IRSp58/53 and
insulin receptor are concentrated at synapses of hippocampal neurons.
Structure of IRSp58/53
I consistently observed that IRSp58/53 migrates as a pair of
polypeptides. However, I could find little evidence that IRSpS8 and
IRSp53 differed in their primary sequences. HPLC chromatograms of
trytic fragments from p58 and pS3 were virtually identical. MADI-TOF
analysis of purified p58 and p53 also revealed similar profiles - only
two p58 masses and one pS3 mass were unique. Although these masses could
represent divergent primary sequences, they could also be due to
posttranslational modification or proteolysis. Indeed, the relative
expression of IRSpS8 and IRSpS3 is cell and tissue specific.
Transfection of the IRSpS3 cDNA into fibroblasts results in expression
of only the IRSp53 species (Yeh et al., 1996). Further, I detected only
IRSp58 in PSD fractions from porcine brain. Finally, using RT-PCR I
detected only a single species of IRSp53 mRA in the brain, and a survey
of the EST database yielded no evidence of multiple mR species.
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However, my comparative analysis of the IRSp53 cDNA to total rat brain
cDNA does not exclude the possibility that differences exist 5' or 3' to
the IRSp53 coding region. Such differences could be uncovered by
performing 3' and 5' rapid amlification of cDNA ends (RACE).
The IRSpS3 cDNA clone was the only cDNA isolated from a CHO
library screened for cDNAs that encoded amino acid sequences matching
two peptides obtained from IRSpS8. It encodes a predicted protein with a
molecular weight of 57. 6 kDa. However, transfection of this cDNA into
fibroblast cell lines induces overexression of only the IRSp53 species,
so Yeh and colleagues reached the conservative conclusion that the cDNA
encoded only IRSpS3, and surmised that IRSp58 was a related splice form
of IRSp53 (Yeh et al., 1996). In contrast, I used a rabbit reticulocyte
system to in vitro translate IRSp53, and observed that the product was a
tight doublet of approximately 60 kDa (see Figure 12B) 
Analysis of the IRSp53 cDNA reveals an open reading frame that
encodes for a predicted protein of 57. 6 kDa (Yeh et al., 1996).
Interestingly, downstream of this first ATG codon are at least six
subsequent potential start sites. Utilization of one of these in
particular would yield a polypeptide with a predicted molecular weight
of 53. 6 kDa. Therefore, it is possible that use of alternative
initiation sites is the basis for the observation of this pair of
polypeptides of 58 kDa and 53 kDa. Nevertheless, my data are most likely
to fit scenario whereby IRSpS8 and IRSp53 derive from an identical mRA
coding region, and the difference in these polypeptides is the result of
a species and cell background-dependent, post translational process.
This investigation of IRSp58/53 was a outgrowth of my use of an
antiseru directed against ~-dystroglycan (Ab98). Comparison of the
IRSp53 and dystroglycan sequences revealed that these proteins have
little to no homology. The immunological cross-reactivity that Ab98
demonstrated for IRSpS8/S3 is presumably due to a proline-rich stretch
of amino acids within its amino acid sequence (KPLPVPPELAPF) that is
similar to the ~-dystroglycan peptide used to generate Ab98
(KAPLPPPEYPSQ). Notably, another group has reported a PSD fraction
protein (not IRSpS8/53) that is immunologically related ~-dystroglycan
:.,=
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(Mumery et al., 1996). To date however, neither the identity of this
164 kDa PSD fraction protein, nor its homology/relationship to ~-
dystroglycan, have been shown.
Interactions of IRSp58/53
There is compelling evidence in support of the functional
classification of IRSp58/53 as an insulin receptor substrate. Yeh and
colleagues demonstrated that IRSp58/53 isolated from brain can be in
vi tro tyrosine phosphorylated by insulin receptors isolated from CHO. T
cells (Yeh et al., 1996). I have found that, following in vitro
phosphorylation of the insulin receptor-containing PSD fraction,
IRSp58/53 experiences a gel shift consistent with phosphorylation by an
endogenous kinase (s). These data implicate IRSp58/S3 as a brain-derived
substrate of the insulin receptor.
The downstream molecules that orchestrate insulin s potential
action at the synapse are unknown. The predicted domain structure of
IRSp53 (Figure 6) indicates may potential sites for protein-protein
interactions including an SH3 domain, an SH2-binding domain, and a
proline-rich WW-binding domain (Yeh et al., 1998). I asked whether
IRSp58/53 interacts with the WW domain of dystrophin, a PSD-enriched
cytoskeletal protein, but I was unable to co-immunoprecipitate in vitro
expressed dystrophin fragments and IRSp58/53. I noted a report of a
human homologue of IRSp53 (FLA3) that interacts with the intracellular
domain of Fas Ligand (FasL) in a yeast two hybrid assay, and I found
that FasL is expressed in brain, but I found no evidence of IRSp58/53
binding to native brain FasL. Lastly, I did not detect co-
immunoprecipitation of any native PSD fraction proteins with IRSp58/53.
Other investigators have similarly been unable to demonstrate binding
partners for IRSp58/53 (Yeh et al., 1996).
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Insulin signaling at synapses
Insulin is likely to have many roles in the brain. One expects
insulin signaling in the brain to playa role in glucose metabolism as
well as in currently unidentified processes. Insulin signaling pathways
may in fact be implicated in the progression of some disease states,
including Alzheimer s disease (Hong and Lee, 1997; Frolich et al., 1998;
Hoyer, 1998; Qiu et al., 1998). Key components of the insulin signaling
mechanism, such as insulin receptor, phosphatidyl inositol-3 kinase, and
IRS-1, are widely expressed and often co-distributed throughout the
brain. These elements are found in various regions of the brain, in
neurons and in some synapse-rich regions (Baskin et al., 1994; Folli et
al., 1994; Yamada et al., 1997). Recent data, including those presented
here, strongly support the tenet that insulin signaling occurs
throughout the brain, as well as specifically at synapses.
One compelling piece of evidence for a direct insulin effect at
synapses is the finding that insulin induces a rapid recruitment of
functional type A GABA receptors, the principal neurotransmitter at
inhibitory synapses, from intracellular to postsynaptic and dendritic
memranes (Wan et al., 1997). Inhibition of protein tyrosine kinases
blocks this translocation, suggesting that an activated insulin receptor
is required to execute insulin I s effect. This translocation of GABAA
receptors is observed in HEK cells, hippocampal neurons in culture, and
neurons in hippocampal slices (Wan et al., 1997).
IRSpS8/S3 may define a synapse-specific insulin signaling
pathway
The expression of the insulin receptor is neither restricted to
the brain nor restricted to the synaptic apparatus. Similarly, IRS-1 and
IRS-2 are expressed both in the periphery and in the CNS: brain IRS-
(and perhaps IRS-2) is localized in neuronal cell bodies, and some
proximal dendrites (Baskin et al., 1994; Folli et al., 1994; Yamada et
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al., 1997). In contrast, IRSp58/ 53 expression is restricted to brain, to
neurons, and specifically to the PSD-enriched biochemical fraction.
Interestingly, IRSpS8/S3 is not the first examle of an insulin receptor
substrate that displays a subellularly restricted exression pattern.
In adipocytes, another substrate of the insulin receptor IRS-3, has been
shown to have a subcellular distribution pattern that distinguishes it
from IRS-1 and IRS- (Anai et al., 1998). The spatial coordination of
IRS proteins may contribute to the determination of tissue, cell, or
subcellular variations in insulin s action.
Thus, the selective expression of different insulin receptor
substrates may facilitate a careful control of insulin-activated
signaling. Indeed, IRSp58/53 may define a special type of insulin
signaling in the brain. The discovery that IRSp58/53 is a synapse-
specific substrate for the insulin receptor tyrosine kinase provides the
first evidence for an insulin signaling mechanism at synapses. It is
likely that other elements of this synaptic insulin signaling pathway
will soon emerge. One expects that the effect of insulin at synapses is
distinct from its global, metabolic control. However, the nature of this
effect, and its effectors, remain to be elucidated.
Future Directions
Work focused at the PSD has to date provided many insights into
the complexity of the synapse. Using the PSD biochemical preparation, I
have found two components of an insulin-dependent signaling pathway at
synapses. IRSp58/S3 and the insulin receptors are components of the PSD
fraction. The protein IRSp58/53 exists in two forms (IRSp58 and IRSp53)
which have similar primary structure and may not differ in
posttranslational additions. Most likely, IRSp58 and IRSpS3 are products
of two different start sites. There are at least two mR transcripts
that encode IRSp58/S3 that are likely to be different in their noncoding
regions. Levels of IRSp58/53 mR are highest in brain and testis.
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IRSpS8/53 is at synapses in vivo in cerebellum and cultured hippocampal
neurons.
The discovery that IRSpS8/S3 is a synapse-specific substrate for
the insulin receptor tyrosine kinase provides the first evidence for
insulin-dependent signaling at central synapses. Localization of the
insulin receptor to the PSD fraction supports this hypothesis. It is
likely that other elements of this synaptic insulin signaling pathway
are buried in the postsynaptic density as well; some may diverge from
the components that have been identified and characterized in peripheral
tissues, while others may be known components of this signaling pathway.
Future studies are required to determine the role of insulin
signaling at synapses. Technologies such as the yeast two hybrid assay
(see Chapter I) should now be exploited to uncover the other crucial
synapse-specific effectors of insulin s synaptic signal. Once a backbone
of signaling elements has been identified, a role for insulin in
learning and memory can be sought. There are numerous pharmacologic
methods that can be used to affect many levels of signaling pathways.
Enzymes that work downstream of the insulin receptor tyrosine kinase can
-- 
be inhibited and the effect of this treatment on the healthy development
and function of a synapse can be monitored. For example, the compounds
wortmannin and LY294002 specifically inhibit the kinase activity of
PI3K. Many mouse models with null mutations in various elements of the
traditional insulin signaling pathway have been and are being created
(Araki et al., 1994; Taremoto et al., 1994; Bruing et al., 1997).
Little attention has been paid to CNS function in these mice. Careful
evaluation of neuronal physiology and synaptic morphology and
functionality in these models and in future "knockouts " would contribute
substantially to the understanding of insulin s role in the brain.
The relationship between FasL and IRSpS8/S3 must be examined
further. An interaction between these proteins will suggest a role,
perhaps in intracellular signaling, for the little studied endodomain of
FasL. A protein-protein interaction between these two might be
demonstrated using in vitro expressed molecules. Similarly,
colocalization of FasL and IRSp58/53 might be appreciated upon co-
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transfection of these proteins in heterologous cells. If a relationship
is found, the domain of IRSp58/53 that mediates this interaction should
then be mapped, since no protein-protein interaction domains have been
identified within the region of IRSp58/S3' s putative FasL interaction. A
direct way to asses the role of IRSpS8/S3 in vivo is to generate
IRSp58/53 null mice. Analysis of brain (and other tissues) from these
animals is likely to indicate what types of biologic functions require
the work of this signaling molecule.
Discovering the focus of insulin signaling elements at synapses
would be a launching pad for future study. It is likely that insulin
role in the brain is important in homeostasis and, as suggested by these
data, in synaptic function. Results from the experiments proposed above
would contribute to dissecting this compelling synaptic signaling
pathway.
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Tables and Figures
1 Figure Legends
Figure 1. Insulin Receptor and Relatives (see Introduction)
Figure 2. Insulin Receptor Signaling (see Introduction)
Figure 3. Insulin Receptor activation, GLUT4 translocation (see
Introduction)
Figure 4. A 58 kDa and a 53 kDa polypeptide are enriched in PSDs
A. Homogenate, synaptosome, and PSD fractions from rat brain were
separated by SDS-PAGE, transferred to nitrocellulose, and probed with
Ab98 (left) or Ab98 that had been pre-incubated with peptide (right). ~-
dystroglycan is observed in the homogenate and synaptosomal fractions
DG) and a pair of polypeptides of 58 and 53 kDa is specifically
detected in the PSD fraction (p58 and p53). Binding of Ab98 to all three
polypeptides is eliminated when the antibody was preabsorbed (Ab98 +
peptide). Mobilities of molecular weight standards are indicated. (H,
homogenate; SX, synaptosomes; PSD, postsynaptic density fraction.
B. Western blots of homogenate, synaptosomes, and PSD fractions from
the indicated brain regions were probed with antibody Ab98. pS8 and p53
are selectively enriched in the PSD fractions from all areas examined.
C. Comparison of PSD blots stained for protein (ponceau S, PS) or
western blots (WE) probed with Ab98 indicates that pS8 and p53 (arrows)
are interdigited between three major PSD proteins (*
Figure 5. Purification of p58 and p53 by 2D gel electrophoresis and
hydrophobic interaction chromatography (HIC)
A. Two-dimensional gel electrophoresis was used to separate PSD
fraction proteins. Gels of equivalent samples were silver stained (left)
or blotted to nitrocellulose and probed with Ab98 (right). Comparison of
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these reveals that p58 and p53 are minor components of the complex PSD
fraction. The migration of pS8 and pS3 in the first dimension indicates
that these polypeptides are basic (pI -9).
B. The PSD fraction proteins were solubilized in urea, loaded onto a
HIC colum in 1M NaCl buffer, and then eluted in 0 . 1M NaCl salt buffer.
2D gels of the HIC eluates were either silver stained (left) or blotted
to nitrocellulose and probed with Ab98 (right). p58 and p53 are readily
visualized in silver stained gels of HIC eluate (arrows), indicating
that they are highly enriched by this procedure.
Figure 6. Structure of Insulin Receptor Tyrosine Kinase Substrate p53
IRSp53 is predicted to contain several protein-protein interaction
domains: one SH3 domain (SH3) , one SH3 binding domain, and one WW
binding domain (Yeh et al., 1998). Additionally, there are 25 potential
serine/threonine phosphorylation sites (protein kinase A, protein kinase
C, and casein kinase; not shown) and two potential tyrosine
phosphorylation sites (pY). The positions of the peptide microsequences
obtained from purified p58 are noted. The positions of the epitope that
is likely to be recognized by Ab98, and of the peptide used to generate
the polyclonal anti- IRSp58/53 antiseru are indicated. The region that
corresponds to the IRSp53 DNA .fragment used as a probe for Northern
blots is also shown.
Figure 7. Relationship of IRSp58 and IRSp53 from PSDs
A. PSD fractions from rat brain were incubated under conditions
promoting in vitro phosphorylation in the either the absence (left) or
presence (right) of added ATP (100 uM), as described in Methods. Western
blotting with Ab98 shows that IRSpS8 and IRSp53 undergo similar gel
shifts following in vitro phosphorylation.
B. Species differences in the expression of IRSp58 and IRSp53 in PSD
fractions. PSD fractions from rat (left) and pig (right) were probed
with antibody Ab98. Although similar amounts of IRSpS8 and IRSp53 are
detected in rat PSDs, only IRSpS8 is detected in porcine PSDs.
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Figure 8. Tissue distribution of IRSp58/53 rnAs
A. A multiple rat tissue Northern blot was probed with a radio labeled
IRSpS8/S3 oligonucleotide probe (248 bPi see Fig. 3) as described in
Methods. Transcripts of 2. 4, 3. 5, and 8 kb are observed. The highest
level of IRSpS8/S3 mR is detected in brain, with the 3. 5 kb transcript
predominating.
B. The blot was rehybridized with a probe for ~actin to verify the
integrity and quantity of the RN from each tissue.
Figure 9. Structural analysis of brain IRSpS8/53 rnA
A. RNA isolated from rat cerebral cortex was reverse transcribed using
random primers. The resulting cDNA was amplified by PCR using seven sets
(1-7) of six primers (A- F; see B. ). PCR products from the cerebral
cortex cDNA (' RT' ) are equivalent in size to those produced using the
cloned IRSp53 cDNA as a template (' c
B. The PCR products (numered 1-7) were generated using a set of three
forward and three reverse primers (A-F, arrows) that spanned the entire
coding region (thick line) of IRSp53.
Figure 10. Characterization of anti-IRSp58/53
Rabbits were immunized with a 13 amino acid peptide from the predicted
amino acid sequence of IRSp58/53 and the resulting antiseru was
affinity purified. On western blots, anti- IRSp58/53 antibody recognizes
polypeptides of 58 and 53 kDa, which are also bound by Ab98. However,
anti-IRSp58/53 does not recognize ~-dystroglycan. All anti- IRSp58/S3
imunoreactivity is abolished if the antibody is preabsorbed with
peptide.
Figure 11. Localization of IRSpS8/53 at intact synapses
A. Localization of IRSpS8/53 in the molecular layer of the cerebellum
Sections of rat cerebellum were imunostained with the affinity purified
anti-IRSpS8/S3 or with anti-synapsin-I antiseru (to reveal the
distribution of synapses). IRSp58/53 immunoreactivity is observed in the
synapse-rich molecular layer as well as in the granule cell layer. Anti-
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IRSp58/53 immunoreactivity is greatly reduced when the antibody was
preabsorbed with peptide. (Scale bar: 50 ; M, molecular layer; PC,
Purkinje cell layer; GC, granule cell layer)
B. Localization of IRSpS8/S3 at synapses in culture
Cultured rat hippocampal neurons were imunostained with the affinity
purified anti-IRSp58/53 antiseru (left). IRSp58/53 immunoreactivity is
distributed in a punctate pattern along the dendrites of the neurons.
The distribution of synapses in the same dendrite was visualized by
double- labeling with anti-synaptophysin (right). IRSp58/S3
immunoreactivity is selectively concentrated at synapses (arrows).
Figure 12. Candidate IRSp58 / 53 binding partners
A. Western blots of subcellular fractions were probed for Fas Ligand.
FasL is present in all brain fractions, and is not concentrated in the
PSD fraction.
B. 35S labeled in vitro translated proteins (DYS, DP71, and IRSp53)
were co-incubated as indicated and immunoprecipitated with appropriate
antibodies as indicated (DYS2 and H720). The WW domain of dystrophin
(present in the DYS in vitro translated protein, shortened in the DP71
protein) does not coimmunoprecipitate IRSpS8/S3 (or vice versa). Probe
that was not labeled with 35S is indicated as -
C. A panel of antibodies was used to immunoprecipitate selected
proteins from the PSD fraction (biotin labeled). Only H720 (and neither
Ab98 nor anti-IRSp58/53) immunoprecipitates native IRSp58/S3. PY99 and
4G10 are anti-phosphotyrosine antibodies (Santa Cruz). No proteins co-
irnunoprecipitate with native IRSp58/53 (arrows).
Figure 13. A potential IRSpS8/53 binding partner
Biotin-labeled PSDs were incubated with a GST-tagged IRSpS3 colum. A
group of PSD proteins specifically bound the IRSpS3 colum (left).
Adjacent blots of equivalent PSD samples were probed with in vitro
expressed 3SS- labeled IRSp58/53, or aO as control (right). Comparison
of the two experiments reveals one band, PSD225, that binds both the
GST- IRSp53 colum and in vitro expressed IRSp53 ligand.
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Figure 14. Localization of Insulin Receptor at synapses and
in PSD fractions
A. Localization of insulin receptor at synapses
Cultured rat hippocampal neurons were immunostained with anti- insulin
receptor ~ subunit antibody (right). Immunoreactivity is distributed in
a punctate pattern along the dendrites of the neurons. The distribution
of synapses in the same dendrite was visualized by double-labeling with
anti-synaptophysin (left). Insulin receptor ~ subunit immunoreactivity
is selectively concentrated at synapses (David Wells, Brown University) 
B. The Insulin Receptor ~ subunit is a component of the PSD fraction
A western blot of rat brain subcellular fractions (homogenate,
synaptosome, PSD) and CHO.T (cell line engineered to overexpress insulin
receptors) cell lysate was probed.with an ant'i:'inslilin receptor 
subunit antibody. The ~ subunit of the insulin receptor is detected in
brain homogenate, synaptosome, and PSD fractions. High levels of insulin
receptor ~ subunit are seen in CHO. T cell lysate.
Tables and Figures
Table 1. Mass Spectrometry and Peptide Microsequence Analysis of p58/53
p58 and p53 trvctic fraaments predicted IRSc53 trvctic fraamentst peptide
c58 masses c53 masses IRSc53 masses position
microseauencett
788. 788. 788. 6 - 11
1336. 1336.4 1336. 19 - 29
912. 913. 51 - 58
GYFDAL VK
1645. 1644. 71 - 84
1374. 1374. 85 - 95
1009. 1010. 123 - 130
912. 913. 129 - 136
1788.2 1789. 1788. 157 - 171
YSDKELQYIDAISNK
1374. 1374.4 161 - 171
1502. 1502. 1502. 172 - 184
1788. 1789. 1789. 201 - 214
877. 877. 207 - 214
2023. 2023. 2023. 223 - 239
1352. 1352. 1352. 334 - 345
1480. 1480. 334 - 346
1009. 1009. 365 - 374
1336. 1336.4 1336. 365 - 377
1426. 1426. 399 - 411
1208. 1208.4 1208. 412 - 421
DGWHYGESEK
1042. 1042.4 1044. 435 - 443
1042. 1042.4 1042. 444 - 452
2298. 2298. 489 - 509
1426. 1427. 510 - 521
804. 804.
824. 824.
842. 842.
942.
952.4
1155. 1155.
1572.
1754. 1754.
2607.4 2607.
t Calculated masses of IRSp53 tryptic fragments that correspond to p58 or p53 masses are listed.
. All masses are in Daltons.
.. Amino acid positions of the fragments are based on the numbering system of Yeh et. aI.
, 1996.
tt Peptide microsequences were obtained from three p58 tryptic fragments (underlined).
These were identical to deduced IRSp53 amino acid sequences.
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I The Insulin Receptor Tyrosine Kinase Substrate p58/53 and the
InSUlin Receptor Are Components of CNS Synapses
, Mary-Alice Abbott,1. David G. Wells,1 and Justin R. Fallon
. 'University of Massachuseffs Graduate Schoof of Biomedical Sciences, Worcester, Massachuseffs 01655 and
Department of Neuroscience, Brown University, Providence, Rhode Island 02912
The synapse is the primary locus of cell-cell communication in
the nervous system. It is now clear that the synapse incorpo-
rates diverse cell signaling modalities in addition to classical
. neurotransmission. Here we show that two components of the
insulin pathway are localized at CNS synapses, where they are
components of the postsynaptic density (PSD). An immuno-
chemical screen revealed that polypeptides of 58 and 53 kDa
(p58/53) were highly enriched in PSD fractions from rat cerebral
cortex, hippocampus, and cerebellum. These polypeptides
. were purified and microsequenced , revealing that p58/53 is
identical to the insulin receptor tyrosine kinase substrate
The Journal of Neuroscience, September 1 1999 , 19(17):7300-7308
p58/53 (IRSp53). Our analysis of IRSp58/53 mRNA suggests
that within rat brain there is one coding region for IRSp58 and
IRSp53; we find no evidence of alternative splicing. We dem-
onstrate that IRSp58/53 is expressed in the synapse-rich mo-
lecular layer of the cerebellum and is highly concentrated at the
synapses of cultured hippocampal neurons, where it co-
localizes with the insulin receptor. Together, these data suggest
that insulin signaling may playa role at CNS synapses.
Key words: insulin receptor; postsynaptic density; insulin re-
ceptor substrate; hippocampal neurons; brain; IRSp53
The synapse is the predominant site of cell-cell communication
in the nervous system. In both the central and peripheral nervous
systems , synapses are characterized by the precise apposition of
Ii the presynaptic nerve terminal and postsynaptic apparatus. Fast
.. synaptic transmission relies on the coordinated localization of
.. synaptic vesicles and neurotransmitter receptors at this site (Sal-
peter, 1987; Peters et al. , 1991). Synapses are also distinguished
by the presence of specialized molecular machinery for regulated
exocytosis, neurotransmitter receptor clustering, and signal trans-
, duction (Hall and Sanes, 1993; Sheng and Wyszynski, 1997; So-
mogyi et al. , 1998). Notably, synapses also support a range of
other cell-cell signaling modalities. For example, neurotrophins
and growth factors can modulate synaptic growth, plasticity, and
function (Lohof et al. , 1993; Kang and Schuman , 1995).
Insulin and its receptor are expressed in the brain, where they
are likely to regulate glucose homeostasis and gene expression
(Wozniak et al. , 1993). Moreover, a number of findings have also
suggested a relationship between insulin and Alzheimer s disease
(Craft et al. , 1996; Frolich et al. , 1998; Hoyer, 1998; Wickelgren
1998). For example, insulin action inhibits tau hyperphosphory-
lation and thus may block the formation of neurofibrillary tangles
(Hong and Lee , 1997). In addition, insulin and its receptor may
also playa role at synapses (Unger et al. , 1989; Wozniak et al.
, 1993; Schechter et al. , 1996). Destruction of insulin receptors by
, intracerebroventricular injection of streptozotocin leads to long-
term deficits in learning and memory (Lannert and Hoyer , 1998).
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Insulin can be released from both cultured neuronal cells and
synaptosomes in an activity-dependent fashion (Clarke et al.
1986; Wei et al. , 1990). Moreover, insulin can recruit GABA
receptors to postsynaptic domains (Wan et al. , 1997), suggesting
a role for this hormone in synaptic plasticity.
The insulin receptor is a tyrosine kinase , but many of its actions
require accessory molecules known as insulin receptor substrates
(e. , IRS- , IRS- , and IRS-3) (White and Yenush, 1998). In
peripheral tissues, these substrates become phosphorylated by the
insulin receptor and then coordinate flexible and diverse signal-
ing pathways (Shepherd et al. , 1998). In addition, IRS proteins
exhibit distinct subcellular localizations, raising the possibility
that they subserve spatially and qualitatively distinct intracellular
signaling events (Anai et al. , 1998). Therefore, characterizing
insulin receptor substrates and determining their localization in
the CNS may provide insights into diverse insulin actions in the
brain.
In the CNS, many synaptic signaling molecules are concen-
trated in the postsynaptic density (PSD) (for review, see Sheng,
1997; Ziff, 1997). In the current study, we show that the insulin
receptor substrate IRSp58/53 is highly enriched in PSD fractions.
Microsequencing of IRSp58 and IRSp53 polypeptides suggests
they difer only in some post-translational modification. A survey
of several tissues revealed that IRSp58/53 and its mRNA are most
highly expressed in the brain. IRSp58/53 is localized in the
dendritic layers of the cerebellum and is concentrated at synapses
in cultured hippocampal neurons. Finally, we show that the insu-
lin receptor is both concentrated at synapses and is a component
of the PSD fraction. Together , these data suggest that the synapse
is an important site of specialized insulin signaling in the brain.
MATERIALS AND METHODS
Brain subcellular fractions. PSD fractions were prepared according to the
method described elsewhere (Carlin et aI. , 1980; Dosemeci and Reese
1993; Wu et aI. , 1998). The absence of presynaptic contaminants and
enrichment of PSD proteins in this fraction was confirmed by Western
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blotting with antibodies to NMDA receptor subunit 1, ex-Ca 2+ /
calmodulin-dependent kinase II (ex- aMKII), and synaptophysin (Wu et
aI., 1998).
Antibodies. Ab98 antiserum was raised by immunizing a rabbit with the
peptide KAPLPPPEYPSQ (a sequence in the cytosolic domain 
f3-dystroglycan that was used for the production of antibody PA3a;
Yoshida et aI. , 1993) and was affnity-purified (Quality Controlled Bio-
chemicals , Hopkinton, MA). The anti-IRSp58/53 polyclonal antibody
- was raised by injecting a rabbit with the MAP-conjugated peptide DK-
DDLALPPPDYGT (Research Genetics, Inc. , Huntsvile, AL) and was
. affnity-purified. Immunoabsorption was performed by mixing the pri-
mary antibody with its corresponding peptide for 2 hr to overnight at 4
The IRSp53 monoclonal antibody H720 is described elsewhere (Yeh et
: aI. , 1996).
Insulin receptor f3-subunit polyclonal antibody (C-19) was obtained
. from Santa Cruz Biotechnology (Santa Cruz, CA). An anti-peptide
antiserum to f3-dystroglycan (12031C) was a generous gift of L. Kunkel
(Howard Hughes Medical Institute, Harvard Medical School). Monoclo-
nal anti-f3-dystroglycan antibody NCL-43DAG was obtained from Vector
, Laboratories (Burlingame , CA). Monoclonal antibodies to synaptophy-
sin (SY38) and to ex-CaMKII (6G9) were obtained from Boehringer
Mannheim (Irvine, CA). Antibody to NMDA receptor subunit NRI
; (54.1) was obtained from PharMingen (San Diego, CA).
Western blotting. Protein concentrations were determined with the
BCA protein assay (Pierce, Rockford, IL) using BSA as a standard.
Equal quantities of homogenate , synaptosomal, and PSD fraction pro-
teins were separated on 10 or 5-15% gradient gels by SDS-PAGE
transferred onto nitrocellulose membranes, and incubated with primary
antibodies followed by alkaline phosphatase-conjugated goat anti-rabbit
or anti-mouse IgG (Boehringer Mannheim, Indianapolis , IN). Bound
antibody was visualized using the 5-bromo-4-chloro- indolyl phosphate/
nitro blue tetrazolium substrate system (Promega, Madison, WI). In
. some experiments , Iysates of Chinese hamster ovary (CHO).T cells
, which overexpress insulin receptors (generously provided by M. Czech
University of Massachusetts Medical Center; Baltensperger et aI. , 1996),
were also analyzed.
Hydrophobic interaction chromatography. For hydrophobic interaction
Ii chromatography (HIC), PSDs were solubilized overnight at 4 C in 8 M
.. urea, 1 M NaCI, 5 mM dithiothreitol (DTT), 50 mM sodium phosphate
buffer, pH 7.5. The soluble fraction was then made 4 M in urea and
incubated with HIC matrix (high-performance phcnyl-Sepharose; Phar-
. macia Biotech, Piscataway, NJ) for 3 hr at 4 e. The HIC matrix was then
washed, preeluted in the same buffer with 0.8 M NaCl, and eluted with
the same buffer in 0. 1 M NaCI. Apomyoglobin (Sigma, St. Louis, MO)
was added as a carrier to the eluate, and the proteins were precipitated
with trichloroacetic acid.
Two-dimensional gel electrophoresis. Isoelectric focusing (IEF) strips
(Immobiline Dry Strips, pH 3- 11 em; Pharmacia) were rehydrated for
6 hr to overnight at room temperature in two-dimensional (2D) sample-
rehydration buffer (8 M urea, 2% 3-((3-cholamidopropyl)dimethyl-
ammonioj- propanesulfonic acid, 2% immobilized pH gradient buffer
10L (Pharmacia), and 0.3% DTT. Samples were loaded at the anodic
end of the IEF strip, and IEF was performed at 20 C on a Multiphor II
apparatus (Pharmacia) for 1 hr at 300 V and 15 hr at 1400 V. The strips
were then equilibrated and electrophoresed in the second dimension
(10% gel, SDS-PAGE), as per the manufacturer s instructions. The 2D
gels were stained with either silver (Morrissey, 1981) or Coomassie blue
or transferred (10 V, 16 hr) to nitrocellulose for Western blotting.
Matrx-assisted laser desorption ionization time-of-flight mass spectrom-
etry and peptide sequencing. HIC eluates separated by 2D electrophoresis
were visualized by Coomassie blue stain, and the bands corresponding to
p58 and p53 were excised from the gel. The polypeptides were recovered
from the gel and subjected to trypsin digestion. Peptide masses were
determined by matrix-assisted laser desorption ionization time-of-flight
mass spectrometry (MALDI- TOF MS). MS-Fit search software was then
used to compare the p58 and p53 mass profiles to known proteins.
Tryptic fragments from p58 and p53 were separated by HPLC, and
peptide sequence was obtained from three fragments of p58 (J. Leszyk
Worcester Foundation Protein Sequencing Facility, Worcester, MA).
In vitro phosphorylation of PSD fraction proteins. The method used is
a modification of a procedure described elsewhere (Dosemeci et aI.
1994). PSDs were pretreated on ice for 3 hr with occasional mixing in 20
mM HEPES , pH 7.4, and 100 mM DTT. PSDs were diluted to a final
concentration of 0.4 mg of protein/ml in phosphorylation solution (5 mM
MgCI , 50 p.g/mlleupeptin, 20 mM DTT, 20 mM HEPES, pH 7.4 , 1 mM
J. Neurosci. , September 1 1999 , 19(17):7300-7308 7301
CaClz, and 1 mM orthovanadate, with or without 100 P.M ATP), and
incubated at 37 C for 5 min. The reaction was quenched by the addition
of SDS sample buffer.
Northern blot hybridization. A 32 Iabeled probe was synthesized by
PCR using the IRSp53 cDNA clone (provided by R. Roth, Stanford
University School of Medicine; described by Yeh et aI. , 1996) as tem-
plate, and the primer pair Fl , AAGAGCGTGACCCCGAAGAA-
CAGC; and Rl , AACCAGCCCCGCATTTTG.
The rat Multiple Tissue Northern Blot (Clontech, Palo Alto, CA) was
probed as instructed by the manufacturer. The most stringent wash
performed was O. IX SSC and 0. 1 % SDS at 65 C for 40 min.
RNA isolation and RT-PCR. RNA was isolated from 20 mg of rat
cerebral cortex by the RNeasy mini kit (Qiagen, Chatsworth, CA). The
total RNA (30 
p.g) 
was reverse-transcribed using random primers , and
this reaction product was used as the template for PCR. The PCR
conditions were 3 min at 94 , 40 cycles (30 see at 94 , 1 min at 55
and 4 min at 68 C), and 8 min at 68 e. The sequences of the primers used
are as follows, 5' to 3' : A , GTGTAGCCGGGACCCAGGACCAT; B
CGAGGAGCGGAGGAGGTTCTGC; C AAGAGCGTGACCCCG-
AAGAACAGC; D, AACCAGCCCCGCATTTTG; E, ACGGCCA-
CACTGTAGGGTCTCTGC; and F, TCTAGTCAGGGGCAGCTC-
AAAATC.
Tissue sections and immunohistochemistry. Brains from adult rats were
immersed in freezing isopentane, mounted in OCT embedding medium
and equilibrated to - e. Frozen sections (8 p.m) were cut, air-dried
onto glass slides, fied in MeOH at - C for 10 min, and rehydrated in
PBS with 0.1 % Triton X- I00 (PBST). The sections were blocked for 1 hr
at room temperature with PBST, 1 % BSA , 10% horse serum, and 1 
goat serum. The primary antibodies anti-IRSp58/53 (with or without
peptide) and rabbit anti-synapsin-I (1:3000; provided by Pietro DeCam-
ili , Howard Hughes Medical Institute, Yale University School of Medi-
cine; Malgaroli et aI., 1989) were diluted in block and were applied
overnight at 4 e. The slides were washed at room temperature for 2 hr in
PBST with stirring and one wash solution change. Cy3-conjugated goat
anti-rabbit IgG (1:500-1:4000; Jackson ImmunoResearch, WestGrove
PA) or FITC-conjugated goat anti-mouse IgG, rat-absorbed (1:100;
Vector Laboratories , Burlingame, CA) was applied for 3 hr at room
temperature. The sections were washed as above, dehydrated in -20
MeOH for 10 min, allowed to air dry, and mounted in Citifluor (Ted
Pella , Redding, CA). Immunostaining was visualized by indirect immu-
nofluorescence using a Nikon E800 microscope. Images were captured
with a Photometries CCD camera using IP Lab systems software.
Hippocampal neuron cultures and immunohistochemistry. Low-density
cultures were created as previously described (Goslin and Banker, 1991;
Wu et aI. , 1998). After 19-21 d , the cells were fied with 4% parafor-
maldehyde at 37 C for 20 min, covered with saponin (0.05%) for 5 min.
and then incubated in blocking solution (MEM, 10% horse serum, 1%
goat serum, and 1% BSA). The primary antibodies, mouse anti-
synaptophysin (1:20; Boehringer Mannheim), rabbit anti-IRSp58/53 (1:
5), and mouse insulin receptor f3-subunit (1:40, C-19; Santa Cruz Bio-
technology) were applied overnight at 4 e. Species-specific secondary
antibodies, directly conjugated to either FITC or Cy3, were applied for
1 hr at room temperature. Coverslips were mounted onto glass slides with
Citifluor.
RESULTS
Polypeptides p58 and p53 are enriched in the
postsynaptic density fraction
We were initially interested in determining the distribution of a
known protein (J3-dystroglycan) in the rat brain. We performed
Western blot analysis on homogenate, synaptosomes, and PSD-
enriched fractions. Antiserum Ab98 recognized a polypeptide of
43 kDa in brain homogenate and synaptosome fractions (Fig.
1A). This polypeptide co-migrated with J3-dystroglycan from
muscle and was also bound by the anti-J3-dystroglycan antibodies
NCL-43DAG and 12031-C (data not shown). Thus we identified
this 43 kDa polypeptide as J3-dystroglycan.
Ab98 also recognized a pair of polypeptides, termed p58 and
p53 , in the PSD fraction (Fig. 1). p58 and p53 were highly
enriched in the PSD fraction, because they were not detected in
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Figure 1. Polypeptides of 58 kDa and 53 kDa are enriched in thc PSD
fraction. Homogenate , synaptosome , and PSD fractions from rat brain
were separated by SDS-PAGE , transferred to nitrocellulosc , and probed
with Ab98 (left) or Ab98 that had been preabsorbed with peptide (right).
f3-Dystroglycan is observed in the homogenate and synaptosomal frac-
tions (f3-DG). A pair of polypeptides of 58 and 53 kDa is specifically
detected in the PSD fraction (p58 , p53). Binding of Ab98 to all three
polypeptides is eliminated when the antibody was preabsorbed (Ab98 +
peptide). Mobilities of molecular wcight standards are indicated. Ho-
mogenate; synaptosomes; PSD postsynaptic dcnsity fraction. West-
crn blots of homogenatc, synaptosomes , and PSD fractions from the
indicated brain regions were probed with antibody Ab98. p58 and p53 are
selectively enriched in the PSD fractions from all arc as examined. C
Wcstcrn blot of homogenate, synaptosome, and PSD fractions from
cerebral cortcx probed with antibodies to NMDA receptor subunit NR1
CaMKII , and synaptophysin.
blots of homogenate or synaptosomes that contained the same
amount of total protein (Fig. lA). p58 and p53 were enriched in
PSD fractions isolated from rat cerebral cortex, cerebellum, and
hippocampus (Fig. IE). The selective enrichment of p58 and p53
closely parallels that of known PSD constituents such as
CaMKII and the NMDA receptor subunit NRI (Fig. lC). 
contrast
, ,B-dystroglycan (migrating at 43 kDa) was present in
brain homogenate and was modestly enriched in synaptosomes
but was not detected in PSD fractions from cerebral cortex (Fig.
lA) or other brain regions (data not shown). Antibodies NCL-
43DAG and 12031- revealed a similar distribution of
,B-dystroglycan in these fractions. However, neither of these re-
agents bound either p58 or p53 (data not shown).
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Purification of p58 and p53
We purified p58 and p53 to determine whether they were related
to ,B-dystroglycan or were unrelated yet immunologically cross-
reactive. Protein staining of one-dimensional SDS gels showed
that p58 and p53 are minor components of the PSD fraction;
moreover , they were not well resolved from other , more abundant
polypeptides (data not shown). To achieve improved separation
of p58 and p53 and to further investigate their biochemical
properties , we separated the PSD fraction proteins by charge and
size using 2D gel electrophoresis (Fig. 2A). This method yielded
substantial improvement in the isolation of p58 and p53: unlike
the majority of the PSD proteins, the doublet migrated to a basic
isoelectric point (pI 9) free from the bulk of PSD proteins. The
p58 and p53 bands migrated as a series of closely spaced spots of
differing isoelectric points, suggesting that these polypeptides
may be post-translationally modified (see below).
p58 and p53 were virtually insoluble in all nonionic detergents
tested. Furthermore, they were not extracted in 3% N-Iauroyl
sarcosinate (data not shown). Such solubility properties indicate
that these polypeptides are tightly associated with the "core" PSD
(Kennedy, 1997). However, p58 and p53 could be effciently
solubilized in 8 M urea. Thus , we fractionated the urea-solubilized
PSD proteins by HIe. p58 and p53 bound to the HIC matrix
whereas the majority of the PSD proteins did not. Elution of the
HIC column thus yielded a fraction that was highly enriched in
p58 and p53. We then used 2D electrophoresis to achieve the final
purification of p58 and p53 (Fig. 2B).
Mass spectrometry analysis and peptide
microsequencing of p58 and p53
To identify p58 and p53 , we used MALDI-TOF mass spectrom-
etry to obtain mass profiles of the gel-purified polypeptides.
Comparison of these profiles with computer-generated mass pro-
files of protein sequences in the National Center for Biotechnical
Information database showed that rat p58 and p53 were highly
homologous to hamster IRSp58/53 (Table 1 , Fig. 3). This pair of
polypeptides was first identified in CHO cells , and the cDNA
encoding IRSp53 was subsequently cloned (Yeh et a!. , 1996).
However, the precise relationship between IRSp58 and IRSp53
was not established in that study.
Sixty-five percent of both the p58 masses (15 of 23) and the p53
masses (13 of 20) we obtained by mass spectrometry matched the
tryptic digest masses computed from the deduced IRSp53 amino
acid sequence (data not shown). There were eight p58 masses that
did not correspond to a computed IRSp53 mass , but six of these
masses were shared by p53. Two p58 masses and one p53 mass
were unique. Only slight differences were observed when the
HPLC chromatograms of the p58 and p53 tryptic digests were
compared (data not shown). Together , these data indicate that
the primary structures of p58 and p53 are very similar to the
polypeptide encoded by IRSp53 and to each other.
To verify the identification of p58 and p53 as IRSp53 , we
obtained amino acid sequence from three of the p58 tryptic
fragments. Of the 33 amino acids obtained , all perfectly matched
the published sequence of the IRSp53 cDNA (Table 1 , Fig. 3;
data not shown). The predicted pI of IRSp53 is 8. , which
corresponds well to the basic pI we determined for p58 and p53.
Western blots of PSD fractions probed with monoclonal antibody
H720 further confirmed the identification of p58 and p53 as
IRSp58/53 (data not shown). We will hereafter refer to p58 and
p53 as IRSp58/53.
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Ab98 western blot
Ab98 western blot
Figure 2. Purification of pS8 and pS3 by 2D gel electrophoresis and hydrophobic interaction chromatography. Two-dimensional gel clectrophoresis
was used to separate PSD fraction proteins. Gels of cquivalent samples were silver-stained (left) or blotted to nitrocellulose and probed with Ab98 (right).
Thc positions of pS8 and pS3 , as visualized by Western blotting, are indicated by the pair of arrows. Thc migration of pS8 and pS3 in the first dimension
indicates that these polypeptidcs arc basic (pI 9). Comparison of silver stain and Western blot shows that pS8 and pS3 are minor components of the
PSD fraction. The PSD fraction proteins werc solubilized in urca, loaded onto a HIC column in 1 M NaCI buffer , and then cluted in 0.1 M NaCl salt
buffcr. 2D gels of the HIC eluates wcrc either silver- stained (left) or blotted to nitrocellulose and probed with Ab98 (right). pS8 and pS3 are readily
visualized in silver-stained gcls of HIC eluate (arrows), indicating that they are highly enriched by this procedure.
Relationship of IRSp58 and IRSp53
In the course of our biochemical studies of IRSp58/53 , we con-
sistently encountered an 5 kDa difference between the molec-
ular weights of IRSp58 and IRSp53. However, neither mass
spectrometry nor HPLC analysis yielded any indication that the
primary structure of these polypeptides differed. Western analysis
revealed that IRSp58/53 was identical in rat and mouse (data not
shown). However, in the porcine PSD fraction the IRSp58 species
was prominent, and the IRSp53 species was barely detectable
(Fig. 4). In vitro phosphorylation of rat PSD proteins resulted in
an upward shift in the mobility of both polypeptides, suggesting
that they are substrates of a kinase(s) in the PSD fraction. How-
ever, this shift could not account for the 5 kDa difference between
IRSp58 and IRSp53 (Fig. 4). Similarly, enzymatic deglycosylation
did not yield any consolidation of the doublet (data not shown).
Thus, we could find no evidence that these post-translational
modifications are the basis for the difference in the apparent
molecular weights of IRSp58 and IRSp53.
Distribution of IRSp58/53 mRNA
We next examined the distribution and configuration of the
IRSp58/53 transcript. We probed Northern blots to determine the
tissue distribution of IRSp58/53 mRNA. Transcripts of 2.4 and
5 kb were detected (Fig. 5). Brain contained the highest level of
IRSp58/53 mRNA, with the 3.5 kb transcript predominating.
Varying amounts of these transcripts were observed in other
tissues. Neither transcript was detected in skeletal muscle.
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p58 and p53 tryptic fragments
Table 1. Mass spectrometry and peptide micro sequence analysis of PSD58/53
p58 masses p53 masses
912.
1788.
1208.
1789.
1208.4
Prcdicted IRSp53 tryptic fragments
IRSp53 masses Position Peptide microscquence
9131
1788.
1208.
51-
157-171
412- 421
GYFDALVK
YSDKELQYIDAISNK
DGWHYGESEK
The calculated masses of the IRSp53 tryptic fragments that correspond to p58 or p53 masses are listed.
All masses are in daltons.
The amino acid positions of these fragments are based on the numbering system of Yeh et al (1996).
peptide micro sequences obtained from the three p58 tryptic fragments were identical to deduced IRSp53 amino acid
sequences.
Ab98
epitope
IRSp58/53
epitope
Figure 3. Structure of IRSp53. IRSp53 is predicted to contain sevcral
protein-protein interaction domains: one SH3 domain , one SH3 binding
domain , and one WW binding domain (Yeh et aI. , 1998). Additionally,
there are 25 potential serine/threonine phosphorylation sites (protein
kinase A , protein kinase C, and casein kinase; data not shown) and two
potential tyrosine phosphorylation sites (pY). The positions of the pep-
tide microsequences obtained from purified p58 are notcd. The positions
of the epitopc that is likcly to be recognizcd hy Ah9R and the peptide used
to gcneratc the polyclonal anti- IRSp58/53 antiserum are indicated. The
region that corresponds to the IRSp53 DNA fragmcnt us cd as a probe for
Northern blots is also shown.
+ATP
53-
PSD PSD
rat pig
58-
PSD PSD
Figure 4. Relationship of IRSp58 and IRSp53 from PSDs. PSD
fractions from rat brain were incubated under conditions promoting 
vitro phosphorylation (see Materials and Methods) in either the absence
(left) or presence (right) of cxogenous ATP. Western blotting with Ab98
shows that IRSp58 and IRSp53 undergo similar gel shifts after in vitro
phosphorylation. Blots of PSD fractions from rat (left) and pig (right)
were probed with antibody Ab98. Comparison of these reveals species
diffcrcnccs in the expression of PSD fraction IRSp58 and IRSp53. Al-
though similar amounts of IRSp58 and IRSp53 arc detected in rat PSDs
only IRSp58 is dctcctcd in pig PSDs.
Organization of IRSp58/53 mRNA
We next considered the possibility that the multiple transcripts
observed in the Northern blots could corrcspond to alternatively
spliced mRNAs. Wc searched the Exprcssed Scqucnce Tag
(EST) databasc using the BLAST algorithm (Altschul et aI.
1990) for sequences that might represent IRSp53 homologs. We
identified a large set of IRSp53-homologous ESTs that spanned
the entire open reading frame of IRSp53 (data not shown).
1 = hear 5= liver
2= brain 6= skeletal muscle
3= spleen 7= kidney
4= lung 8= testis
Figure 5. Tissue distribution of IRSp58/53 mRNAs. A multiple rat
tissue Northern blot was probcd with a radio labeled IRSp58/53 oligonu-
cleotide probe (248 bp; see Fig. 3) as described in Matcrials and Methods.
Transcripts of 2.4, 3.5 , and 8 kb arc obscrved. The highcst level of
IRSp58/53 mRNA is dctccted in hrain , with the 3.5 kb transcript predom-
inating. Thc blot was rehybridized with a probe for f3-actin to verify the
intcgrity and quantity of the RNA from each tissue.
However, this analysis revealed no divergences from the reported
IRSp53 cDNA sequence and thus provided no evidence for
alternatively spliced transcripts.
As a further test for variations in the coding sequence of the
IRSp58/53 mRNAs, we performed RT-PCR. We isolated total
RNA from rat cerebral cortex and reverse-transcribed it using
random primers. We then used an array of specific primers that
spanned the IRSp53 coding region for PCR analysis. Each of the
RT-PCR products generated corresponded in size to a product
obtained using IRSp53 cDNA as template; no major additional
products were detected (data not shown). Together, these PCR
products covered the entire coding region of IRSp53. Thus , in rat
brain we find no evidence of alternative splicing within the coding
region of I RSp53 , suggesting that both IRSp58 and IRSp53 are
products of a highly similar or identical mRNA.
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Ab98
anti-
IRSp58/53
anti-
IRSp58/53
+ peptide
58 ..
53 ..
DG ..
H ax PSD H ax PSD H ax PSD
Figure 6. Characterization of the anti- IRSp58/53 antibody. Rabbits were
immunized with a 13 amino acid peptide from the predicted amino acid
sequence of IRSp58/53 , and the resulting antiserum was affnity-purified.
On Western blots, anti- IRSp58/53 antibody recognizes polypeptides of 58
and 53 kDa , which are also bound by Ab98. However, anti-IRSp58/53 does
not recognize f3-dystroglycan. All anti-1RSp58/53 immunoreactivity is
abolished if the antibody is preabsorbed with peptide. Homogenate;
synaptosomcs; PSD postsynaptic density fraction.
Localization of IRSp58/53 to synapses
To determine whether IRSp58/53 is expressed at intact synapses
we raised and affnity purified a specific anti- IRSp58/53 anti-
serum. The specificity of this reagent for IRSp58/53 was verified
by Western blotting and immunoabsorption (Fig. 6). In contrast
to Ab98, this antiserum did not recognize (3-dystroglycan.
To determine the distribution of IRSp58/53 in intact brain , we
performed immunohistochemistry on frozen sections. The cyto-
architecture of the cerebellum consists of granular and pyramidal
cell soma layers and a synapse-rich molecular layer. Staining with
--.
synapsin-
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the anti-IRSp58/53 antibody demonstrated that I RSp58/53 immu-
noreactivity is prominent in the synapse-rich molecular layer as
well as in the granule cell layer of this tissue (Fig. 7A). The
specificity of the IRSp58/53 antibody staining was demonstrated
by peptide immunoabsorption.
To assess the distribution of IRSp58/53 in further detail , we
exploited a system in which individual synapses can be resolved.
Primary hippocampal neurons in low density cultures have well
differentiated axons and dendrites and numerous synapses. These
synapses can be reliably visualized using antibodies to synapto-
physin (Fletcher et aI., 1991). Double labeling with anti-
synaptophysin and anti- I RSp58/53 showed that IRSp58/53 immu-
noreactivity was localized at the majority of synapses on these
cells (Fig. 7B). Little nonsynaptic localization was observed. To-
gether, these studies indicated that IRSp58/53 is a component of
CNS synapses.
Localization of insulin receptors at synapses
IRSp58/53 has been shown to be an insulin receptor substrate in
cultured fibroblasts. Furthermore , I RSp58/53 isolated from brain
can be tyrosine-phosphorylated in vitro by the insulin receptor
(Yeh et aI. , 1996). To determine whether the insulin receptor is
localized at synapses , we immunostained cultured hippocampal
neurons with an antibody directed against the insulin receptor
(3-subunit and with an anti-synaptophysin antibody. Figure 8
and shows that insulin receptors arc highly concentrated at
synapses on these cells. Insulin receptors are also localized at
nonsynaptic regions of the dendrite (Fig. 8B).
anti-IRSp58/53 anti-IRSp58/53 + peptide
anti-IRSp58/53
,- , .".
:!ttJ''''''' .
',. - .. ,. "
"16.".
, '
anti-synaptophysin
.,., .. " " .' " , '
ftL .
Figure 7. Localization ofIRSp58/53 in the cerebellar cortex. Sections ofrat cerebellum were immunostained with the affnity-purified anti-IRSp58/53
or with anti-synapsin-I antiserum. The synapsin-I immunoreactivity reveals the distribution of synapses. IRSp58/53 immunoreactivity is observed in the
synapse-rich molecular layer as well as in the granule cell layer. Anti-IRSp58/53 immunoreactivity is greatly reduced when the antibody was pre absorbed
with peptide. Scale bar , 50 !Lm. M Molecular layer; Purkinje cell layer; granule cell layer. Localization of IRSp58/53 at synapses. Cultured
rat hippocampal neurons were immunostained with the affnity-purified anti-IRSp58/53 antiserum (left). IRSp58/53 immunoreactivity is distributed in
a punctate pattern along the dendrites of the neurons. The distribution of synapses in the same dendrite was visualized by double labeling with
anti-synaptophysin (right). IRSp58/53 immunoreactivity is selectively concentrated at synapses (arrows).
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Insulin Recepor
97. subunit
CHO. SX PSD
Figure 8. Insulin receptor localization in cultured neurons and brain subcellular fractions. Cultured rat hippocampal neurons were double-
immunostained with anti-synaptophysin and anti-insulin receptor J3-subunit antibody (IR-J3). Insulin receptor immunoreactivity is distributed in a
punctate pattern along dendrites. Note that insulin receptor J3-subunit immunoreactivity is concentrated at synapses. Scale bar, 20 f.M. B High-
magnification view of a single dendrite of a cultured hippocampal neuron double labeled with antibodies to the insulin receptor J3-subunit and
synaptophysin. IR-J3 immunoreactivity is concentrated at both synaptophysin-positive regions (arrowheads) as well as distributed in apparently
nonsynaptic regions (arrows). Scale bar , 5 f.M. , A Western blot of rat brain subcellular fractions (homogenate, synaptosome , and PSD) and lysate from
CHO.T cells was probed with an anti-insulin receptor J3-subunit antibody. High levels of J3-subunit are seen in CHO.T cells (a cell line engineered to
overexpress insulin receptors). The J3-subunit of the insulin receptor is detected in brain homogenate and is enriched in synaptosome and PSD fractions.
Insulin receptors are a component of PSD fractions
We next wished to compare the biochemical fractionation profiles
of insulin receptor and IRSp58/53 from brain. In agreement with
earlier findings , the molecular weight of the insulin receptor
f3-subunit in brain is 5 kDa less than that expressed by periph-
eral tissues (Heidenrcich et aI. , 1983). Western blotting showed
that the insulin receptor f3-subunit was detected in homogenate
and was enriched in both synaptosome and PSD fractions (Fig.
8C). The degree of enrichment of insulin receptor in PSD frac-
tions was not as great as that obscrvcd for PSD components such
as NMDA receptor subunit NRl , a-CaMKII, and IRSp58/53
(Fig. 1). This observation is in agreement with the localization of
the insulin receptor to both nonsynaptic and synaptic regions
(Fig. 8B; see Discussion). Together , these findings show that both
the f3-subunit of the insulin receptor tyrosine kinase and its
substrate IRSp58/53 are components of the PSD fraction. This
co-localization suggests that these molecules are part of an
insulin-dependent signaling pathway at the postsynaptic
apparatus.
DISCUSSION
Insulin is likely to have diverse roles in the CNS. In addition to its
probable function in glucose mctabolism, there is a growing body
of evidence that insulin signaling may factor in cell-cell commu-
nication and plasticity (for reviewed, see Wickelgren , 1998). The
diverse outcomes of insulin signaling may be coordinated through
the spatially regulated expression of insulin receptor tyrosine
kinase substrates. Here , we show that the insulin receptor sub-
strate I RSp58/53 , and insulin receptors themselves, are localized
at synapses in the brain and are components of the postsynapti
density. Signaling via IRSp58/53 may define a synapse-specifi
role for insulin in the brain.
IRSp58/53 and insulin receptor are localized
to synapses
We began our investigation of synaptic insulin signaling protei
at the level of the PSD, an electron-dense conglomeration of
proteins that lies just below the postsynaptic membrane at exci-
tatory synapses. We purified a pair of previously unidentified
proteins that were selectively concentrated in PSD fractions.
MALDI-TOF mass spectrometry, peptide sequencing, two-
dimensional electrophoresis , and Western blotting demonstrated
that these PSD proteins , p58 and p53, are the insulin receptor
substrate p58/53 (IRSp58/53). The IRSp58/53 that we purified
from rat is very similar to that cloned from hamster (Table 1).
The striking enrichment of IRSp58/53 in PSD fractions sug-
gested that it may be predominantly expressed at excitatory
synapses. Indeed, immunocytochemistry showed that IRSp58/53
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is expressed in the synapse-rich layers of the ccrebellum. Further-
more , labeling of cultured hippocampal neurons dcmonstrated
that IRSp58/53 is selectively concentrated at synapses. Neither
Westcrn blotting nor immunocytochemistry detected IRSp58/53
expression in culturcd glial cells (our unpublished observations).
Thus , IRSp58/563 is selectively localized at synapses in the CNS.
The synaptic distribution of IRSp58/53 raised the possibility
that insulin receptors are also localized at these structures. Pre-
vious work has shown that insulin receptors have been detectcd in
both neurons and glia throughout the brain (Wozniak et aI.
1993). Howcvcr, their subcellular localization was not estab-
lished. Using immunocytochemistry and Western blotting of
brain fractions wc show that the insulin receptor is localized at
synapses. Togethcr, these findings support the proposal that in-
sulin signaling plays a role at synapses.
Structure of IRSp58/53
We consistently observed that IRSp58/53 migrates as a pair of
polypeptides. Howcvcr , we could find little evidence that IRSp58
and IRSp53 differed in their primary sequences. HPLC chro-
matograms of tryptic fragments from p58 and p53 were virtually
identical. MALDI-TOF analysis of purified p58 and p53 also
rcvcaled similar profiles; only two p58 masses and onc p53 mass
wcrc unique. Although thcse masses could represcnt divergent
primary sequences, they could also be attributable to post-
translational modification or protcolysis. Indeed , the relative cx-
pression of IRSp58 and IRSp53 is cell- and tissue-specific. Trans-
fection of thc IRSp53 cDNA into fibroblasts results in expression
of only the IRSp53 species (Yeh et aI. , 1996). Furthermore , we
detect only IRSp58 in PSD fractions from porcine brain. Finally,
using RT-PCR we detected only a singlc species of IRSp53
mRNA in the brain , and a survey of the EST database yielded no
evidence of multiplc mRNA species. Howcvcr, our comparative
analysis of thc I RSp53 cDNA and total rat brain cDNA does not
exclude the possibility that differences exist 5' or 3' to the IRSp53
coding region. Analysis of the IRSp53 cDNA reveals an open
reading frame that encodes for a predicted protein of 57.6 kDa
(Yeh et aI. , 1996). Intercstingly, downstream of this first ATG
codon are at least six subsequent potential start sites. Use of one
of these in particular would yield a polypeptide with a prcdicted
molecular weight of 53.6 kDa. Therefore , it is possible that use of
alternative initiation sites is the basis for the observation of this
pair of polypeptides of 58 and 53 kDa. Nevertheless , we think our
data best fit a scenario whereby IRSp58 and IRSp53 derive from
an identical mRNA coding region, and the difference in thcse
polypeptides is the result of a species- and cell background-
dependent , post-translational process.
Our investigation of I RSp58/53 was an outgrowth of our use of
an antiserum directed against ,B-dystroglycan (Ab98). However
comparison of the IRSp53 and ,B-dystroglycan sequences revealed
very limited sequence homology. The immunological cross-
reactivity that Ab98 demonstrated for IRSp58/53 is presumably
attributable to a proline-rich stretch of amino acids within its
amino acid sequence (KPLPVPPELAPF) that is similar to the
,B-dystroglycan peptide used to generate Ab98 (KAPLPPPEY-
PSQ). Notably, another group has reported a PSD fraction pro-
tein (not IRSp58/53) that is immunologically related to
,B-dystroglycan (Mummery et aI. , 1996). To date , however , neither
the identity of this 164 kDa PSD fraction protein nor its relation-
ship to ,B-dystroglycan has been shown. In sum, our data provide
no evidence for the expression of ,B-dystroglycan or a related
molecule in PSD fractions.
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Interactions of IRSp58/53
There is compelling evidence in support of the functional classi-
fication of IRSp58/53 as an insulin receptor substrate in cell lines
(Yeh et aI. , 1996). Furthermore , Yeh and colleagues (1996) dem-
onstrated that IRSp58/53 isolated from brain can be tyrosine-
phosphorylated in vitro by insulin receptors isolated from CHO.
cells. We have found that after in vitro phosphorylation of PSD
fractions, IRSp58/53 displayed a gel shift consistent with phos-
phorylation by an endogenous kinase(s). Moreover, the insulin
reccptor is localized at synapses and is a componcnt of PSD
fractions. Together, these observations suggest that IRSp58/53
acts as a substrate of the insulin receptor tyrosine kinase at
synapses. Studies are currently in progress to determine whether
insulin stimulation leads to phosphorylation of IRSp58/53 in
intact neurons.
The predicted domain structure of IRSp53 indicatcs many
potential sites for protein -protcin interactions , including an Src
homology region 3 (SH3) domain , an SH3-binding domain , and a
proline-rich WW-binding domain (Yeh ct aI. , 1998). An interac-
tion bctween an IRSp53 homolog and the intracellular domain of
Fas ligand (FasL) has been detected using a yeast two-hybrid
assay (GenBank accession U70669). However, we have been
unable to demonstrate an intcraction between IRSp58/53 and
FasL biochemically. We also tested whether IRSp58/53 intcracts
with the WW domain of dystrophin , a PSD-enriched cytoskelctal
protein , but we were unable to co-immunoprecipitate IRSp58/53
and in vitro-expressed dystrophin fragments. Finally, we did not
detect co- immunoprecipitation of any nativc PSD fraction pro-
teins with I RSp58/53 (our unpublished observations). Other in-
vcstigators have similarly been unable to dcmonstrate binding
partners for IRSp58/53 (Yeh et aI. , 1996).
IRSp58/53 may define a synapse-specific insulin
signaling pathway
In the periphery, the actions of insulin are effected by distinct sets
of signal transduction molccules with characteristic ccllular and
subcellular distributions (Anai et aI. , 1998). Similar compartmen-
talization may also occur in the CNS. Key components of the
insulin signaling mechanism, such as insulin receptors and IRS-
are widely expressed in the brain, where they are often co-
localized. However, there are several areas of the brain, including
regions of the cerebellum , in which insulin receptor but not IRS-
is detected (Baskin et aI. , 1994; Folli et aI. , 1994; Yamada et aI.
1997). In the current study we found that insulin receptors
although co-localized with IRSp58/53 at synapses , are also found
in nonsynaptic areas of the dendrite. It seems likely that the
insulin receptor will associate with other insulin receptor sub-
strates at these sites. These observations indicate that insulin
action in the brain is likely to be subserved by distinct sets of
downstream signaling elements.
The data presented here suggest that IRSp58/53 may define a
novel class of insulin signaling at excitatory synapses in the brain.
One expects that the effect of insulin at synapses is distinct from
its global, metabolic control. It seems likely that elucidating the
role of insulin signaling at synapses will provide important in-
sights into synaptic function and plasticity.
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